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 The purpose of this retrospective cohort research study was to explore the 
relationship between frailty and recurrent Clostridium difficile (CDI) in adults 55 years 
and older hospitalized between December 31, 2013 through December 31, 2015, with 
data extracted from 2012 to 2016 to identify initial and recurrent admission for CDI. A 
researcher-derived frailty index, based on the Accumulation of Deficits framework by 
Mitnitski, Mogilner, and Rockwood (2001), was created after careful review of the 
components contributing to frailty and following the guidance by Searle, Mitnitski, 
Gahbauer, Gill, and Rockwood (2008). As per Searle et al. (2008), the FI-CDI was 
constructed by following the method of selecting variables that are associated with 
health, increase with age, do not present early in the aging process, cover a wide 
representation of organ systems and not just one system, and items for the index remain 
unchanged when performing serial measurements in the sample. Variables for the FI-CDI 
included laboratory abnormalities, chronic diseases, functional status, and psychosocial 
indicators. The deficits were coded as “1” for present and “0” for absent, calculating the 
FI-CDI by dividing the number of deficits in an individual by the total number of deficits 
measured (36 in this study) as per the standard procedure for calculating the frailty index 
(Searle et al., 2008). Based on the derived FI-CDI, frailty was defined as ≥ 0.25.  
The initial sample for the inclusion criteria consisted of 871 patients with CDI. 
Only 450 patients had complete data on admission to calculate the FI-CDI for the 36 
deficits. The overall sample (n=871) had a recurrence rate of 23.9% (n=208) for the study 
iii 
period. The average age for the overall sample was 73.6 years (SD=10.7), with 9.1% of 
the sample expiring during first hospitalization over the study period. Caucasian females 
comprised over half of the sample. Almost two-thirds (n=576, 66.1%) resided in a private 
residence prior to initial admission, followed by skilled nursing facility (n=125, 14.4%). 
About one-third of the patients were discharged to either home/self-care (n=279, 32.0%) 
or a skilled nursing facility (n=261, 30.0%) after initial admission. CDI recurrence was 
more prevalent for those discharged to a skilled nursing facility (37.5% vs. 27.6% with 
no recurrence) and with home health care services (24.5% vs. 15.2% no recurrence) 
(p<0.001). The average frailty score for the FI-CDI sample (n=450) was 0.37 (SD=0.10) 
on admission. The age group of 55 to 64 was significantly associated with recurrent CDI 
admission for both bivariate and logistic regression analyses. The chronic diseases found 
to be significantly more prevalent in recurrent CDI included hypertension (88.0% vs. 
78.4%; p=0.003), heart failure (36.1% vs. 25.6%; p=0.005), and chronic kidney disease 
(34.1% vs 24.9%: p=0.011).  Frailty prevalence, as measured by the FI-CDI (n=450) was 
89.1% on admission as indicated by a FI-CDI score of ≥ 0.25.  The FI-CDI scores on 
admission were significantly related to CDI recurrence, adjusting for sociodemographics. 
Proton pump inhibitor (PPI) use prior to initial admission was significantly associated 
with frailty in bivariate analysis, but PPI use was not associated with recurrent CDI.   
Evidence from this study bridges a knowledge gap that exists regarding frailty and 
recurrent CDI. Limited research has been explored with frailty and recurrent CDI, and 
this study provides a foundation for prospective studies. The FI-CDI could be used with 
existing medical record data at time of hospitalization, assessing frailty and allowing 
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opportunities for intervention. The hospitalized frail older adult is vulnerable, with CDI 
as a stressor that can result in prolonged recovery time and possible recurrence. 
Recognition of frailty in this population through already existing medical record data can 
guide interventions to address the underpinnings contributing to frailty and decrease 
readmissions, recurrence, morbidity, and mortality. 
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CHAPTER I 
INTRODUCTION
 
The concept of frailty is complex, characterized by age-associated decreases in 
reserve throughout many systems, resulting in an increased vulnerable state and 
subsequent poor outcomes (Maxwell & Wang, 2017). Multiple methods of measurement 
exist, with most falling into a physical phenotype or multi-dimensional approach 
(Walston & Bandeen-Roche, 2015). Frailty and functional deficits in the older adult are 
not new concerns, as articles dating to the 1960s called for recognition of the frail state 
in the older adult (Binks, 1968). Today, frailty is recognized as a geriatric syndrome and 
known to be an independent risk factor for detrimental outcomes and even mortality 
(Clegg, Young, Iliffe, Rikkert, & Rockwood, 2013). As the population continues to live 
longer, the complexity of healthcare deepens. The recognition of frailty is paramount to 
provide appropriate care.  
Background 
The National Institute on Aging, National Institutes of Health, and World Health 
Organization (2011) estimated 524 million of the global population were 65 years and 
older. This estimation is expected to increase to 1.5 billion by the year 2050. Eight 
percent of ages 65 and older are in the group 85 years and older. By 2050, centenarians 
are expected to increase 10-fold compared to 2010.  In North America, 15.1% of the 
population is 65 and older, which is expected to increase to 22.5% by the year 2050 
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(Federal Interagency Forum on Aging Related Statistics, 2017). The United States 
continues to age at a steady rate, yet this has increased significantly as the generation 
born in 1946-1964 turns 65 through the years 2011 to 2029 (Federal Interagency Forum 
on Aging Related Statistics, 2017).  
Frailty prevalence increases with age, yet it is independent from age 
chronologically (Clegg, Young, Iliffe, Rikkert, & Rockwood, 2013). The concept of 
frailty is important to grasp, as frailty may not be recognized in older adults as an area to 
intervene and maximize care and interventions, leading to improved outcomes. The 
factors contributing to frailty, including pathological processes, malnutrition, and 
psychological components (Dent, Kowal, & Hoogendijk, 2016), should be recognized in 
order to provide excellent care of the older adult. Frailty concepts and frailty prevalence 
are further described, providing a background on the need for frailty recognition.  
Frailty Concepts 
 Frailty is known as a “cornerstone of geriatric medicine” (Walston, Buta, & Xue, 
2018, p 25), with decreased defenses from recognized geriatric syndromes and poor 
resulting outcomes for individuals. Although chronological years result in normal 
processes of aging, not all older adults are frail. Frailty is a process that is dynamic, with 
physiologic abnormal underpinnings that propel the pathway of frailty (Maxwell & 
Wang, 2017). Due to the dynamic characteristic of frailty, early intervention may help to 
improve frailty status (Lekan et al., 2017; Maxwell & Wang, 2017). 
Multiple pathophysiological processes contribute to frailty (Dent, Kowal, & 
Hoogendkijk, 2016; Maxwell & Wang, 2017), and multi-dimensional components such 
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as psychosocial factors, sociodemographics, and polypharmacy are recognized as 
contributors. Frailty is not synonymous with co-morbidities, aging, or disability (Dent et 
al., 2016). The decline of physiological systems accumulate deficits in an individual, 
with frailty increasing as reserves decrease (Dent et al., 2016). Although the 
pathophysiology of homeostasis is affected with advancing age, an individual is felt to 
have approximately 30% of reserves whereby one is still able to function, and frailty 
occurs when this threshold is exceeded (Lang, Michel, & Zekry, 2009).  
 A recent meta-analysis of 31 studies reviewed frailty concepts and the prediction 
of negative health outcomes in the older adult community, finding 29 different frailty 
instruments utilized that fell into the categories of physical measurement, multi-domain, 
and deficit accumulation (Vermeiren, et al., 2016). The association between mortality 
and frailty were reviewed from 24 prospective studies, with 25 different measurement 
tools. Findings were overall consistent with mortality likelihood increased with frailty 
presence (Vermeiren et al., 2016). Eleven studies reviewed hospitalization, with 16 
different frailty instruments, confirming frailty increasing the risk of hospitalization 
(Vermeiren et al., 2016).  
Frailty was shown to increase the risk of institutionalization for both frail and 
pre-frail individuals. Only physical measurement and accumulation deficit methods were 
used in measuring frailty during emergency room visits, with frailty increasing the risk 
of emergency room presentation. Basic and instrumental activities of daily living were 
included in 11 and 7 studies, respectively (Vermeiren et al., 2016). Frailty was shown to 
increase the risk of disabilities in basic and instrumental activities of daily living. 
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Increased risk of physical limitation and dependency were associated with frailty, and 
frailty significantly increased risk of falls and fractures after review of 11 articles (six 
studying falls and five studying fractures) (Vermeiren et al., 2016). Cognitive decline 
was measured with presence of frailty increasing potential cognitive decline. Body 
composition was only measured in one study, with significant findings for changes in 
frailty but not pre-frailty (Vermeiren et al., 2016), prompting the need for further 
research. Finally, lower overall life satisfaction was found to be associated with frailty 
but not a pre-frail status (Vermeiren et al., 2016).  
 Assessment of frailty remains a challenge, as appropriate utilization of clinical 
and research measurements are debated (Dent et al., 2016). A review of frailty 
measurements over the years 2009 to 2015 were performed by Dent and colleagues 
(2016). This review included research and review articles for samples that included ages 
65 and older, objective measurement of frailty in observation, cross-sectional, or 
randomized control trials with the outcome of prognosis or classification of frailty (Dent 
et al., 2016). The authors reviewed 422 studies identified in the literature, with 29 
varying frailty measurements for patient populations of cardiovascular, renal, geriatric, 
oncology, surgical, and orthopedic (Dent et al., 2016). The phenotype measurement and 
frailty index were most common, with measurement serving as prognostic (Dent et al., 
2016). The review found many modifications of frailty measurements from original 
versions, with recommendations for identifying appropriate frailty measurements 
depending upon the clinical setting and population. The review emphasized the 
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importance of frailty measurements to accurately identify frailty, predict outcome and 
response to treatment, and have a foundation of biologic theory (Dent et al., 2016).  
 Finally, hospitalization of a frail older adult can result in longer lengths of 
inpatient stays and need for higher acuity of care, and a systematic review with meta-
analysis by Muscedere et al. (2017) purposed to explore frailty consequences for older 
adults who are critically ill. The overall prevalence of frailty in the studies reviewed was 
30%, with measurements of frailty in the study by clinical frailty scale, a frailty index, 
and physical phenotype (Muscedere et al., 2017). Frail patients were at an increased risk 
for inpatient mortality versus non-frail patients, and discharge to home after admission 
was less likely for frail patients (Muscedere et al., 2017). Interestingly, the meta-analysis 
did not find a significant difference between frail and non-frail patients for length of 
intensive care stay, receiving mechanical ventilation, or vasoactive drugs (Muscedere et 
al., 2017). Muscedere and colleagues (2017) raised the concern for choosing appropriate 
frailty assessments in clinical setting, similar to the discussion by Dent et al. (2016).  
 Common frameworks to support frailty include the phenotype by Fried et al. 
(2001) and the deficit accumulation by Mitnitski, Mogilner, & Rockwood (2001). 
Additional frameworks include the bio-psychosocial framework (Engel, 1981), applied 
to frailty by Lekan and colleagues (2017) and more recently the Systems Addressing 
Frail Elder (SAFE) Care model (Ansyran et al., 2018). The bio-psychosocial framework 
is comprised of three domains to include the biological, psychological, and social 
aspects of a person, emphasizing the interaction between these domains and bringing a 
holistic view to the person and their health care need. The SAFE Care model was piloted 
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as an inpatient intervention 2012-2013 with processes to include screening risk for skin 
integrity, problems eating, incontinence, confusion, evidence of falls, and sleep 
disturbance (SPICES) (Ansyran et al., 2018). SPICES screening was then followed by 
interdisciplinary assessments. These assessments included the assistance of nursing 
staff, social work, pharmacy, and a physician assessment of the medical record. The 
SAFE Care model used a multi-disciplinary approach to proactively assess frailty and 
provide intervention. The framework for purposes of this study will be discussed in 
further detail in Chapter I.  
Frailty Prevalence 
The prevalence of frailty in the United States differs depending on measurement 
used, with estimates ranging between 4% to 59% for older adults in the community and 
between 19-76% for nursing home residents (Vermeiren et al., 2016). The National 
Health and Aging Trends Study assessed 7,439 community-dwelling and residential care 
individuals (excluding nursing homes), utilizing the Fried phenotype measurement of 
frailty. Frailty was noted in 15% of the older adults, and 45% were pre-frail (Bandeen-
Roche et al., 2015). Frailty prevalence increased to 38% for ages 90 and older. 
Additionally, the prevalence of frailty in the hospitalized older adult has been reported 
from 27% to 87.1% (Andela, Dijkstra, Slaets, & Sanderman, 2010; Chong et al., 2017; 
Dent et al., 2014; Eeles et al., 2012; Ekerstad et al., 2011; Joseph et al., 2015; Krishnan 
et al., 2014; Patel et al., 2014; Purser et al., 2006). Frailty prevalence is higher in 
women, racial and ethnic minorities, residential care facilities, and lower socioeconomic 
statuses (Bandeen-Roche et al., 2015). African American and Hispanics have shown 65-
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85% more frailty prevalence than Caucasian, and the prevalence of frailty increases 
significantly with age (Bandeen-Roche et al., 2015). As the authors stated,  
 
Frailty is a strong predictor of disability and high multimorbidity, but a 
considerable portion of frail persons are free of these, consistent with 
conceptualizing frailty as an underlying physiological process and not merely an 
outcome or marker of disease and disability (Bandeen-Roche et al., 2015, 
p1432). 
 
Frailty and Age, Co-Morbidity, and Disability 
Despite the link between frailty and older age, chronologically advanced age 
does not immediately equate to frailty. Frailty is a dynamic entity, with possibilities of 
improving or worsening over time periods (Morley et al., 2013). Multiple factors 
surround the improvement or persisting and worsening of frailty in an individual. The 
combination of physiological diseases and already present age-related factors may be 
antecedents to frailty (Morley et al., 2013). 
The literature has shown that frailty can be associated with disability, physical 
impairment, cognitive impairment, falls, hospitalization, increased length of stay, post-
operative mortality and morbidity, discharge to a care facility, and death (Boyd et al., 
2005; British Geriatrics Society, 2014; Cesari, Calvani, & Marzetti, 2017; Dent et al., 
2016; Fried et al., 2001; Maxwell & Wang, 2017; Mitnitski, Mogilner, & Rockwood, 
2001). The age of 65 and older has been extensively studied regarding frailty. The term 
disability is not interchangeable with frailty; however, the frailty syndrome may be a 
precursor to disability. Some researchers have used functional decline as a means to 
demonstrate frailty, with examples to include Lawton’s Instrumental ADL, the Katz 
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score of activities of daily living, and the Score Hospitalier d’Evaluation du Risque de 
Perte d’Autonomie (Dent et al., 2013). However, this is not a true representation of 
frailty, as frailty may be a predictor of functional decline, as well as an outcome (Fried 
et al., 2004). In 2012, a Frailty Consensus Conference, comprised of six societies 
(International Association of Gerontology and Geriatrics; Society on Sarcopenia, 
Cachexia, and Wasting Diseases; International Academy of Nutrition and Aging; 
European Union Geriatric Medicine Society; American Medical Directors Association; 
American Federation for Aging Research ) was held in Orlando, Florida, to define 
frailty, with the aim of describing an operational definition for frailty, discuss 
appropriate screening and treatment for frailty, and identifying populations who should 
be screened (Morley et al., 2013). Historically, multiple definitions of frailty caused lack 
of agreement, with explanations ranging from very broad to narrow in scale (Morley et 
al., 2013). The group developed the definition of physical frailty as  
 
a medical syndrome with multiple causes and contributors that is characterized 
by diminished strength, endurance, and reduced physiologic function that 
increases an individual’s vulnerability for developing increased dependency 
and/or death (Morley et al., 2013, p 4).  
 
 
The broader definition of frailty, encompassing co-morbidities, disability, cognition,  
and psychosocial factors was proposed as a construct by Rockwood and colleagues 
(2005) as a  
 
state of increased vulnerability due to impairments in many systems that may 
give rise to diminished ability to respond to even mild stresses, incorporates 
multimorbidity and central nervous system impairments that can be recognized 
in relation to cognitive and affective disorders (2013, p 4). 
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The Frailty Consensus Group meeting in 2012 confirmed that frailty in the older 
adult population increases the risk of morbidity and mortality (Abellan van Kan et al., 
2008; Morley et al., 2013). The group recommended screening for frailty in all 
individuals older than 70 years and/or any individual with 5% weight loss or greater in 
the setting of chronic diseases (Morley et al., 2013). The presence of frailty is a better 
indicator than age for predicting hospitalization and possible early mortality (Mitnitski 
et al., 2001). When frail older adults experience an acute illness, the risk of death is 
increased when compared to healthier peer counterparts (Evans, Sayers, Mitniski, & 
Rockwood, 2014).   
The International Academy on Nutrition and Aging (I.A.N.A) and the 
International Association of Gerontology and Geriatrics (I.A.G.G.) met in 2013 to 
discuss cognitive frailty with the aim of designing preventive, personalized intervention 
strategies that were multi-dimensional to target physical, cognitive, nutritional, and 
psychological components for the older adult (Kelaiditi et al., 2013) The frailty concept 
had been predominantly focused on physical characteristics, but recognition of the 
pathophysiology of the aging process prompted further definition and clarification for 
the cognitive component.  Cognitive frailty was recognized as different from dementia, 
as the Alzheimer’s dementia and other dementias were part of exclusion for Cognitive 
Frailty. Indeed, cognitive Frailty was proposed to be defined by cognitive impairment 
paired with physical frailty (Kelaiditi, 2013). Research has shown that frailty is linked 
with decreased cognitive performance in those with or without dementia (Kelaiditi, 
2013). For this reason, cognitive impairment is now recognized as one of the factors 
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contributing to frailty. The I.A.N.A/I.A.G.G (2013) outlined four groups for 
characterization of Cognitive Frailty. These were defined as 1) robust older adults 
without physical frailty or cognitive deficits, 2) physically frail with normal cognition 
and may include those with subjective memory concerns, 3) older adults without 
physical frailty but portraying cognitive impairment, and 4) both physical frailty and 
cognitive impairment manifested in the older adult. Interventions for cognitive frailty 
may include one or both approaches of preventive care and rehabilitation (Kelaiditis, 
2013).  
The British Geriatrics Society (2014) developed best practice guidelines, 
defining frailty as a multi-dimensional decrease in body system reserves related to the 
aging process. The British Geriatrics Society advised against routine population 
screening but rather assessing individuals with each encounter and recognizing frailty 
characteristics, which would prompt the comprehensive geriatric assessment (CGA). 
The CGA would then prompt interventions for care, support, and referral to appropriate 
specialists (2014).  
Despite multiple tools for capturing frailty, consensus for a standardized frailty 
measurement has yet to be accepted for acutely-ill, hospitalized older individuals (Dent, 
Chapman, Howell, Piantadosi, & Visvanathan, 2013). Existing frailty screening tools are 
numerous, but the reliability and clinical feasibility of these tools requires further 
research (Warnier et al., 2016). Frailty screening tools are helpful to identify those with 
higher risk for poor outcomes; yet, translating the results from screening to clinical 
practice interventions remains a challenge and agreement upon which instrument to use 
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varies. Lack of a standardized frailty definition and measurement affects recognition of 
frailty, resulting in inconsistent measurement of frailty and difficulty in establishing a 
dedicated tool (Warnier et al., 2016). However, literature has noted different 
measurement tools are appropriate for specific settings, depending on need such as 
general screening versus assessment of risk for outcomes in subspecialties (Walston, 
Buta, & Xue, 2018).  
Several simple methods for routine screening of frailty would include 
questionnaires, assessment of gait speed and physical assessment such as the Timed up 
and Go test (TUGT), self-reporting of health, provider assessment, polypharmacy 
whereby five or more medications are taken, and the Groningen Frailty Indicator 
questionnaire (British Geriatrics Society, 2014). In urgent situations, the aforementioned 
tools would not be appropriate for frailty assessment. Instead, timing is essential, 
requiring prompt assessment of current functioning status and evidence of confusion. 
The outpatient surgical arena holds opportunity to screen for frailty, utilizing an 
approach such as the Edmonton Frail Scale (British Geriatrics Society, 2014; Dent et al., 
2016).  The phenotype approach, accumulation of deficits approach, and FRAIL scale 
have been used in both the clinic and population setting (Dent et al., 2016).  
Frailty Measures 
Although many frailty measures are available, a standardized method of 
measurement has not been accepted (Partridge, Harari, & Dhesi, 2012). The two main 
categories that broadly encompass the measurements of frailty include the phenotype 
and the deficit accumulation approach (Dent et al., 2013). The Frailty Phenotype 
 
12 
incorporates physical measurements, and the Deficit Accumulation approach includes a 
multidimensional approach (Dent et al., 2013; Mitnitski, Mogilner, & Rockwood, 2001). 
The necessary frailty measurements for specific patient populations continues to remain 
unclear (Partridge et al., 2012).   
Frailty phenotype framework. The frailty phenotype utilizes five indicators to 
measure frailty (Fried et al., 2001):  recent weight loss, self-reported weakness and 
fatigue, slow gait speed, and decreased physical activity, where the presence of three of 
the five indicators indicate frail, and two of the five indicate pre-frail. This approach 
views frailty as a syndrome, based on age-related changes as measured by the five 
variables assessing weight loss, weakness, fatigue, slowed gait, and decreased physical 
activity. The frailty cycle is proposed in this phenotype, with many entry points in the 
cycle that may precipitate and progress frailty (Fried et al., 2001).  
Accumulation of deficits. The accumulation of deficits framework measures the 
quantity of deficits in an individual instead of the actual health conditions individually 
(Theou, Walston, & Rockwood, 2015). The number of the deficits in an individual is 
more important than the nature, as the body accumulates these deficits resulting in 
system impairment to overcome and repair damage that is either an external or internal 
process (Theou et al., 2015). The accumulation of deficits is a multidimensional risk 
state, and the health deficits are not weighted. Operationalization of this approach is 
through a frailty index (Mitnitski, Mogilner, & Rockwood, 2001). Frailty is viewed as a 
state instead of a syndrome, which Fried and colleagues portray with the phenotype 
approach (2001). When frailty is viewed as a state, the individual is characterized in a 
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whole manner (Rockwood & Mitnitski, 2007). To describe the accumulation of deficits 
approach as a syndrome would not be appropriate, as a syndrome is a comprised of “a 
collection of specific symptoms and signs” (Rockwood & Mitnitski, 2007, p 725).  
Frailty measurement examples. Many common operational definitions exist in 
measuring frailty, with examples to include the Edmonton Frail Scale (Rolfson, 
Majumdar, Tsuyuki, Tahir, & Rockwood, 2006) the Tilburg Frailty Indicator (Gobbens, 
van Assen, Luijkx, Wijnen-Sponselee, & Schols, 2010), the Groningen Frailty Indicator 
(Schuurmans, Steverink, Lindenberg, Frieswijk, & Slaets, 2004),  the FRAIL scale 
(Abellan et al., 2008), and Clinical Frailty Scale (CFS) (Rockwood et al., 2005). 
Description of these common measurements are located in Table 1.  
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Table 1. Frailty Measurements 
Frailty Instrument Description Reference 
Frailty Phenotype Five indicators including 
recent weight loss, self-
reported weakness and 
fatigue, slow gait speed, 
decreased physical activity.  
Fried et al., 2001 
Accumulation of Deficits Operationalized by a frailty 
index comprising variables 
that are counted as deficits, 
dividing deficits by total 
number of variables 
measured to calculate frailty 
score.  
Mitnitski, Mogilner, & 
Rockwood, 2001.  
Edmonton Frail Scale comprising 11 questions 
that include cognition, 
functional independence 
and performance, health 
status, social support, 
medications, nutrition, 
mood, and continence 
Rolfson et al., 2006 ,  
Tilburg Frailty Indicator 25 questions  that cover 
physical, psychological, and 
social domains 
 
Gobbens et al., 2010  
Groningen Frailty 
Indicator 
15 questions that measure 
physical (mobility, vision, 
hearing), nutrition, co-
morbidity, and psychosocial 
components 
Schuurmans et al., 2004  
FRAIL Scale scale forms the acronym 
“fatigue, resistance, 
ambulation, illness, and loss 
of weight”, comprised of 
five questions 
Abellan et al., 2008 
Clinical Frailty Scale 9 point scale ranging from 1 
(very fit) to 9 (terminally 
ill). Uses brief descriptions 
attached to silhouette 
pictures 
Rockwood et al., 2005  
 
15 
The use of existing electronic medical record data to assess frailty is an approach 
that has been explored by researchers. Such research has produced a frailty risk score 
comprised of 16 variables that include geriatric syndromes, symptoms, and biomarkers 
pulled from existing data that included the combination of physiologic and 
biopsychosocial data (Lekan, Wallace, McCoy, Hu, Silva, & Whitson, 2017).  Clegg and 
colleagues (2016) developed an electronic frailty index for the outpatient setting using 
medical codes in the United Kingdom that identify 36 deficits from multiple organ 
systems. The electronic medical record offers the opportunity to use existing data in real 
time to calculate a frailty score.  
Frailty Research in Specialties 
 The impact of co-morbid conditions and frailty is emerging as an area for 
additional research. Multiple specialties have studied frailty. Heart disease, including 
atrial fibrillation, heart failure, and myocardial infarction (MI), have been studied in 
relation to frailty and adverse outcomes (Dominiquez-Rodriquez et al., 2016; Jha et al., 
2016; Nguyen, Cummings, & Hilmer, 2016; Vidan et al., 2016). Older frail adults with 
atrial fibrillation had longer lengths of inpatient stays and increased mortality (Nguyen 
et al., 2016). Frailty in hospitalized heart failure patients was associated with increased 
1-year-mortality rate in comparison to non-frail counterparts after adjusting for age, 
gender, co-morbidities, and severity of heart failure (Vidan et al., 2016). Frailty in older 
adults who had an MI was associated with inpatient and 1-month- mortality after 
adjustment for age, sex, previous history of MI, ejection fraction, diabetes, 
cardiovascular risk, and other health conditions (Ekerstad et al., 2011)  
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 Pulmonology has focused on patients with chronic obstructive pulmonary 
disease (COPD) and increased risk of death with increasing frailty (Galizia et al., 2011). 
The presence of frailty in COPD patients awaiting transplant increased the risk of 
mortality prior to lung transplantation (Singer et al., 2015). Nephrology specialists noted 
that frail hemodialysis patients had a greater risk of death compared to non-frail 
counterparts when accounting for age, sex, comorbidities, and disabilities (McAdams-
DeMarco et al., 2013). In the field of endocrinology, diabetes mellitus and frailty have 
been studied, with increased mortality in frail women and men by 31% and 60% 
(Cacciatore et al., 2013).  The field of rheumatology has reported that osteoarthritis 
patients have increased risk of long-term mortality in the presence of frailty (Cacciatore 
et al., 2014). The field of gastroenterology has studied frailty with chronic liver diseases, 
noting an increased transplant waiting list mortality associated with increased frailty 
scores (Lai et al., 2014). The Model for End-Stage Liver Disease (MELD) score was 
measured in this population, and frailty continued to predict mortality even after 
adjustment for the MELD score (Lai et al., 2014). 
Surgical and trauma specialists have also studied frailty in relation to their 
population. Trauma patients with index scores ≥0.25, which classifies frailty from a 
deficits approach, have higher incidence of hospital-related complications related to 
cardiac and pulmonary events, infection, deep venous thrombosis, and mortality in 
comparison to patients with index scores < 0.25 (Joseph et al., 2014). Although many 
specialties have undertaken frailty research, Clostridium difficile infection (CDI) and 
frailty have rarely been studied together, which is discussed further in Chapter II.  
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     As frailty may predict hospitalization and mortality, an acute hospitalization of a 
frail older adult may result in an increased mortality rate compared to a healthy 
counterpart who is not frail.  Hospitalization for disease processes and acute illnesses 
can be challenging, as the most common method of care is focusing on the admitting 
complaint with aims of discharge once improved. However, in the older frail adult, 
multiple deficits may be present, and recovery during and after hospitalization can be 
prolonged (Hatheway, Mitnitski, & Rockwood, 2017).  For this reason, older frail adults 
admitted with CDI are a vulnerable population for increased morbidity, mortality, and 
prolonged hospitalization.  
Clostridium difficile and the Older Adult  
Multiple disease processes may affect the older adult and lead to hospitalization, 
and the bacterial illness Clostridium difficile infection (CDI) in this vulnerable 
population has the potential to lead to prolonged hospitalization, adverse outcomes, and 
possibly death. Age-related changes in this population, combined with a 
pathophysiological adverse process, could potentially affect the person’s frailty status 
(Morley et al., 2013). For this reason, the relationship between frailty in the older adult 
and CDI needs further exploration. 
One of the first published studies regarding CDI was in 1974, where Tedesco, 
Barton, and Alpers recognized the use of antibiotics as precipitating the disease. This 
prospective study of 200 patients had received clindamycin, with 21% having diarrhea 
and 10% with pseudomembranous colitis. Colonoscopy can confirm the presence of CDI 
by documentation of pseudomembranes, but the absence of pseudomembranes does not 
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confirm the absence of CDI. Tedesco and colleagues (1974) felt that early colonoscopy 
was necessary for diagnosis and advocated discontinuing the antibiotic.    
As the use of antibiotics has become more routine, the prevalence of CDI has 
increased. Individuals 65 and older are at an increased risk for CDI compared to the 
younger population, and this age group is more prone to increased severity of CDI 
(Keller & Surawicz, 2014; Louie et al., 2013; Surawicz et al., 2013). Etiology for 
increased CDI prevalence in the older adult is felt to be secondary to multiple factors to 
include but not limited to co-morbidities (diabetes mellitus, cardiopulmonary disease, 
renal disease, neurological diseases and neoplasm), increased exposure to hospitalization 
and institutional care for other reasons, decreased immune response, and alterations in 
intestinal microbiota (Louie et al., 2013). Treatment success may falter with increasing 
age, while the risk of recurrence increases with age (Louie et al., 2013). CDI recurrence 
and mortality have been shown more prevalent with healthcare acquired CDI versus 
community acquired CDI (Lessa et al., 2015). 
CDI is the leading cause for all gastroenteritis-associated deaths (Hall, Curns, 
McDonald, Parashar, Lopman, 2012; Moudgal & Sobel, 2012). CDI is spread via the 
fecal-oral route, and the bacteria produces spores that may reside on flat surfaces and 
objects such as door handles, toilets, and equipment. Spores have the capability to live 
up to several months, regardless of environmental severity (Keller & Surawicz, 2014). 
Bacteremia may occur in CDI, with mortality estimated at 20% (Johnson et al., 2012). 
Severe CDI in an older population are associated with a prior history of CDI, limited 
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ability to perform daily living tasks, advanced age, depression, heart failure, and 
immunocompromised state (Rao et al., 2013).  
Recurrent CDI. A recent large study of Medicare beneficiaries (n= 8,465) noted 
an 8.5%  readmission rate for those who survived initial admission for CDI 
approximately one month after first discharge (Collins, Ayturk, Anderson, & Santry, 
2015). This study used Medicare claims from the years 2009-2011 to identify patients 65 
years and older who had been hospitalized for CDI or developed CDI during an 
admission for other health reasons. ICD-9 code (008.45) was used to define CDI, and 
admissions to long-term care facility or skilled nursing facility was not included. Collins 
and colleagues reviewed antibiotic exposure after initial admission, length of stay, 
intensive care monitoring, mortality while hospitalized, and need for colectomy (2015).  
This study found that 29% were admitted within 2 weeks, and 56% were 
readmitted within 30 days (Collins et al., 2015). Co-morbidities in this sample of 65 
years and older increased the risk of readmission for CDI, and antibiotic use was the 
greater predictor for readmission in those who had not been hospitalized between an 
initial and recurrent admission (Collins et al., 2015).  Hospitalization unrelated to CDI 
between initial diagnosis and recurrent CDI admission was a strong predictor for 
readmission (Collins et al., 2015) Although Collins et al. noted a readmission rate of 
almost 10%, estimates for recurrence of CDI indicate up to 40% chance of recurrence 
after an initial treatment (Garey, Sethi, Yadav, & DuPont, 2008; Kelly & LaMont, 
2008). CDI recurrence with readmission is similar to heart failure at 20% within 30 days 
(O. Connor, 2017), COPD ranging from 5.6% to 20% (Harries et al., 2017), and 
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pneumonia estimated 1 in 5 patients within 30 days (De Alba & Amin, 2014). The need 
for intensive care monitoring increases during readmission. Interestingly, increasing age 
in this study did not correlate with risk of readmission, although age greater than 65 has 
been recognized as a risk factor for recurrence. Co-morbidity burden in the sample did 
predict increased risk of recurrence (Collins et al., 2015).  
Risk factors. However, other literature supports risk increasing with advancing 
age. Antibiotics after CDI treatment, PPI therapy, and specific virulent strains of CDI 
continue to be risk factors for recurrence (Chakra, Pepin, Sirard, & Valiquette, 2014; 
Trifan et al., 2017). Risk factors for complicated CDI disease course includes older age, 
leukocytosis, renal failure, co-morbidities, and hypoalbuminemia (Chakra et al., 2014). 
Decreased ability of the older adult to respond with an appropriate immune response is 
felt to contribute to adverse effects in CDI (Louie et al., 2013). Recurrent CDI occurs 
usually one to three weeks after initial completion of antibiotics, characterized by 
diarrhea and positive stool test for CDI (Chopra & Krishna, 2014). Fifty percent of 
recurrent CDI episodes are likely from a different bacterial strain than the original 
infection (Chopra & Krishna, 2014). Recurrence and morbidity from CDI is associated 
more with healthcare-acquired infections than community-acquired infections (Lessa et 
al., 2015). 
Significance 
The increased risk of CDI and recurrence in older adults, coupled with the 
growing interest in frailty and preventing its adverse outcomes, requires further 
investigation. Understanding the relationship between CDI in the older adult and frailty 
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may provide guidance towards a holistic approach to providing care for the hospitalized 
older adult with CDI.   The risk of recurrence in older adults is greater than the general 
population, but age alone does not account for the higher risk of recurrence in the elderly 
(Collins, et al., 2015). Further, recurrent CDI is not always explained by coexisting 
conditions (Schmid et al., 2014).  
Wenisch and colleagues (2012) reviewed hospitalized patients with CDI and 
those without who were admitted between January 2009 and December 2009; the 
authors found that patients with CDI were more likely to die than patients hospitalized 
without CDI, independent of sex, age, or severity of co-morbidities. The literature 
differs regarding mortality from CDI and age, for instance, Bloomfield et al. (2012) 
performed a systematic review of literature to evaluate potential risk markers for CDI 
mortality during hospitalization. This review found that age (65 and older) was a marker 
for risk of mortality with CDI, along with increased creatinine, low serum albumin level, 
and increased white blood cell count, concluding these characteristics could be useful as 
part of a risk factor assessment at time of diagnosis (Bloomfield et al., 2012). 
Chintanaboina et al. (2017) conducted a retrospective study of patients with CDI, noting 
in multivariate logistic regression analyses, peptic ulcer disease, advanced age, Charlson 
comorbidity index, and intensive care admission were associated with a 30-day 
mortality.  
Statement of the Problem 
Although current research findings contribute to the knowledge base regarding 
CDI, to date there is a paucity of research in older adults exploring the relationship 
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between recurrent CDI and frailty. Gut microbiota of the older adult differs in 
composition compared to younger counterparts (Claesson et al., 2011; Mariat et al., 
2009). The relation between microbiota and frailty has been explored in the literature, 
with increased frailty associated with less diverse microbiota (Jackson et al., 2016; 
Milani et al., 2016; Tongeren et al., 2005). Altered gut microbiota has been shown in 
older adults with CDI (Milani et al., 2016), which raises the question of a relationship 
between frailty and CDI in the hospitalized older adult. A knowledge gap remains, as 
chronological age alone continues to be unpredictable as a factor for the recurrence of 
CDI (Collins et al., 2015). Although many risk factors are known surrounding CDI, 
antibiotics are the only constant, independent risk factor.  The relationship between 
frailty in the older adult and CDI deserves investigation, as recurrent CDI, severe CDI, 
and CDI-associated morbidity and mortality could be potentiated by the presence of 
frailty. 
Purpose and Research Questions 
         The purpose of this study was to explore relationships between frailty and CDI 
as addressed by the following research questions: 
1. What sociodemographic variables are related to recurrent CDI admission?  
2. What sociodemographic variables are related to frailty during an initial 
admission for CDI? 
3. What is the prevalence of the frailty index variables among members of the 
sample?  
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4. What proportion of the sample has a frailty index score of 0.25 and above 
indicating frailty?  
5. What is the relationship between the frailty index score during the initial 
admission for CDI and documented recurrence of CDI within a year?  
6. What is the relationship between proton pump inhibitor (PPI) use prior to 
admission, frailty, and recurrent hospitalization for CDI?  
Conceptual Framework 
 This study used the Accumulation of Deficits framework as a guide, developed 
by Mitnitski, Mogilner, and Rockwood (2001). Operationalization of frailty was 
performed by using a researcher-derived frailty index. In this frailty measurement, 
numerous health deficits were combined and comprised into an index. The number of 
deficits present in an individual were summed, with the outcome calculated as the 
number of deficits present divided by the total number of deficits in the index (Mitnitski 
et al., 2001; Theou, Walston, & Rockwood, 2015). This provided a score from 0 to 1, 
with higher scores indicating severity of frailty. A continuum exists between fit and frail 
individuals, with the frailty index placing individuals on this continuum. The 
accumulation of health problems predisposes to vulnerability (Mitniski, Song, and 
Rockwood, 2013). The Reliability Theory of Aging and Longevity by Gavrilov and 
Gavrilova (2001) was inspiration for the accumulation of deficits model (Mitnitski, 
2001).  
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The Reliability Theory of Aging and Longevity 
Reliability Theory of Aging and Longevity (Gavrilov & Gavrilova, 2001) states 
that living organisms are designed with only a finite number of redundant capabilities to 
maintain life. Through the aging process, deficits accumulate and result in decreased 
physiological reserve and the potential for increasing mortality (Gavrilov & Gavrilova, 
2001). This theory proposes the process of aging as a “system redundancy” (p. 539). 
Mitnitski, Song, and Rockwood (2013) derived the deficit accumulation model from the 
Reliability Theory of Aging and Longevity, whereby the interactions between 
environmental stress (causing distress in multiple areas of the organism) and recovery 
result in the degree of deficit accumulation. 
Mitnitski, Song, and Rockwood (2013) used a mathematical stochastic dynamics 
approach to support the accumulation of deficits. Although individuals may have 
multiple differing health issues, the common theme remains that the total number of 
health problems actually increases with age but also increases quicker in individuals 
with poor health (Kulminski et al., 2007; Yashin et al., 2007). This mathematical 
concept describes the length of a queue in relation to the stream of arrivals to a system, 
the systems schedule priorities, service, and waiting times (Mitnitski et al., 2013).  
Little’s Law further explains this mathematical concept, stating, “the average 
number of items in a queuing system (L) equals the average arrival rate (入) multiplied 
by the average waiting time of an item in the system, (W)” (Mitnitski et al., 2013, p. 
711). For the accumulation of deficits, Little’s Law is then revised to state that the 
average number of deficits in a given time in an individual (N), will equal environmental 
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stress rate (入), multiplied by the average recovery time (R) (Mitnitski et al., 2013). This 
mathematical relationship represents that recovery in an individual is a proportional 
equation associated with the average deficits in an individual at a given time. As the rate 
of an individual’s recovery becomes slower, resulting in longer recovery times, the 
deficits accumulate with age (Mitnitski et al., 2013). The slowing of recovery increases 
with age, which is not completely explained in this model.  
Increased maintenance and metabolic demands are placed on the individual 
during the normal aging process (Mitnitski et al., 2013). Deficit accumulation is viewed 
as a state of an individual, focusing on number of deficits impaired in an individual 
instead of the nature of the health problems (Theou, Walston, & Rockwood, 2015, p. 
67). The deficits accrued affect the individual’s system to heal. Aging involves 
accumulation of deficits, but the number of these deficits present will affect the recovery 
time in an individual (Mitnitski & Rockwood, 2015). 
The recovery time of each individual is different and varies in individuals the 
same age (Mitnitski & Rockwood, 2015). Recovery is dependent on genetic factors, 
health, access to health care, living environment, and underlying cellular characteristics 
of the aging process (Howlett & Rockwood, 2013; Theo et al., 2013; Yashin et al., 
2013). The frailty index of an individual will increase an average of 10-fold between the 
ages of 20 and 90. Little’s Law reinforces that the recovery time is the changing factor 
over the lifespan (Theou et al., 2015). This concept explains the reasoning behind the 
increased score of the frailty index.  This index consistently is associated with poor 
health outcomes, women are noted to have more accumulation of deficits than men of 
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similar age, and a maximum frailty index score is around 0.7 (Theou et al., 2015). The 
frailty index score and mortality rate are considered a “dose-response” function (Theou 
et al., 2015, p. 68). A frailty index may be researcher-derived, following specific 
guidelines (Searle et al., 2008). The development of the frailty index for purposes of this 
study is discussed in Chapter 3.  
 Frailty indices are used with the assumption that the more deficits an individual 
has is more important than understanding exactly what is wrong with the individual 
(Theou & Rockwood, 2015). The pathway to frailty is unique to each individual. The 
value of the frailty index is not affected by the precise variables that are included; when 
enough variables are included in the index, even randomly selected, similar results are 
found (Rockwood, Mitnitski, Song, Steen, & Skoog, 2006). Although random variables 
may be selected, a strict method to composing the index must be followed. Any health-
related variables that cover a broad range of bodily systems, are linked with adverse 
outcomes, and are known to increase with age but not universal may be included 
(Mitnitski & Rockwood, 2015).  
The frailty index has consistent reproducibility regarding association with 
adverse outcomes, without a linear increase, threshold of limits in deficits, and increased 
scores in women versus men despite the combination of variables in various studies 
(Mitnitski & Rockwood, 2015). This consistency is due to the interdependent play 
amongst the health deficits, relating to the premise of system redundancy; many deficits 
may hold information regarding other deficits, supporting the accumulation of deficits. 
Although the frailty index has been controversial (Mitnitski & Rockwood, 2015), it must 
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be understood that the emphasis is not on each individual deficit but rather the 
synergistic effects of deficits on the individual, giving rise to frailty. The biological 
systems-perspective of viewing a human, comprising many mutually interacting 
subsystems that contribute to health, encompasses the understanding of the 
accumulation of deficits approach.  
Components of Framework 
         The Accumulation of Deficits framework was used to guide this study, with CDI 
as an acquired infection from the environment, hereby depicted as an external stressor 
that causes physiologic changes in the individual. The interdependent deficits included 
in the frailty index are affected by the presence of CDI. The interdependent deficits as 
symptoms, signs, diseases, disabilities, and laboratory abnormalities comprise the 
accumulation of deficits, as illustrated in the model.  
The proposed model for frailty, derived from the accumulation of deficits 
framework, is depicted in Figure 1.  As the number of deficits affect the potential 
recovery time in an individual, it was hypothesized that higher frailty scores would 
result in impaired and longer recovery time and potentially increase the risk of recurrent 
CDI and hospital readmission. 
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Figure 1. The Accumulation of Deficits Model for CDI  
 
 
In this model, the external, physiologic stressor of CDI is a threat. This may 
affect recovery time, in turn leading to a recurrence of CDI in a system already 
compromised by multiple deficits.  A system with the burden of deficits, translated into 
a frailty score, may not be able to adequately recover if the deficits are too great; this 
results in poor recovery and possible recurrence of CDI or other adverse events. These 
deficits were derived from the literature as entities that are related to frailty and 
discussed in Chapter 2. 
Definitions  
Frailty. For this study, frailty was conceptually defined as a multidimensional 
state, secondary to the accumulation of deficits that are externally or internally 
generated, hindering the individual from recovery and increasing risk for adverse 
outcomes (Mitnitski et al., 2001; Theou, Walston, & Rockwood, 2015).  Frailty was 
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operationalized using a researcher-derived frailty index based on variables available in 
the electronic health record (EHR). The Frailty Index for Clostridium difficile infection 
(FI-CDI) was developed by following the procedure outlined by Searle and colleagues 
(2008). The deficits must be signs, symptoms, disabilities, and diseases; the deficits 
must be associated with health status, general increase with age, do not saturate quickly 
(such as routine age-related processes), cover a range of body systems, and the derived 
frailty index must be identical for measurement in the sample if it is serially applied 
(Searle et al., 2008). Further development of the frailty index is discussed in Chapter 3. 
The FI-CDI score was derived by adding the number of deficits present in an individual 
divided by the total number of deficits possible. Therefore, the FI-CDI result is a 
decimal number, used to identify the severity of frailty. Research demonstrates that a 
threshold has been consistently shown, whereby the maximum number of deficits that 
any one individual will have approximates two-thirds of the total number of deficits, 
with an empirical limitation of a Deficit Index score of 0.7 (Rockwood & Mitniski, 
2007; Theou et al., 2015).  The use of a continuous Frailty Index score instead of a cut 
point score for frailty has been recommended (Theou & Rockwood, 2015). 
Clostridium difficile infection. CDI was determined from the EHR by the ICD-9 
and/or ICD-10 codes of 008.45 and A04.7, in the electronic health record. The presence 
of these codes indicates a diagnosis by a healthcare provider during hospitalization, 
which could be prompted by the collection of stool studies to diagnose the presence or 
absence of CDI or through clinical judgment by the provider if stool testing is 
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inconclusive and suspicion is high for CDI.  CDI is recognized as the external stressor 
on the system in this conceptual framework.  
Frailty index variables and demographic variables. The sociodemographic 
variables and frailty index variables extracted from the EHR are listed and operationally 
defined in Table 2 and 3, respectively.  Sociodemographic variables include age, sex, 
race, ethnicity, marital status, residence prior to admission, living arrangements prior to 
admission, discharge plan at first admission, length of hospital stay, days from first 
discharge to recurrent admission, and expired during admission. 
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Table 2. Sociodemographic Variables  
Variable Definition/Choices Available in EHR 
Age Measured chronologically in years and recorded 
as a whole number on initial admission 
Sex Male or female  
Race American Indian, Asian, Black/African 
American, White, Other, Unavailable 
Ethnicity Hispanic, Non-Hispanic, unavailable 
Marital Status Divorced, Legally Separated, Married, Single, 
Unknown, Widowed  
Living Arrangements Spouse/Significant other, Alone, Children, 
Other 
Residence prior to admission  Assisted Living, Group Home, Nursing Home, 
Private Residence, Skilled Nursing Facility, 
Other  
Discharge plan at first 
admission  
Home/Self Care, Transferred Short Term 
Hospital, Skilled Nursing Facility, Intermediate 
Care Facility, Home Health Care, Left against 
medical advice, Expired, Federal Hospital, 
Hospice/Home, Hospice/Medical facility, 
Rehab facility, Long Term Care, Another 
institution, Inpatient rehab/Acute care Hospital  
Length of hospital stay  Date of admission to date of discharge defined 
as number of days  
Days from discharge to 
recurrent admission  
Length of time measured in days  
Expired  Death during admission, yes or no  
 
Summary 
         The relationship between frailty in the hospitalized older adult and CDI (initial or 
recurrence) has not been directly explored in the literature. CDI affects young and old 
alike, but the older population has been shown to experience more adverse effects, 
increased risk of recurrence, morbidity, and mortality (Wenisch et al., 2012). Frailty 
may be an important factor that influences CDI recurrence and treatment failure. The 
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identification of frailty may be a vital component to preventing recurrent disease and 
numerous adverse outcomes. This retrospective cohort research study focuses on the 
association between frailty and recurrent CDI with hospital admission, utilizing a 36 
item frailty index. The accumulation of deficits framework guided the study design and 
identification of the variables in the EHR for the frailty index, and the data obtained 
shall be used to bridge a known gap between frailty in the older adult and risk of 
recurrence and readmission for CDI. The measurement of frailty in the acute care setting 
is challenging, as no clinical tool has been identified as optimal for risk prediction and 
care planning.  There remains inconsistency in choice of frailty tools, when to measure 
frailty, and which patients should be identified; frailty assessment should be a priority in 
providing care for adults during the normal aging process (Lekan et al., 2017). The  
researcher-derived frailty index utilizes existing collected data in the EHR, offering 
practical advantages over other frameworks that require new data collection or lengthy 
new data collection.   
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CHAPTER II 
 
LITERATURE REVIEW
 
 
Frail individuals are at risk for prolonged hospitalizations, morbidity, and 
mortality; age-related changes in this population, combined with a pathophysiological 
adverse process could potentially affect the person's frailty status. Recognition of frailty 
in the hospitalized older adult for CDI is vital to deliver care in both the inpatient and 
outpatient management. In this chapter, the concept of frailty will be further discussed. 
Clinical studies that have addressed frailty in the hospitalized older adult using a specific 
frailty index are presented here. Finally, current research surrounding the relationship 
between CDI and frailty will be discussed.  
Pathophysiology of Frailty 
Frailty is dynamic and requires a myriad of failures across the physiologic 
workings in an individual (Clegg et al., 2013). With frail individuals, multiple different 
failures in the system give rise to the state of frailty.  Aging, in itself, is a natural process 
of a breakdown in the physiological processes and reserves of the body; however, in 
frailty, the process is quickened and failing systems occur (Ferrucci et al., 2002). The 
imbalance in homeostasis of the human body and stressful occurrences in health result in 
poorer health. 
Numerous studies outline markers correlating with frailty. From a standpoint of 
dysfunction, certain markers of inflammation, hormonal changes, blood clotting pathway 
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activation, and metabolic derangements exist with frailty (Cappola, Xue, & Fried, 2009; 
Reiner et al, 2009; Walston et al., 2006). Sarcopenia and its associated consequences of 
decreased strength, speed of gait, and overall physical function are well known frailty 
indicators (Zasvlavsky, Thompson, & Demeris, 2012). Neurological indicators of frailty 
include impaired sensory function, cognitive impairment, and even psychological entities 
such as depression (Zasvlasky et al., 2012). 
The human body is comprised of many organ systems; however, the overlapping 
qualities of many of these systems allow for physiological stamina, which propels the 
overall body in functioning despite aging and disease (Lipsitz, 2002). Skeletal muscle, 
immune system, endocrine system, neurological system, respiratory system, 
cardiovascular, renal, and hematological system have been studied in frailty (Clegg et al., 
2013). The brain, skeletal muscle, endocrine system, and immune system will be 
reviewed in further detail, as they have been most studied in frailty development (Clegg 
et al., 2013). 
Brain 
The brain undergoes natural aging processes, with the neurons that necessitate 
higher metabolic demands possibly more affected in function (Bishop, Lu, & Yankner, 
2010). An example of this type of neuron would be those in the hippocampus, which are 
responsible for metabolic needs. Cognitive failing would be linked to the hippocampus, 
which is an important ingredient in the physiological stress response (Miller & 
Callaghan, 2005). The link between frailty, dementia, and cognitive impairment has 
shown increasing frailty linked with a quicker cognitive decline rate (Clegg et al., 2013). 
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This cognitive impairment and affective disorders lead to a vulnerable state in the 
individual. (Rockwood et al., 2005). The presence of frailty leads to a higher risk of 
cognitive deficits long-term (Boyle, Buchman, Wilson, Leurgans, & Bennett, 2010). 
Cognitive frailty is recognized as a subcategory of frailty, whereby the individual 
demonstrates both physical frailty and impaired cognition that is unrelated to Alzheimer 
dementia or other clinically diagnosed dementias (Kelaiditi et al., 2013; Maxwell & 
Wang, 2017).  
Endocrine 
 The endocrine system and brain are interconnected via the hypothalamo-pituatary 
axis, responsible for homeostasis properties (Bishop et al., 2010). Growth hormone, sex 
hormones, and cortisol have been posited as linked with frailty (Clegg et al., 2013). 
Persistently elevated cortisol in the older adult has been thought to result in an increase in 
catabolism, resulting in muscle mass loss, loss of appetite, loss of weight, and decreased 
energy, all of which are linked to frailty. Diabetes is a risk factor for the development of 
frailty. Elevated blood glucose levels in individuals without a diagnosis of diabetes 
increase risk for frailty (Zaslavsky, Walker, Crane, Gray, & Larson, 2016). Glucose 
levels have been highly predictive of mortality in the hospitalized older adult (Fontana et 
al., 2013).  
Immune 
With aging, stem cells wane, T-lymphocytes production change, and the antibody 
response is altered and less effective (Clegg et al., 2013). During stress-free periods, the 
older adult will continue to function well but may not be able to have an appropriate 
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immune response during an acute inflammatory event (Sahin & Depinho, 2010). A state 
of inflammation is linked with loss of appetite, breakdown of fatty tissue and skeletal 
muscle, muscle fatigue, and loss of weight, contributing to poor overall nutrition and 
linked with the frailty picture (Clegg et al., 2013). Markers recognized as associated with 
frailty include interleukin-6 (IL-6), C-reactive protein (CRP), tumor necrosis factor-α 
(TNFα), and CXC chemokine ligand-10 (CXCL-10). However, these are not routinely 
measured on hospital admission, making inclusion in frailty measurement difficult.  
Skeletal Muscle 
Skeletal muscle mass loss and decreased ability in strength is a known 
characteristic of frailty (Manini & Clark, 2012). Decreased mobility is recognized in frail 
states. (Bandeen-Roche et al., 2006).  The degree of frailty has been related to mobility 
recovery in acute hospital admission, with recovery time of mild mobility impairment 
individuals quicker than those who were less frail (Hatheway, Mitnitski, & Rockwood, 
2017). Although actual weight loss is identified with the syndrome of frailty, the 
morbidly obese patient has been reported frail as well (Waters et al., 2013).  Sarcopenia, 
which is a triad of lost skeletal muscle mass, strength, and power, is a recognized marker 
of frailty (Clegg et al., 2013). A term "sarcopenic obesity", is recognized as the presence 
of increased body fat in conjunction with decreased skeletal muscle (Cooper et al., 2012, 
p. 1843). Sarcopenic obesity is linked with mobility impairment in the older adult.  
Homeostasis upset by neurological, endocrine, and immunological components in the 
frailty syndrome may affect the decline to sarcopenia (Clegg et al., 2013). Physical frailty 
is also recognized as a subcategory of frailty (Maxwell & Wang, 2017).  
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Chronic Diseases  
Individuals with heart failure, cancer, kidney disease, and diabetes are more prone 
to frailty and subsequent adverse effects (Afilalo, 2011; Ng, Feng, Nyunt, Larbi & Yap, 
2014; Ruiz, Reske, Cefalu & Estrada, 2013; Shilpak et al., 2004; Sinclair et al., 2012). 
Frailty risk is also increased in individuals who have both diabetes and dementia (Ulley 
& Abdelhafiz, 2017).  
Other chronic diseases found in frail persons include asthma, COPD, stroke, 
depression, hearing and visual impairment, anemia, and renal disease (Galizia et al., 
2011; Ng et al., 2014). A historical diagnosis of cancer has led to a higher state of frailty 
with advancing age, and a higher risk in those with a recent diagnosis (Pérez-Zepeda, 
Cárdenas-Cárdenas, R, Navarrete-Reyes, & Gutiérrez- Robledo, 2016). Arthritis 
increases severity of frailty, leading to higher mortality rates (Cacciatore et al., 2014). 
Non-alcoholic fatty liver disease (NAFLD) is prevalent in the older adult population, 
with severity of liver fibrosis associated with advancement of age and higher risk of 
mortality (Frith, Day, Henderson, Burt, & Newton, 2009). NAFLD severity has been 
associated with low albumin and higher alkaline phosphatase levels (Frith et al., 2009). 
Sarcopenia and NAFLD share similar pathophysiological pathways, with insulin 
resistance mediating accumulation of fat in the liver and muscle mass (Bertolotti et al., 
2014).  
Polypharmacy is strongly associated with likely development of frailty (Morley et 
al., 2013). Older adults taking five or more medications have an increased likelihood for 
risk of falls and delirium (Inouye, 1998). The literature has recognized that the presence 
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of six or more drugs are indicative of polypharmacy, which in turn may result in adverse 
outcomes (Rolland & Morley, 2016). The risk for 30-day hospital readmission is 
increased in older adults who have multiple medication adjustments (Shapiro et al., 
2017). The frailty syndrome coincides with changes in pharmacokinetics, thereby altering 
bioavailability of drugs (McMillian & Hubbard, 2012).  
Depression has been linked with frailty, and the presence of depression increases 
risk of mortality (Almeida et al., 2015; Makizako et al., 2015). Urinary incontinence has 
been shown to contribute to frailty and felt to be a marker of frailty (Berardelli et al., 
2013). Finally, with older adults at risk for falls and adverse outcomes, the association of 
frailty and falls has been studied. Higher frailty scores have been associated with higher 
risk for falls, along with frailty as a predictor for risk of falls in the future (Li et al., 2014; 
Liu et al, 2016; Sanchez-Garcia et al., 2017). Lifestyle behaviors to include alcohol use 
and smoking in midlife has been associated with progression to frailty over time (Kojima, 
Iliffe, Jivraj, Liljas, & Walters, 2017; Ulley & Abdelhafiz, 2017). Kojima and colleagues 
noted that current smokers were also were found to be significantly frailer in comparison 
to those who did not smoke (2017). 
Functional Status  
The inability to perform activities of daily living (ADLs) is associated with 
frailty, with the literature supporting the association of frailty with deficits in one or more 
difficulty in performing ADLs (Sanchez-Garcia, 2017). The multi-faceted aspect of 
frailty that affects normal day to day activities include decreased cognition, weakness and 
exhaustion, loss of weight, all of which are reflected in measurement by the Braden scale 
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(Ogg, 2016). The Braden scale is a commonly used measurement to assess risk of 
pressure ulcers, including the following six domains: sensory perception/communication, 
moisture, activity, mobility, nutrition, friction and shear (Braden & Bergstrom, 1994).  
Clinical Laboratory Markers of Frailty 
Laboratory studies are easily accessible in the hospitalized patient, and many 
researchers have studied markers in relation to frailty. Serum sodium imbalances place 
the older adult at risk for hospitalization, mental status changes, and falls, thereby 
contributing to frailty (Morley, 2015). Inflammatory markers such as increased white 
blood cells and increased CRP have been associated with frailty in the older adult 
(Kanapuru & Ershler, 2009; Lekan et al., 2017; Mitnitski et al., 2015; Ng et al., 2014). 
Thrombocytopenia, low hemoglobin, and low albumin have been identified as 
biomarkers that contribute to the development of frailty (Fontana et al., 2013; Mitnitski et 
al., 2015). Low or low normal hemoglobin has been shown to be an independent risk 
factor for frailty (Chaves et al., 2005). Leukocytosis and hypoalbuminemia are 
biomarkers that are not only contributors to the development of frailty but strongly 
associated with mortality in the hospitalized older adult (Fontana et al., 2013). A 
decreased serum level of ALT in an older adult could be indicative of frailty and stem 
from decreased liver size and decreased blood flow (Liu, Que, Xu, & Peng, 2014). 
Vitamin D is vital for many purposes, including maintaining appropriate calcium and 
phosphorous concentration in the body, contributing to bone strength, and influential in 
immunological processes (Adams & Hewison, 2010). Vitamin D deficiency may be 
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found in pre-frailty and frail individuals (Fernandez-Garrido, Ruiz-Ros, Buigues, 
Navarro-Martinez, & Cauli, 2014).          
Psychosocial Variables 
The lack of psychosocial support for the older adult has been linked with the 
potential for frailty and poor outcomes (Hoogendijk et al., 2014a). Solitary living status, 
depression, and socioeconomic status have been linked with frailty (Ng et al., 2014).  
Increased social support has shown to be associated with decreased frailty (Woo, 
Giggins, Sham, & Ho, 2005).  Social support is important in the older adult population as 
it can improve outcomes (Hoogendijk et al., 2014a).  Although the psychosocial 
component is linked to frailty, more research is needed to assess the outcomes in relation 
to the association between frailty, functional decline, and mortality. Hoogendijk and 
colleagues did not find a statistically significant association between psychosocial factors 
with functional decline and mortality, after adjusting for age, sex, educational level, and 
frailty (2014b). Psychosocial factors in the study by Hoogendijk and colleagues (2014b) 
were identified through mastery and self-efficacy, identification of instrumental and 
emotional support through personal networks such as friends and family. Further research 
over time is needed to investigate the psychosocial component to frailty outcomes in the 
older adult. 
Depression has been linked with higher frailty scores (King, Fillenbaum, & 
Cohen, 2017). Low educational level may affect availability of psychosocial resources, 
and these individuals are more likely to have experienced environmental adverse effects 
(Hoogendijk et al., 2014b). Older adults with lower educational levels were more likely 
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to be frail than higher educational level counterparts, but frailty rate did not 
disproportionately increase over time in those with lower educational frailty levels. This 
finding shows that there was not an interaction effect between time and educational status 
(Hoogendijk et al., 2014b). The association between educational level and frailty was 
mediated by income, self-efficacy, cognitive status, chronic diseases, and obesity 
(Hoogendijk et al., 2014b). These findings support the multifactorial properties of frailty. 
A higher socioeconomic status was linked with greater perceived control of situations, in 
turn resulting in lesser degree of frailty (Mooney, Elliot, Douthit, Marquis, & Seplaki, 
2016).  
Self-neglect in the older adult has been associated with functional limitations, co-
morbidities, living alone, and greater likelihood of frailty (Lee, Burnett, & Dyer, 2016; 
Papaioannaou, Raiha, & Kivela, 2012). Self-neglect has been shown as an independent 
risk factor for early demise of the older adult (Papaioannaou, Raiha, & Kivela, 2012). J. 
Lee and colleagues performed a secondary data analysis to explore frailty and self-
neglect, with findings of pre-frail individuals more likely to exhibit self-neglect, and 
those who were self-neglecting were more overweight and obese than counterparts in the 
study (2016).  This finding was hypothesized as the result of possible physical constraints 
and decreased activity promoting a more sedentary lifestyle, progressing more to frailty 
and self-neglect. Frailty status was felt to lead to worsening self-neglect, but further 
research is needed with frailty and self-neglect.  
Frailty, physical decline, and difficulty with ADLs are risk factors for elder abuse, 
with abuse encompassing the realms of psychological, physical, sexual, financial, and 
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neglect (Johannesen & LoGiudice, 2013). Psychological abuse is further delineated by 
verbal and social abuse displayed in actions or threats. Cooper and colleagues estimated 
that approximately 6% of older community-dwelling adults will likely have experienced 
abuse (2008).  
CDI and the Older Adult 
CDI is a spore-forming, gram-positive, anaerobic bacteria that releases toxins in 
the intestinal system, specifically flourishing in the setting of an altered, post-antibiotic 
exposure intestinal tract. Asymptomatic colonization and carrier of the bacteria is 
possible (Behar et al., 2017). Due to persistent overuse of antibiotics, potent strains of the 
bacterium now exist, which may lead to complicating features (Postma, Kiers, & 
Pickkers, 2015). CDI has doubled in prevalence from the years 2000 to 2010, with an 
estimated 453,000 cases in 2011 (Lessa et al., 2015).  In 2011, The Centers for Disease 
Control and Prevention (CDC) reported 29,000 deaths secondary to CDI (Centers for 
Disease Control and Prevention, 2015a).  Long-term care patients have an incidence of 
this infection varying from 4% to 50% (Kee, 2012). The incidence of CDI is four times 
higher in individuals aged 65 and older versus counterparts, and 70-80% of CDI cases are 
comprised of age 65 and older (Lessa et al., 2015; Simor, 2010).  
All ethnicities are affected, but Caucasians have been found to have higher 
incidences than other ethnicities (Lessa et al., 2015; Yang, Rider, Baehr, Ducoffe, & 
Hughe, 2016).  A large retrospective study noted the CDI incidence in Caucasians was 
57% more than African Americans (Argamany, Delgado, & Reveles, 2016).  Yet, African 
Americans developed more severe disease courses and a higher rate of mortality than 
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Caucasians (Argamany et al., 2016). Freedberg and colleagues noted the African 
American race as an independent risk factor for recurrent CDI (2013).  The reason for 
disparities in race and ethnicity is unclear. Argamany and colleagues hypothesized that 
incidences of CDI in younger ages of black individuals, health insurance obstacles, and 
access to care could contribute to less recognition of the disease (Argamany et al., 2016). 
Although this disease affects both male and female, females have a higher rate of CDI 
(Lessa et al., 2015). 
Risk Factors 
 Risk factors for CDI are multiple. Advanced age, prior antibiotic use, and facility 
admissions are the most widely known and accepted risk factors; however, other factors 
also include proton pump inhibitor use, presence of feeding tube, inflammatory bowel 
disease, immunosuppressive states, hepatic and renal disease, and history of 
gastrointestinal surgeries (Keller & Surawicz, 2014; Leibovici-Weissman et al., 2017; 
Surawicz et al., 2013; Zilberberg, Shorr, Wang, Baser, & Yu, 2016).  Individuals with 
chronic comorbidities have a higher risk of developing CDI than those without 
comorbidities (Zilberberg et al., 2016). Also, the risk for CDI increases with intensive 
care admission, a recent hospital admission within several months, respiratory support via 
ventilation, enteral feedings, histamine blockers, proton pump inhibitors (PPIs), 
malnutrition, and hypoalbuminemia (Kim et al., 2012; Morrison et al., 2011; Roughead et 
al., 2016; Tleyjeh et al., 2013). Prolonged stays in health care facilities increase risk of 
exposure to CDI, specifically if common toilets are shared. Co-existing malignancy and 
poor host immune response are also risks (Hessen, 2010; Kim, Lee, & Jeong, 2010; 
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Morrison, Hall, Said et al., 2011; Tleyjeh et al., 2013). The use of PPIs as a risk factor for 
recurrent CDI requires further investigation, as the literature reports mixed findings. 
Although observations have noted a significant association between PPI usage and CDI 
recurrence (Linksy, Gupya, Lawler, Fonda, & Hermos, 2010; McDonald, Milligan, 
Frenette, & Lee, 2015; Roughead et al., 2016; Trifan et al., 2017), Freedberg and 
colleagues (2013) did not find an association between PPI usage and recurrent CDI.  
Freedberg et al., (2013) did not adjust for antibiotic re-exposure, which must be 
considered. A large systematic review and meta-analysis of PPI therapy and CDI risk 
reviewed 56 studies, which showed a significant association between PPI use and CDI 
risk, compared with those not on a PPI (Trifan et al., 2017). Also of note, the risk for CDI 
while on a PPI was not statistically different for adults 65 and older, compared to those 
younger (Trifan et al., 2017). Causality was not confirmed, as the studies in the meta-
analysis were all observational.  
Some chemotherapeutic agents may increase risk for CDI, but the literature is 
mixed regarding findings (Cozar-Llisto, Ramos-Martinez, & Cobo, 2016).  Body mass 
index (BMI) has recently been studied in association with severe CDI. A BMI greater 
than 35 kg/m
2
 was an independent predictor for severe presentation of CDI in both a 
community and hospital-acquired infection (Mulki et al., 2016). Any exposure to 
antibiotics has the potential to increase CDI risk, but common offenders include 
fluoroquinolones, broad-spectrum penicillins to include amoxicillin/clavulanate, 
clindamycin, and second and third generation cephalosporins (Clark & Wiselka, 2008; 
Hensgens, Goorhuis, Dekkers, & Kujper, 2012; Hessen, 2010; Keller & Surawicz, 2014). 
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Further classification of offending agents by tier was noted by Clark and Wiselka (2008), 
with clindamycin, second and third generation cephalosporins, penicillins, and 
quinolones as high risk; macrolides, tetracyclines, and aminoglycosides medium risk; and 
metronidazole and vancomycin as rare risk for CDI.  
Fluoroquinolones are associated with a specific strain of CDI most often seen in 
the older population, increasing recurrence rate and challenging to achieve remission 
(Keller & Surawicz, 2014; Surawicz et al., 2013).  Freedberg and colleagues examined 
the risk of CDI associated with sequential bed placement in patients (2016). Individuals 
who were placed in beds of those who had previously received antibiotics were at a 
statistically significant increased risk for development of CDI, after adjusting for 
comorbidity, CDI colonization of prior individual, type of room, and exposure to 
antibiotics in patient taking over the bed. CDI development could be a concern in patients 
who are occupying beds of those who previously received antibiotics, regardless of CDI 
exposure. This raises the concern for the shedding of spores from an asymptomatic 
patient thereby passed to a new individual who takes up residence in the room. 
Historically, asymptomatic carriage of Clostridium difficile has felt to be protective of the 
host developing CDI (Cozar-Llisto et al., 2016). Yet, colonization present prior to an 
intensive care admission was found to be an independent risk factor for development of 
CDI during hospitalization (Tschudin-Sutter et al., 2015).  
Furthermore, Behar and colleagues (2017) noted asymptomatic carriers compared 
to those who are non-carriers were more likely to have been hospitalized in the preceding 
three months, have had a prior diagnosis of symptomatic presentation for CDI, and had 
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higher Barthel scores and MUST scores (used as measurements to identify frailty for the 
study). The rate of asymptomatic Clostridium difficile colonization for hospitalized adults 
was found to be close to 10%, similar to other findings (Alasmari, Seiler, Hink, Burnham, 
& Dubberke, 2014; Behar et al., 2017; Bruminhent et al., 2014; Ziakas et al., 2015).  
Clinical Manifestations 
Clinical manifestations of CDI exist on a broad spectrum, ranging from 
unaffected carriers to a fulminant process leading to death. The most common 
characteristic of CDI is foul-smelling, watery diarrhea (Sams & Kennedy-Malone, 2017).  
Mild and moderate presentation of CDI may include the presence of diarrhea only, but 
other clinical manifestations may include abdominal discomfort and pain, nausea, and 
mild fever. In older adults, pyrexia may be an indication for severe CDI (Kee, 2012). 
Severe presentation is characterized by serum albumin less than 3 g/dL and either 
leukocytosis greater than 15,000 cells/mm or tender abdomen on physical exam 
(Surawicz et al., 2013). Severe and complicated presentation is characterized by at least 
one of the following indicators: intensive care hospital admission, hypotension, ileus, 
mental status changes, fever greater than 101.3º F, leukocytosis greater than 35,000 mm³ 
or leukopenia, serum lactate greater than 2.2 mmol/L, or organ failure (Surawicz et al., 
2013).  
Rectal bleeding is not common with CDI. Clinical signs that could lead to adverse 
outcomes include sudden diarrhea cessation, worsening renal function, and colonic 
dilatation on imaging studies. Upon physical exam, extreme tenderness to palpation 
should raise suspicion for possible megacolon or perforation. The older adult may present 
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in an atypical fashion, with acute confusion, mental status changes as an initial symptom 
(Kee, 2012). The older adult may be afebrile, with other non-specific symptoms to raise 
concern for infection to include loss of appetite, weight loss, weakness, falls, and 
decreased physical capacity (Kee, 2012). 
The incubation period of CDI is unclear but several studies have noted a time 
period of less than 1 week (Cohen et al., 2010; McDonald et al., 2007). The risk for CDI 
development may range from weeks to months after discharge. CDI within 4 weeks after 
hospitalization is felt to be hospital-acquired, whereas CDI after 4-12 weeks of a recent 
hospitalization is possibly linked with the prior hospitalization (Cohen et al., 2010). 
Treatment 
Hospitalization for supportive care is indicated for individuals with hypotension, 
multi-organ involvement, leukocytosis, pyrexia, dehydration, abdominal distension, and 
possible obstruction (Sams & Kennedy-Malone, 2017).  While inpatient, supportive care 
may include intravenous fluids, anti-emetics, pain control, and diet as tolerated depending 
on clinical presentation. Close monitoring of intake and output, stool frequency and 
characteristics, and serial laboratory monitoring are imperative to document clinical 
improvement or worsening of status (Sams & Kennedy-Malone, 2017). Contact isolation 
precautions should be instituted for those with suspected or confirmed CDI.  
The mainstay of pharmacological treatment for CDI includes metronidazole and 
vancomycin, but patients with diabetes and/or sepsis may be at risk for metronidazole 
treatment failure (Jung et al., 2010). An additional FDA approved antibiotic, 
Fidaxomicin, has shown similar effectiveness as vancomycin (Cornely et al., 2012; 
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Crawford, Husgen, & Danziger, 2012; Louie et al., 2012). Microflora has shown to be 
protected with Fidaxomicin, which translates to lower recurrence rates of CDI (Louie et 
al., 2012).  
         Metronidazole and vancomycin are preferred via oral rate; however, complicating 
features require alternate routes (Chopra & Krishna, 2014). Vancomycin colonic enemas 
may be required in complicated disease, as the intravenous rate is not highly effective 
(Chopra & Krishna, 2014). Fecal microbiota transplantation (FMT) is a promising and 
efficacious treatment for persistent and recurrent CDI (Yoon & Brandt, 2010; Musgrave, 
Bookstaver, Sutton, & Miller, 2011; Surawicz et al., 2013). Oral capsules containing 
frozen fecal microbiota have been studied for recurrent CDI, with CDI resolution in 82% 
of patients after single treatment and improvement to 91% curative rate after two 
treatments in a recent study by Youngster and colleagues (2016). 
   Treatment of choice for mild presentation of CDI was historically metronidazole; 
however, the Infectious Disease Society of America (IDSA) and Society for Healthcare 
Epidemiology of America (SHEA) updated guidelines advise vancomycin 125 mg orally 
four times a day for 10 days as initial treatment for non-severe of severe episode 
(McDonald et al., 2018). Fidaxomicin may also be used for initial non-severe or severe 
episodes. If neither vancomycin or fidaxomicin is available, metronidazole may be used 
500 mg orally three times a day for 10 days. Initial fulminant episode, characterized by 
hypotension, shock, ileus, or megacolon, should be treated with vancomycin 500 mg 
orally four times a day, metronidazole 500 mg intravenously every eight hours, and 
consideration of rectal vancomycin enemas if ileus or inability to tolerate oral medication 
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(McDonald et al., 2018; Surawicz et al., 2013). Recurrent infections are managed similar 
to first episode; repeated recurrences may require vancomycin in a pulse dosed fashion or 
tapering; fidaxomicin may also be considered if vancomycin was the initial treatment. 
Fecal microbiota transplants (FMT) are indicated after second and subsequent 
recurrences, showing promising results for longstanding resolution.  
  Thirty days following treatment of CDI is crucial, as the colonic flora has been 
disrupted, providing a window of time for potential recurrence and additional infection 
(Kelly, 2012). The treatment of CDI is with antibiotics, typically metronidazole or 
vancomycin, depending on severity of clinical presentation. Metronidazole and 
vancomycin both alter colonic flora, possibly contributing to the inability to resist 
recurrence or reinfection (Kelly, 2012). Diabetes and sepsis have been found to be 
independent factors for treatment failure (Jung et al., 2010) 
Diagnosis 
 Diagnosis of CDI may be challenging due to multiple tests available. CDI is 
confirmed through stool sample, with multiple laboratory tests available to include C. 
difficile culture, toxigenic culture, C. difficile cytotoxin neutralization assay, enzyme 
immunoassays (EIAs) that detect toxins A and B or glutamate dehydrogenase (GDH), 
and nucleic acid amplification tests (NAAT) (Sethi et al., 2010; Surawicz et al., 2013).   
A two-step algorithm is recommended, whereby a GDH EIA or NAAT is used first, 
which both have a higher negative predictive value; the second step in the algorithm 
includes a high positive predictive value test, which would be the EIA toxin A/B, which 
identify free toxin (Cronbach et al., 2016). If the original NAAT or GDH EIA are 
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negative, CDI is highly unlikely. However, if the NAAT or GDH EIA are positive, a 
positive EIA toxin A/B would indicate likely CDI but a negative test would require 
clinical expertise. In this scenario, the individual could be a carrier. In complicated cases 
such as an ileus, rectal swabs may be used and tested via NAAT, TC, or GDH EIA 
(Cronbach et al., 2016). The decision to treat lies with the provider, as diagnostic testing 
requires the art of interpretation. Repeat testing for cure of CDI is not indicated. 
Risk Factors for Mortality in CDI 
Risk factors for 30-day mortality in the older adult include a high comorbidity 
burden as measured by Charlson comorbidity index, diabetes, hypoalbuminemia with 
albumin 2.5 g/dL or less, elevated creatinine, low hemoglobin, low diastolic blood 
pressure, sepsis upon initial presentation with CDI (Leibovici-Weissman et al., 2017). 
Chintanaboina and colleagues had similar findings with predictors of 30-day mortality 
including Charlson comorbidity index (2017). However, advanced age, PUD, heart 
failure, recurrent CDI, histamine-2 receptor blocker usage, and intensive care admission 
were significantly associated with a 30-day mortality in the population sample studied; 
yet, this sample included ages 18 and older, with a mean age of 62 years. There was no 
significant association between recurrent CDI and 30-day mortality noted (Chintanaboina 
et al., 2017).  
Clostridium difficile and Frailty 
      The review of current literature provides limited information regarding the 
specific relationship between frailty and CDI. The focus of current CDI research includes 
fecal microbiota, functional deficits, age-related factors, and attempts to explain risk 
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factors for recurrence in the older adult. Understanding of the potential relationship 
between CDI and frailty is further explored by reviewing the literature involving prior 
frailty measurements with CDI, functional status and CDI, and co-morbidity relationships 
with recurrent CDI.  
Frailty Measurements with CDI  
The relationship between the intestinal microbiota and frailty is emerging as a 
topic of interest, but further research is needed. Intestinal flora plays a role in formation 
and excretion of important vitamins for the body, prevents harmful pathogens from 
colonizing in the GI system, aids in metabolism, and encourages immune and lymphatic 
systems (Biedermann & Rogler, 2015). The digestive pathway from the esophagus to the 
rectum holds different amounts of bacteria, starting with a lower amount in the esophagus 
and stomach, leading to a more concentrated bacterium in the terminal ileum and colon 
(Biedermann & Rogler, 2015).  
Microbiota was not designed to enter the actual body, and the intestinal 
epithelium provides a first-line defense by acting as a protective barrier; other factors to 
keep bacteria at bay include gut motility, mucin and chloride secretion by goblet cells, 
and defensins, which are “human antibiotics” (Biedermann & Rogler, 2015, p 153).  
Finally, the last line of defense occurs when a battle is fought between healthy and 
pathogenic bacteria, with imbalance in the flora allowing a pathway for bacterial invasion 
and acute illness (Biedermann & Rogler, 2015). CDI is an example of a pathogenic 
bacteria taking up residence in the GI system due to dysbiosis.  
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It is known that older adult microbiota composition is different than younger 
individuals (Claesson et al., 2011; Mariat et al., 2009; Meehan, Langille, & Beiko, 2015). 
The bacterial composition of the gastrointestinal tract has been shown to be affected by 
many entities to include physiological, dietary, environment, microbiological, and host 
factors (Tongeren, Slaets, Harmsen, Welling, 2005). The microbiota composition may 
change as the human body ages, and it is affected by mobility, nutrition, and psychosocial 
stressors (Biedermann & Rogler, 2015; Tongeren et al., 2005). When CDI is treated with 
antibiotics, healthy bacterial flora is also affected, potentially resulting in a cascade effect 
of dysbiosis (Meehan et al., 2015). Further research is needed to determine the etiology 
of this phenomenon, with potential factors including physiological reasons or additive 
changes over the lifespan (Biedermann & Rogler, 2015). Possible signatures of frailty 
found with microbiomes has been posited by frailty experts, with a call to further 
research of the microbiome (Meehan et al., 2015).  
Milani et al. (2016) investigated the composition of gut microbiota in three 
cohorts of older adults, measuring frailty using the Clinical Frailty scale by Rockwood 
(Rockwood et al., 2005). The cohorts were divided into hospital-acquired CDI group, 
antibiotic-exposed group without CDI, and non-antibiotic exposed group without CDI. 
This sample was comprised of hospitalized adults older than age 65, more than two 
comorbidities, and hospitalized secondary to an illness other than gastrointestinal 
etiology. The frailty scores across the group were similar, without statistical significance 
noted. As this was a cross-sectional study, repeated frailty measures were not undertaken, 
and the implication of the frailty score was unable to be determined. However, findings 
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of altered gut microbiota were noted in those with CDI, which is a known 
pathophysiologic process during this infection. A similar finding regarding frailty scores 
between a CDI group and control group was noted in a separate study (Van Esch, Van 
Broeck, Delmée, & Catry, 2015). Van Esch et al. (2015) used a frailty index previously 
created by Drubbel et al. (2012) for the outpatient setting. No statistical difference was 
noted in frailty index scores between the two groups, nor were there any differences in 
BMI and mini mental status examination scores.  However, total protein and prealbumin 
in the CDI group was significantly lower compared to the control group without CDI. 
Interestingly, hypoalbuminemia has been linked with frailty (Kim, Higgins, Canaday, 
Burant & Hornick, 2014; McMillan & Hubbard, 2012). 
Jackson et al. (2016) utilized fecal samples to further investigate microbiota and 
its association with frailty. By creating a frailty index by Rockwood, 39 domains were 
used to create a proportion of deficits (Jackson et al., 2016). Data from the Healthy Aging 
Twin Study was used to assess frailty indices and correlation with fecal samples 
containing microbiota (Jackson et al., 2016). After adjusting for age, alcohol intake, 
dietary habits, smoking, and BMI, frailty was negatively associated with microbiota 
diversity, indicating that higher frailty indices were linked with less diverse microbiota 
present in the gut (Jackson et al., 2016). These findings do not establish frailty as a cause 
or effect related to microbiota diversity; however, the authors relay that imbalance of 
intestinal flora may have negative effects on the overall health of these frail individuals. 
Higher frailty scores and reduced health flora was demonstrated by Tongeren et 
al. (2005). The Groningen Frailty Indicator (GFI) was used as a measurement of frailty, 
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with high frailty scores correlating with statistically significant reduced amount of 
lactobacilli (Tongeren et al., 2005). Lactobacilli is vital in immunological functions, 
assisting with digestion and absorption, and thwarts growth of harmful bacteria that may 
be present in the gut (Tongeren et al., 2005). Older adults with high frailty scores from 
the GFI also exhibited a statistically significant reduced percentage of hybridizable 
bacteria, meaning the overall bacterial flora was reduced in the GI tract (Tongeren et al., 
2005). Interestingly, the sample was provided the same dietary menu during the study, 
had no exposure to antibiotics during the study or at least four weeks prior, and were 70 
to 100 years old (Tongeren et al., 2005). Although this study does not include CDI 
exposure, the intestinal flora is examined, which is already known to be altered in 
individuals with CDI.  
Behar and colleagues (2017), studied the prevalence of asymptomatic carriage of 
Clostridium difficile and discussed risk factors for colonization. The study used the 
MUST score (malnutrition measurement) and Barthel score (activities of daily living) to 
assess frailty (Behar et al., 2017). The patients were inpatient and recruited if over age 18 
and no current diagnosis of CDI. Stool samples were collected on admission and weekly 
while hospitalized. Stool samples were assessed for toxin A, B, and PCR. The sample 
size was 727, with 410 testing positive for Clostridium difficile. Of the 410 who had 
positive stool samples, 9.8% were carriers. Participants who were carriers had a higher 
likelihood of prior CDI and were more frail compared to non-carriers. PPI was not 
associated with colonization (Behar et al., 2017). Mortality amongst the carriers was 
predicted by male gender, prior admission from a residential facility, increased co-
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morbidities, and malnutrition as characterized by the MUST score, which was used to 
measure frailty in this population.  
A modified frailty index (mFI) was used to identify frailty in patients who had 
undergone colectomy for CDI due to complicating/severe features (Venkat, Telemi, 
Oleksandr, & Nfonsam, 2016). A total of 356 patients had a total colectomy, with 127 
patients undergoing partial colectomy; as the frailty index score increased, so did 
morbidity. The mFI independently predicted overall morbidity and mortality in this 
patient population (Venkat et al., 2016).  
Functional Status and CDI 
Functional status and severe CDI was explored by Kyne and colleagues (1999), 
by utilizing Barthel scores as a measurement for functional status. Severe CDI was 
associated with lower Barthel scores; however, these scores were not included in the final 
statistical modeling with multivariate logistic regression. Instead, an abbreviated mental 
test was used in place of the Barthel score, as both correlated with each other.  
A study by Rao et al. (2013) investigating functional status and severity of CDI 
was undertaken to further explore what had previously been evaluated by Kyne and 
authors years before. Although frailty was not directly studied, the authors found that 
impaired functional status was actually an independent risk factor for CDI after adjusting 
for possible co-founding variables of comorbidities, immunosuppression, and acid 
suppression therapy. Behar and colleagues (2017) studied Clostridium difficile 
colonization in older adults, using the Barthel score (a measurement of activities of daily 
living), Waterlow score (risk of pressure ulcers), and MUST scores (risk of malnutrition) 
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to identify frailty. Carriers of the bacteria were more likely to have higher MUST and 
Barthel scores (p=0.001 and 0.036, respectively), which coincided with frailty as per 
study definitions.  
CDI Recurrence 
The knowledge gaps involving the relationship between frailty and CDI are 
numerous. The risk of CDI recurrence in the elderly is greater than the general 
population, but age alone has been found insufficient as explaining the higher risk of 
recurrence in the elderly. This was demonstrated by a retrospective national review of 
Medicare patients ages 65 and older (Collins et al., 2015). During the years 2009-2011, 
the ICD-9 code for CDI (008.45) was used as a marker to identify patients admitted to 
acute care facilities with a primary or secondary diagnosis of CDI. Patients were further 
separated into community-acquired and healthcare-acquired groupings. Readmission was 
defined by any second admission to an acute facility with CDI as a primary diagnosis, but 
nursing homes and long-term care facilities were excluded. 
In this study, patients were usually readmitted within one month after the initial 
discharge. The readmissions had low mortality rates but 1 in 5 required intensive care 
monitoring during the second hospitalization (Collins et al., 2015). Of those patients 
readmitted, 20% were admitted an additional time, which confirms the risk of increased 
recurrence with each CDI event. This study did not find a statistically significant risk of 
readmission related to increased age. This research confirmed that although older adults 
are at risk for recurrence, chronological age does not completely explain this 
phenomenon.  
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D’ Agostino, Collins, Pencina, Kean, and Gorbach (2014), developed a predictive 
model to evaluate the risk of recurrence for CDI. Multiple factors to include 
demographics, comorbidity, medications, vital signs, laboratory findings, severity of 
disease, and symptoms were placed into a logistic regression model. Four independent 
risk factors were identified as statistically significant as predictors for recurrence 
(D’Agostino et al., 2014). Predictors included dichotomous variables of age (greater than 
or less than 75), number of loose bowel movements in the past 24 hours (greater than 10 
or less than 10), baseline serum creatinine (greater than 1.2 mg/dL or less than 
1.2mg/dL), and a prior occurrence of CDI (yes or no) (Agostino et al., 2014).  
In another study, the relationship between CDI and multiple co-morbidities was 
explored using a Cumulative Illness Rating Scale (CIRS) (Ticinesi et al., 2015). The 
findings showed that only the highest quartile of scoring on the CIRS was significantly 
associated with risk for CDI (Ticinesi et al., 2015). This study was limited due to 
retrospective qualities, and the use of anti-depressants, narcotic therapy, and functional 
status was not explored as possible cofounding variables (Ticinesi et al., 2015).  
CDI and Mortality 
Additional knowledge gaps reside in the mortality surrounding CDI. A 
prospective study over one year in a large community hospital in Austria supported the 
risk of death with CDI and hospitalized patients. The findings noted that regardless of 
age, sex, or co-morbidity severity, patients with CDI were twice as likely to die during 
hospitalization compared to other hospitalized patients (Wenisch et al., 2012). Differing 
findings were noted in a systematic review by Bloomfield et al (2012), as the authors 
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identified age as a marker for mortality with CDI for hospitalized patients. This review 
found that white blood cells, serum creatinine levels, and serum albumin levels were 
markers for mortality secondary to CDI (Bloomfield et al., 2012). The presence of prior 
corticosteroids was raised as a possibility to be utilized as a risk factor for adverse 
outcomes in CDI. 
Summary  
The topic of frailty, CDI, and the older adult is sparse and needs further 
evaluation with repeated measures of frailty.  Several studies called for dedicated 
research regarding frailty and CDI, but this remains a knowledge gap that needs to be 
bridged. Some potential factors were identified as risk factors for recurrence in CDI. 
Further research should evaluate whether these factors are independently operating or 
synergistic in nature with the presence of CDI. Chronological age alone is unreliable in 
the recurrence of CDI (Collins et al., 2015). The presence of comorbidities alone does not 
explain the recurrence or severity of CDI (Wenisch et al., 2012). Finally, the constant 
factor that is known surrounding CDI is the leading independent role that antibiotics play. 
The intestinal microbiota may be an area that deserves further research, as the treatment 
for CDI alters colonic flora, leading to dysbiosis and decreased defenses against risk of 
recurrence.  
The Accumulation of Deficits approach with frailty index has been used in 
multiple studies to include outpatient care, elective hospital surgical admissions, long-
term care facilities, and community research.  Exploration of the syndrome with the 
frailty index has been used in descriptive studies, frailty and falls, delirium, mobility, and 
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fractures (Dent, Chapman, Howell, Piantadosi, Visvanathan, 2014; Eeles, White, 
O’Mahony, Bayer, & Hubbard, 2012; Hatheway et al., 2017; Joseph et al., 2015; 
Krishnan et al., 2014; Patel, Brennan, Brennan, Jupiter, Shar, & Davis, 2014; Ridda, 
Lindley, & MacIntyre, 2008). Adverse outcomes related to frailty and rehab (Singh et al., 
2012), assessment of predictive validity of a frailty index related to discharge, length of 
stay, and mortality (Evans et al., 2014), and comparison of the frailty index to other tools 
was explored (van Iersel & Rikkert, 2006; Ritt et al., 2016; Wou et al., 2013).  Multiple 
studies have explored frailty using a modified index in relation to elective procedures 
such as colorectal surgery, esophagectomy, head and neck surgery, vascular surgery, 
tracheostomy, and gynecological surgery (Adams et al.,2013; Brahmbatt et al., 2015; 
Farhat et al., 2012; George et al., 2015; Johnson, Bailey, Schmid, Lydiatt, & Johanning, 
2014; Hodari, Hammoud, Borgi, Tsiouris, & Rubinfield, 2013;  Karam, Tsiouris, 
Shepard, Velanovich, & Rubinfeld, 2013; Keller, Bankwitz, Nobel, & Delaney, 2014; 
Obeid et al., 2012).  Although the frailty index has been used with a population having 
CDI (Van Esche et al., 2015; Venkat et al., 2016), the literature is sparse regarding 
measurement of frailty and CDI in this patient population.  
 The relationship between frailty and CDI in the hospitalized older adult deserves 
further exploration. Frailty is a dynamic entity, and further research following hospital 
admission and recurrent CDI is lacking in the literature. The Accumulation of Deficits 
framework and model proposed in Chapter I was used to guide this study. As prior 
evidence has shown, the presence of frailty, as operationalized by the frailty index, will 
affect recovery time in an individual. The environmental stressor of CDI is hypothesized 
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to adversely affect a compromised system, ultimately leading to adverse outcomes to 
include readmission for recurrent CDI, morbidity, and mortality.  Recognition of frailty 
in the older adult is vital in the inpatient setting, with this research addressing a known 
knowledge gap surrounding the relationship between CDI and the older adult, utilizing 
the Accumulation of Deficits framework as a guide throughout the study.  
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CHAPTER III 
METHODOLOGY
 
The purpose of this study was to explore the relationship between frailty in older 
adults and the recurrence of CDI. The literature supports the risk of recurrence and severe 
CDI more prevalent in adults over the age of 65 (Keller & Surawicz, 2014; Louie et al., 
2013; Surawicz et al, 2013). Frailty is also associated with hospitalization and even death 
(Fried et al., 2001; Mitnitski et al., 2001). Details regarding the research design, setting, 
research procedures, measurements, data analyses, and power and sample size are 
described.  
Design 
By using a retrospective cohort design, an analysis of existing data from 
electronic medical records was undertaken exploring the relationship between frailty in 
the older adult and recurrent CDI. The electronic medical record system provided 
demographic information, documented admissions, progress notes, laboratory studies, 
radiological data, and vital health history for each individual who was admitted through 
the hospital system in North Carolina.  This analysis examined the association between 
frailty and CDI, specifically the presence of frailty during an index admission for CDI 
and readmission for recurrent CDI over the span of one year.  
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Setting 
The setting for this research included three hospitals belonging to a large hospital 
system in North Carolina. The hospital system serves the triad region and surrounding 12 
counties and 1.6 million people (Piedmont Triad Regional Council, 2012).  
Sample 
Inclusion criteria consisted of a) age 55 and older, b) diagnosis of CDI via ICD-9 
code 008.45 and ICD 10 code A04.7 and c) inpatient hospitalization. Exclusion criteria 
consisted of any observation admission less than 24 hours. The target population dates 
included December 31, 2013 through December 31, 2015. The EHR was electronically 
queried for health system inpatient admissions from December 31, 2012 through 
December 31, 2016, capturing any admission or discharge ICD codes for CDI for the 
specified timeframe. The recurrence of CDI was ensured by a review of each index 
admission and any prior admissions from that point that could potentially be the initial 
admission. Each patient was followed for a year, to capture recurrence after initial 
admission; therefore, the cutoff date of query was December 31, 2016, ensuring any 
patients that were admitted during the inclusion timeframe were followed an entire year.  
Additionally, patients captured at the beginning of December 31, 2013 were reviewed for 
any prior admissions the year before, ensuring the true index admission was captured.. 
The minimum age of 55 was selected as chronologically advanced years do not equate to 
frailty (Morley et al., 2013), and hospitalization of the older adult with physiologic 
abnormal underpinnings that propel the pathway of frailty (Maxwell & Wang, 2017). The 
majority of frailty research in the hospitalized older adult focuses on those ages 65 and 
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older (Afilalo et al., 2012; Dent et al., 2014; Eeles et al., 2012; Evans et al., 2014; Joseph 
et al., 2015; Krishnan et al., 2014; Purser et al., 2006). Components of frailty may be 
present in middle-age adults (Pol et al., 2011) Although the literature supports recurrence 
within one to three weeks after antibiotic completion (Chopra & Krishna, 2014; Schmid 
et al., 2014), the timeframe of one year was reviewed in order to capture any repeat 
admissions for CDI, as development may occur months after discharge (Cohen et al., 
2010).  
Human Subjects Protection 
The Institutional Review Board (IRB) guidelines at the University of North 
Carolina at Greensboro (UNCG) and hospital system were reviewed and followed during 
this study. Full application for IRB approval was submitted first to UNCG for approval. 
Once approved, this was submitted to the hospital’s nursing research council, per 
protocol. IRB approval was then submitted and received by the hospital system.  A Data 
Use Agreement was obtained per the hospital system policy and agreed upon by UNCG 
and the hospital system prior to data collection. De-identified data were stored in a safe, 
password protected system, following HIPPA compliant guidelines and accessed via a 
virtual desktop that was created by the hospital system for research purposes.  
Data Collection 
The data were extracted from the medical record by approved personnel at the 
hospital system. A consolidated database was created using data obtained from the EHR. 
ICD-9 and ICD-10 codes were used as identifiers of Clostridium difficile infection-
related admissions. The diagnosis codes for admission and discharge were included in the 
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report request, as individuals admitted for hospitalization may not have the diagnosis of 
CDI at time of admission, and, CDI may occur during hospital stay. Specific dates that 
corresponded to laboratory results included in the frailty index were derived in the study 
database.   As stool tests require time to collection and reporting of results, including the 
final discharge diagnosis identified individuals with CDI. In addition, diagnosis of CDI 
may not occur on initial day of admission, as healthcare providers use clinical judgment 
when interpreting stool test results, assessing patients, and identifying signs and 
symptoms of potential CDI if stool tests are inconclusive. No personal identifiers were 
included with each grouping of individual data.  
Hospital approved personnel transferred the data to the virtual desktop for data 
analyses and followed privacy laws. Randomized data audits were performed, ensuring 
the accuracy of data input.  
Measurements 
Basic demographic information was extracted from the medical record. This 
information had no personal identifying information. These variables are recorded on 
admission in the electronic medical record by nursing personnel, staff, and providers and 
located in Table 2. This demographic information was routinely captured on admission, 
with static measurements of sex, ethnicity, and race unchanging. Place of residence, 
living arrangements, and marital status was assumed unchanged during the hospital 
admission, as these are present prior to admission.  PPI use prior to admission was 
captured, which is documented on outpatient medication record at time of admission. 
These medications included omeprazole (Prilosec), pantoprazole (Protonix), 
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esomeprazole (Nexium), dexlansoprazole (Dexilant), rabeprazole (Aciphex), 
lansoprazole (Prevacid) and omeprazole/sodium bicarbonate (Zegerid). PPI use was 
coded as “0” for no PPI use and “1” for PPI prescription on admission.  
Clostridium difficile infection was defined by the presence of ICD- 9 codes and 
ICD-10 codes identified either on admission or as a discharge diagnosis. At times, a 
hospitalization evolves as the database on a patient expands, and CDI diagnosis may be 
obtained several days into a hospital admission. For purposes of this study, CDI was not 
classified as hospital-acquired or community-acquired, as the research focus is regarding 
frailty and the presence of CDI leading to a recurrence after hospitalization. The ICD-9 
and ICD-10 codes are applied to the medical record once a diagnosis of CDI is confirmed 
via stool specimens during the hospitalization or at the discretion of the provider after 
review of clinical presentation, signs, and symptoms. The most widely used stool 
specimen during this timeframe was a Clostridium difficile polymerase chain reaction 
(PCR), defined as positive or negative in the medical record. An additional test for CDI 
for this timeframe could include stool samples for the presence of toxins A or B.  
An initial admission was documented, with review of the medical record within 
the defined study period to ensure no previous admission for CDI was present. Once the 
initial admission was verified, the frailty index scores were created from the initial 
admission data, using the components for the frailty index as outlined in Table 3. The 
frailty index score was calculated by dividing the total number of deficits present in an 
individual by the total number of variables measured in the frailty index (36 in this 
study). Each frailty deficit component in the frailty index was coded into “0” for absent 
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or “1” for present.  For laboratory indices, abnormal values derived from the literature 
were coded as “1”, with normal laboratory values coded as “0”, as defined in Table 3.  
Health conditions were coded into “0” or “1”, corresponding to absent or present, 
respectively. Smoking status was documented with choices of “current every day 
smoker”, “current some day smoker”, “former smoker”, “heavy tobacco smoker”, “light 
tobacco smoker”, “never assessed”, “never smoker”, “passive smoke exposure”, and 
“smoker status unknown”. A value of “0” was given if “never assessed”, “never smoker”, 
and “smoker status unknown” and “1” otherwise. The psychosocial item of the frailty 
index included support system, physical abuse, verbal abuse, sexual abuse, and self-
neglect as outlined in Table 3. A code of “0” was given if patient denied any physical, 
verbal, or sexual abuse, and denied self-neglect. Support system was coded as “1” if no 
support system was identified.   
Decreased mobility was documented on admission with choices to include: 
completely immobile, very limited, slightly limited, and no limitation. A “0” was coded if 
“no limitation”, and a “1” otherwise. The decreased mobility component was documented 
by healthcare personnel as part of the Braden scale questionnaire, as this was the clearest 
information to obtain on mobility in the medical record in a retrospective fashion.  The 
total Braden score was included in the frailty index, with a score of 18 or less determined 
as at risk for pressure ulcers, consistent with recommendations in the literature 
(Bergstrom & Braden, 2002). The Braden score of 18 or less was coded as a “1”.  
Fall risk was documented in the medical record on admission by hospital staff, 
utilizing the Johns Hopkins Fall Risk Assessment and including variables of age, fall 
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history, bowel and urine elimination, medications, patient care equipment, mobility, and 
cognition. Scores included low fall risk (0-5 points), moderate (6-13 points), and high fall 
risk (greater than 13 points). A low fall risk was coded as “0”, otherwise “1”. Full outline 
of the frailty index with definitions is located in Table 3.  As medical record 
documentation may contain multiple choices, coding of variables absent or present may 
be difficult. Searle and colleagues stated clinical judgment could be employed if no 
identified “cut-off” points are present. Clinical judgment was utilized in this study, as 
noted in coding of variables.  
Frailty Index 
The frailty index was derived systematically according to the guidelines set forth 
by Searle and colleagues (2008). The deficits included in the frailty index may include 
symptoms, signs, diseases, disabilities, laboratory abnormalities, radiographic or 
electrocardiographic findings. Any deficits included in an FI should meet strict criteria to 
include deficits associated with health, increases with age, should not saturate early such 
as a deficit that is commonly present early in the aging process, should cover a 
representation of organ systems and not only associated with one system, and items 
should be used the same on each individual in the cohort applied so that the measurement 
is the same universally.  
Including a wide representation of organ systems in a frailty index helps to take 
into account the natural aging process (Howlett & Rockwood, 2013). Individuals, despite 
their age, may vary in the level of function for each organ system. By utilizing laboratory 
tests, possible abnormalities may be assessed prior to actual organ dysfunction, which 
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could give rise to frailty (Howlett &Rockwood, 2013). Howlett et al. (2014) used a frailty 
index consisting of routine laboratory findings that showed predictive validity in relation 
to risk of mortality. Further support for laboratory markers included in a frailty index was 
demonstrated by Blodgett and colleagues, noting that even with small laboratory changes 
accumulating together can increase risk of mortality (2017).  For purposes of this 
research, the frailty index was created by following the guidelines set forth by Searle et 
al. (2008) and including laboratory measurements are discussed.  
Development of frailty index. The frailty index for this study included 36 
components. Clinical laboratory markers, diseases, disabilities, psychosocial variables, 
and polypharmacy were included as deficits. Laboratory markers included in this frailty 
index were as follows: Albumin, ALT, alkaline phosphatase, hemoglobin, creatinine, 
BUN, white blood cell count (WBC), glucose, sodium, and platelets. These were 
gathered due to known association with frailty, as outlined in Chapter 2. Chronic diseases 
included Vitamin D deficiency, arthritis, hypertension, stroke, cancer, diabetes mellitus 
(Type 1 and 2), COPD, asthma, BMI (<18 or >30), chronic kidney disease, depression, 
dementia, heart failure, and smoking status. Disability in functional status and activities 
of daily living was assessed by decreased mobility, independently performing ADLs, 
total Braden scale, incontinence, presence of falls within past 6 months, fall risk, and 
polypharmacy. Finally, psychosocial variables included support system, physical abuse, 
verbal abuse, sexual abuse, and self-neglect.  These variables were chosen based on 
review of the literature as discussed in Chapter I and II, further outlined in the following 
table.  
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Table 3. Frailty Index for Older Adults with CDI (FI-CDI) 
Variable Positive Frailty Definition Supportive Evidence 
Laboratory   
   Albumin less than 3 g/dL Kim et al., 2014 
McMillan & Hubbard, 
2012 
Mitnitski et al., 2015 
   ALT <17 or >30 U/L Liu et al., 2014 
   Alkaline phosphatase >140 U/L Frith et al., 2009 
   Hemoglobin <11.5 g/dL (male) 
< 11.0 g/dL (female) 
Chaves et al., 2005 
Mitnitski et al., 2015 
Ng et al., 2014 
   Creatinine >1.2 mg/dL Howlett et al., 2014 
Ng et al., 2014 
   BUN >28 mg/dL Howlett et al., 2014 
Ng et al., 2014 
   WBC count  
    
<3 or >9 K/uL Fontana et al., 2013 
Kanapuru & Ershler, 2009 
Mitnitski et al., 2015 
   Glucose <70 or >120 mg/dL Fontana et al., 2013 
Zaslavsky et al., 2016 
   Sodium <135 or >145 mmol/L Morley, 2015 
   Platelets <150 or >400 K/uL Mitnitski et al., 2015 
Chronic Diseases   
   Vitamin D deficiency ICD-9 268  
ICD-10 E55 
FernÃ¡ndez-Garrido et al., 
2014 
   Arthritis ICD-9 715.0 
ICD-10 M15-M19 
Cacciatore et al., 2014 
   Hypertension ICD-9 401 
ICD-10 110-116 
Theou et al., 2015 
   Stroke ICD-9 430-438 
ICD-10 I60-I69 
Ng et al., 2014 
   Cancer ICD-9 140-239 
ICD-10 C00-D49 
Pérez-Zepeda et al., 2016 
   Diabetes mellitus 
   (Type 1 and Type 2) 
ICD-9 250 
ICD-10 E08-E13 
Sinclair et al., 2012 
Ulley & Abdelhafiz, 2017  
   COPD ICD-9 491, 491.2, 492 
ICD 10 J44 
Galizia et al., 2011 
Ng et al., 2014 
   Asthma ICD-9 493 
ICD 10 J45 
Ng et al., 2014 
   BMI <18 or >30 Cooper et al., 2012 
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Variable Positive Frailty Definition Supportive Evidence 
Waters et al., 2013 
   Chronic Kidney   
   Disease 
ICD-9 585 
ICD-10 N18 
Shilpak et al., 2004 
   Depression ICD-9 311 
ICD-10 F32.9 
Almedia et al., 2014 
King et al., 2017 
Makizako et al., 2014 
Ng et al., 2014 
   Dementia ICD-9 290 
ICD-10 F03.90 
Boyle et al., 2010 
Clegg et al., 2013 
Rockwood et al., 2005 
   Heart Failure ICD-9 428 
ICD-10 I50-50.9 
Afilalo, 2011 
Ng et al., 2014 
   Smoking Status Smoker status unknown (0) 
Never assessed (0) 
Never smoker (0) 
Current every day smoker (1) 
Current some day smoker (1) 
Former smoker (1) 
Heavy tobacco smoker (1) 
Light tobacco smoker (1) 
Passive smoke exposure (1) 
 
Kojima, Iliffe, Jivraj, 
Liljas, & Walters, 2017 
Ulley & Abdelhafiz, 2017  
 
Functional Status and 
Activity of Daily Living 
  
   Decreased Mobility No limitation (0) 
Completely immobile (1) 
Very limited (1) 
Slightly limited (1) 
 
Bandeen-Roche et al., 
2006 
Hatheway et al., 2017 
Sanchez-Garcia et al., 
2017 
   Independently  
   performs ADLs 
Yes (0) or no (1) Sanchez-Garcia et al., 
2017 
 
   Braden Scale Score 18 or less (1) Bergstrom & Braden, 
2002  
Ogg, 2016 
   Urinary Incontinence Yes (0) or no (1) Berardelli et al., 2013 
   Falls Yes (1) or no (0)within past 
6 months 
Li et al., 2014 
Liu et al., 2016 
Sanchez-Garcia et al., 
2017 
 
   Fall Risk 
   (Johns Hopkins Fall 
Low fall risk (0) 
Moderate (1) 
Li et al., 2014 
Liu et al., 2016 
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Variable Positive Frailty Definition Supportive Evidence 
   Risk Assessment) High fall risk (1) Sanchez-Garcia et al., 
2017 
 
   Polypharmacy Patient takes 7 or more 
medications at time of 
admission (1)  
Inouye, 1998 
McMillian & Hubbard, 
2012 
Morley et al., 2013 
Rolland & Morley, 2016 
Shapiro et al., 2017  
Psychosocial    
   Support System Spouse/significant other, 
children, parent, other 
relatives, friends/neighbors, 
church/faith community, 
home care staff, case 
manager/social worker, 
organized support group, 
shelter, therapist (0) 
None (1)  
Hoogendijk et al., 2014 
Ng et al., 2014 
   Physical Abuse Denies (0) 
Denies and provider 
concerned (1) 
Yes in past (1) 
Yes in present (1)  
Cooper et al., 2008 
Johannesen & LoGiudice, 
2013 
 
   Verbal Abuse Denies (0) 
Denies and provider 
concerned (1) 
Yes in past (1) 
Yes in present (1) 
Cooper et al., 2008 
Johannesen & LoGiudice, 
2013 
 
   Sexual Abuse Denies (0) 
Denies and provider 
concerned (1) 
Yes in past (1) 
Yes in present (1) 
Cooper et al., 2008 
Johannesen & LoGiudice, 
2013 
 
   Self-Neglect Denies (0) 
Denies and provider 
concerned (1) 
Yes in past (1) 
Yes in present (1) 
J. Lee et al., 2016  
Papaioannou et al., 2012 
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Laboratory reference ranges were chosen based on the known age-related changes 
that occur in the older adult. Reference ranges from standard laboratories are routinely 
derived from sampling well, younger individuals (Edwards & Baird, 2005). Therefore, 
the laboratory markers in this study were defined according to known changes that occur 
with the aging process, so as to more precisely identify any subtle changes that could be 
occurring in this population.  Albumin levels will decline each decade after the age of 60, 
so this will be slightly more decreased than a younger counterpart (Beers & Berkow, 
2000).  ALT levels in ages 65 and older tend to be lower than those of younger adults 
(Kelso, 1990), and alkaline phosphatase increased with age and is linked with 
malabsorption, bone abnormalities, and liver and kidney abnormalities (Brigden & 
Heathcote, 2000).  Hemoglobin and hematocrit may trend lower in the older adult for 
numerous reasons to include but not limited to anemia, chronic blood loss, renal 
insufficiency, nutritional inadequacy, and other chronic conditions (Edwards & Baird, 
2005). Likewise, an increase in hemoglobin and hematocrit above normal would be 
concerning for dehydration.  
As the adult ages, the BUN and creatinine will stay fairly close to standardized 
normal values; this is explained by reduced lean body mass and other factors that affect 
decreased BUN and creatinine (Brigden & Heathcote, 2000).  Although lower white 
blood cell counts should not be attributed to age alone, immunity does slowly decline 
after the third decade of life (Rybka et al., 2003).  Decreased WBC counts could indicate 
disease, infections/sepsis, medications, and increased WBC counts may indicate acute 
infection or stress response. Glucose ranges are wider for the older adult, and the serum 
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glucose levels slowly increase with age, yet glucose tolerance decreases (Edwards & 
Baird, 2005).  Platelet function may be affected by age; however, the normal range value 
is not significantly changed in older adults when compared to younger counterparts 
(Brigden & Heathcote, 2000).  
Although the frailty index score can be placed as a trichotomous variable (frail, 
pre-frail, and not frail or pre-frail), the use of a continuous frailty score has been 
recommended for more robust outcomes and higher statistical power (Theou & 
Rockwood, 2015). Operationalizing the definition of frailty is through the frailty index 
(Mitnitski, Mogilner, & Rockwood, 2001). The trajectory to frailty may be different for 
each individual, so multiple items that are linked with frailty may be used in a frailty 
index (Theou et al., 2015). A minimum of 30 deficits is estimated to be sufficient for 
appropriate estimation of frailty (Rockwood & Mitnitski, 2011).  
The frailty index, even with varying deficits included in various indices, has noted 
an overall consistent average of 0.03 deficits accumulated per year after age 70 (Theou et 
al., 2015). A threshold has been consistently shown, whereby the most that any one 
individual will have in deficits equals ⅔ of the total deficits, approximately a score of 0.7 
(Rockwood & Mitniski, 2007; Theou et al., 2015). Recent literature has supported an 
even lower limit of 0.5 (Armstrong, Mitnitski, Launer, White, & Rockwood, 2015). The 
threshold between fit and frail has been described as 0.25, with lower scores identifying 
fit and higher identifying frail (Hubbard et al., 2017).  
Criterion validity. The FI has been shown to predict adverse outcomes in 
relation to frailty (Drubbel et al., 2014; Rockwood, 2005). The FI has been used primarily 
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in the outpatient setting extensively. A review by Drubbel et al. (2014) noted criterion 
validity was upheld in multiple studies that used the FI to predict mortality, 
hospitalization, length of hospital stay, emergency care, falls and fractures, changes in 
activities of daily living, and mental status changes. After adjusting for age, gender, and 
other comorbidities, the FI appropriately predicted these adverse outcomes. The FI has 
also been found to better predict risk of mortality in the older adult population versus the 
frailty phenotype (Kulminski et al., 2008). The FI helps to define frailty differences in 
people of similar ages, which can raise awareness for likely development of adverse 
outcomes (Drubbel et al., 2014).  
Construct validity. The FI has noted strength of correlation with the Consolice 
Study of Brain Ageing score with r=0.72 (Lucicesare, 2010), Frailty Phenotype (r=0.65) 
(Rockwood, Andrew, Mitnitski, 2007), and Edmonton Frail Scale (r = 0.61) (Armstrong, 
Stolee, Hirdes, Poss, 2010). When compared with the Mini Mental State exam, the FI 
showed a strong negative correlation (r = -0.58) (Rockwood et al., 2007). The FI has also 
been used with dichotomized variables, with the frailty phenotype as a reference for 
measuring frailty; the FI had a sensitivity of 45.9 to 60.7% and specificity of 83.5 to 90% 
(Cigolle, Ofstedal, Tian, & Blaum, 2009; Kulminski et al., 2008). 
Inpatient FI. Inpatient use of the FI has been documented. Krishnan et al. (2014) 
noted patients with hip fracture and higher FI scores had increased mortality and greater 
lengths of stay. Delirium and frailty was studied with older adults admitted to a general 
medicine floor, with poor prognosis noted if frailty and delirium present in an individual, 
and delirium was associated with higher frailty indices (Eeles et al., 2012). Dent et al. 
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(2014) evaluated frailty and the ability to predict poor outcomes in a geriatric unit, with 
measurements at discharge and six months later. Several different measurements of 
frailty were utilized to include the FI and phenotypic measurements; however, only the 
frailty index was able to show good prediction of poor outcomes both at discharge and 
six months. Joseph et al. (2015) compared risk of fracture between frail older adults and 
non-frail, using an FI. After adjustment for age, sex, injury severity, vital signs, and 
fracture development, an FI of 0.25 or greater was an independent risk factor for post-
discharge dedicated care. Singh et al. (2012) noted frailty as significantly correlating to 
length of stay and predictor of poor function. Hatheway et al. (2017) used an inpatient 
frailty index based on the comprehensive geriatric assessment to explore the relationship 
between mobility recovery time and frailty in acute inpatient admission for the older 
adult. Evans et al. (2014) used an FI to assess predictive validity in acute care related to 
discharge, length of stay, and risk of mortality. Increased FI was associated with 
increased risk of death, long-term care, and length of stay. As noted, the FI has been used 
in multiple inpatient arenas with the older adult.  Song, Mitnitski, and Rockwood (2010) 
posited an FI score of  0.08 as non-frail, FI ≥ 0.25 as frail, and the remainder as pre-
frail.  For purposes of this study, frailty was measured on a continuous scale, with 0.25 as 
the minimum score for frailty in an individual.  
Data Analyses 
All data were examined for missing data or outliers after initial randomized 
accuracy checks. Descriptive statistics were used to describe the study sample and 
outcomes such as frequency (n) and percentage (%) for categorical measures and mean 
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(M), standard deviation (SD), median (Med) and range for continuous measures. All 
analyses were performed in R statistical software v3.4.2 (R Core Team, 2017). A two-
sided p-value < 0.05 was considered statistically significant. 
The following questions, guided by the Accumulation of Deficits framework, 
(Figure 1) will be used for this research:  
1. What sociodemographic variables are related to recurrent CDI admission?  
2. What sociodemographic variables are related to frailty during an initial admission 
for CDI?  
3. What is the prevalence of the frailty index variables among members of the 
sample?  
4. What proportion of the sample has a frailty index score of 0.25 and above 
indicating frailty?  
5. What is the relationship between the frailty index score during the initial 
admission for CDI and documented recurrence of CDI within a year?  
6. What is the relationship between proton pump inhibitor (PPI) use prior to 
admission, frailty, and recurrent hospitalization for CDI?  
For RQ1, sociodemographic variables were tested for differences between CDI 
patients with and without any recurrent admissions using Chi-square tests or Fisher’s 
exact tests (if any expected counts < 5) for categorical variables and independent-samples 
t-tests or Mann-Whitney U nonparametric tests (if within-group Normality cannot be 
assumed) in bivariate analysis. Logistic regression with any recurrent CDI admission vs. 
none as the dependent variable was performed to identify sociodemographic factors in a 
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multivariable framework. Adjusted odds ratios (AORs) and their 95% confidence 
intervals (CIs) were estimated and reported. Logistic regression assumptions were 
checked according to Osborne (2015), including overall goodness-of-fit using Hosmer-
Lemeshow testing.  
For RQ2, Pearson correlations (r) or Spearman rho rank correlations (rs) (if 
Normality cannot be assumed or outliers exist) along with scatterplots with linear and 
local regression (LOESS) trend fits were examined first in bivariate analyses among 
continuous sociodemographic variables (e.g., age) and frailty index scores. For 
categorical sociodemographic variables, bivariate analyses were performed using t-tests 
and analysis of variance (ANOVA) or Mann-Whitney U and Kruskal-Wallis tests (if 
within-group Normality cannot be assumed). Linear regression with frailty index score as 
the dependent variable (transformed by multiplying by 100%) was performed to identify 
sociodemographic factors in a multivariable framework. Unstandardized (b) and 
standardized () coefficients and their 95% CIs were estimated and reported. Linear 
regression assumptions, including linearity, homoscedasticity, independence, and 
Normality, were assessed with knowledge of the study design, analysis of residuals and 
Durbin-Watson statistics. Multicollinearity was assessed and presence of 
multicollinearity was considered to be any variance inflation factor (VIF) > 10.  
For RQs 3 and 4, the percentage of CDI patients experiencing each individual 
frailty index deficit component was estimated. In addition, the mean frailty index score 
and percentage of patients with index score ≥ 0.25, defining frailty in this study, were 
estimated along with 95% CIs.  
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Analyses similar to those used to address RQ1 were used to investigate RQ5 in 
comparing frailty index scores on CDI patients with and without recurrence. Logistic 
modeling adjusted for sociodemographic factors in RQ1 results was performed to assess 
the association of frailty and CDI recurrence after accounting for sociodemographic 
characteristics. Analysis assumptions were again checked as appropriate.  
For RQ6, a Chi-square test or Fisher’s exact test (if any expected count < 5) was 
performed to test the association of proton pump inhibitor (PPI) use prior to admission 
and recurrent CDI vs. no recurrence in bivariate analysis. Additionally, the final logistic 
regression modeling from RQ4 was expanded to include PPI use prior to admission, and 
associations with recurrent CDI tested accordingly. Changes in the adjusted association 
of frailty index scores and CDI recurrence was noted and discussed. Logistic regression 
assumptions were again checked according to Osborne (2015). 
Power and Sample Size 
 It was anticipated that data extracted from the electronic medical record from 
approximately 800 patients will be available over the study period. Further, it was 
anticipated that approximately 20% of patients will experience at least one CDI 
recurrence during this time-period (approximately 160 patients with ≥1 recurrent CDI 
admission). Statistical power and sample size considerations were therefore evaluated 
with these assumptions in mind along with exploring alternative scenarios. Among all 
planned analyses, the multivariable logistic regression analyses for RQ6, “What is the 
relationship between outpatient PPI therapy prior to admission, frailty, and recurrent 
hospitalization for CDI?”, dictates the overall sample size requirement for the current 
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study as it is the most complex. The following table illustrates model size (number of 
independent variables (IVs) based on the required number of CDI recurrence events and 
total sample size (depending upon the prevalence of recurrent CDI) according to sample 
size guidelines evidence of 5 to 9 events per predictor variable (EPV) from Vittinghoff 
and McCulloch (2007): 
 
Table 4. Required Number of Events and Sample Size by Prevalence of CDI Recurrence 
and Model Complexity 
 
No. events 
CDI 
recurrence 
prevalence (%) 
Total sample 
size required 
Total No. IVs 
using 5 EPV 
Total No. IVs 
using 9 EPV 
80 10% 800 16 8 
80 20% 400 16 8 
80 40% 200 16 8 
160 10% 1,600 32 17 
160 20% 800 32 17 
160 40% 400 32 17 
240 10% 2,400 48 26 
240 20% 1,200 48 26 
240 40% 600 48 26 
  
Assuming 17 total independent variables (IVs) in a logistic regression, modeling 
frailty index score and PPI use prior to admission would leave 13 independent variables 
to accommodate sociodemographic characteristics, including hospital site. As evidenced 
in Table 4, this model size is appropriate given the measured characteristics and planned 
analyses for the study research questions of interest. With 17 IVs and conservatively 
assuming the stricter requirement of 9 events per IV (EPV) based on Vittinghoff and 
McCulloch (2007), a total of 153 CDI recurrence events are required. If the prevalence of 
CDI recurrence is 20% and conservatively rounding up to 160 events, a total sample size 
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of 800 patients is required under these assumptions. In particular for the adjusted 
association between frailty index score and CDI recurrence, an adjusted odds ratio (AOR) 
of 1.35 can be detected with sufficient power (≥80%), assuming a two-sided Type I error 
= .05, normal distribution of frailty index scores, and a squared correlation (
2
) of frailty 
index scores with other model included IVs of .20 and under similar other assumptions. If 
the squared correlation is higher, 
2
 = .50, then an AOR = 1.46 can be detected with 
≥80% power under all other similar assumptions.  
Limitations 
Due to the retrospective nature of this study, chart documentation was not 
complete or consistent on each individual. With older populations, the possibility 
remained that individuals may be deceased prior to a recurrence of CDI and for this study 
were considered as non-recurrent CDI cases. The assumption was made that routine 
laboratory studies, nursing care documentation, and admitting history and physicals 
would provide sufficient data for the frailty index to be calculated retrospectively. 
However, missing data was a limitation and resulted in the inability to apply the frailty 
index to the entire sample. In this case, those with all variables accounted for in the frailty 
index were used for analyses with questions specifically pertaining to frailty. Care was 
taken to ensure that once ICD-9 and ICD-10 codes were identified, that the individual’s 
initial admission was verified and not a subsequent admission. Multiple admissions for 
the same individual required detailed and specific reports to be run using the specific 
diagnostic identifiers. All of these factors were considered while obtaining data and 
reporting the final study outcome in order to ensure validity. 
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Summary 
 The relationship between CDI in the frail older adult and recurrent CDI has not 
been explored extensively in the literature.  The Accumulation of Deficits framework was 
used to guide this research study to explore the relationships proposed. The FI-CDI 
served as operationalization of frailty, including many variables that were easily attained 
from the electronic medical record. These findings contributed to a known knowledge 
gap in the literature regarding the relationship between frailty in the older adult and CDI.  
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CHAPTER IV 
 
RESULTS
 
 
 The findings from the retrospective cohort of existing medical record data are 
given in this chapter. This study explored the relationship between frailty and recurrent 
CDI in adults ages 55 years and older who were hospitalized for CDI infection in the 
acute care setting. The FI-CDI was used to measure frailty. Results for preliminary data 
analysis, sample characteristics, and research questions are given in this chapter.  
Preliminary Analysis 
All CDI admissions and readmissions from December 31, 2012 to December 31, 
2016 were extracted from the participating hospitals’ database by hospital personnel. 
Three hospitals, serving the Triad area and surrounding counties, were sites of care for 
the study. After extraction, 1,598 patients had presented during this timeframe with 2,146 
total admission records. Records were reviewed for inclusion and exclusion criteria, 
resulting in a final analysis sample of 1,199 admissions on 871 patients (see Figure 2). 
First, 372 patients under 55 years old were excluded. Next, nine patients had admissions 
that lasted less than one day and were additionally excluded. Finally, 346 patients 
presenting in 2016 were excluded from the final analysis sample, as these patients had 
less than a year of follow-up. Approximately half of the sample had data available for 
application of the FI-CDI on admission (n=450, 51.7%) and discharge (n=468, 53.7%). 
Due to missing data, FI-CDI was applied to 51.7% (n=450) of the original analysis 
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sample for specific research questions pertaining to frailty. Logistic regression for 
analyses was performed for those with non-missing data, as outlined in Table 16. Logistic 
regression used FI-CDI on initial admission for analyses, as this is the most accurate 
representation of initial frailty status upon initial presentation for CDI, prior to possible 
healthcare interventions.  
Missing data was expected in this retrospective study, as not all laboratory 
markers may be indicated for each individual presenting. Furthermore, data for functional 
status/ADLs and psychosocial variables were not included for some individuals as 
documentation varies with healthcare staff.  Documentation by healthcare staff was 
completed in the EHR with availability of multiple choices as noted in Table 3. The first 
availability of laboratory markers on admission were used as initial data for admission 
laboratory data, and the last recorded laboratory measures were used to indicate discharge 
laboratory markers.  Non-missing data for analyses is documented further in the outlined 
tables per variable as indicated.  
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Figure 2. Study Flow Chart  
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Sample Characteristics 
 
Among the 871 patients, the total number of admissions over the study period 
(between 12/31/2012 to 12/31/2016) ranged from one to ten, with 663 admitted just once 
(76.1% of 871; see Table 5). Additionally, there were 79 deaths during first admission 
(9.1%), where these patients were unable to be subsequently followed for CDI 
recurrence. The number of deaths by admission number are described in Table 6.  The 
average age on initial admission for those who expired was 75.1 (SD=9.5), with the 
majority of those expired age 65 and older (n=67, 84.8%). Over half of those who expired 
were female (n=44, 55.7%), and the majority were White (n=56, 70.9%) followed by 
Black/African-American (n=19, 24.1%). The non-Hispanic population (n=78, 98.7%) 
was largely represented in those who expired (see Table 7).  
 
Table 5. Number of Admissions by Year of Admission 
 
Admissions 2012 2013 2014 2015 2016 Total 
1 2 209 201 251 0 663 
2 0 88 75 97 10 270 
3 0 20 40 53 16 129 
4 0 28 22 26 8 84 
5 0 7 10 10 3 30 
6 0 3 1 2 0 6 
7 0 3 2 2 0 7 
8 0 0 0 0 0 0 
9 0 0 0 0 0 0 
10 0 2 3 2 3 10 
Total 2 360 354 443 40 1,199 
*Note. Total of 1,199 admissions among N=871 patients. 
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Table 6. Number of Deaths (Expired) by Admission 
 
Admission # No. with Admission No. Deaths (%) 
1 871   79 (9.1%) 
2 208   10 (4.8%) 
3 73     7 (9.6%) 
4 30     4 (13.3%) 
5 9     2 (22.2%) 
6 3     0  
7 2     0  
8 1     0  
9 1     0  
10 1     0  
 
 
Table 7. Demographic Characteristics of Patients who Expired on Initial Admission  
              (n=79) 
 
Characteristic M  SD or n (%) 
Age at initial admission (years) 
   55 to < 65 
   ≥ 65 
75.1  9.5  
12 (15.2) 
67 (84.8) 
Sex 
   Female 
   Male 
 
44 (55.7) 
35 (44.3) 
Race 
   American Indian 
   Asian 
   Black/African American 
   White 
   Other 
   unavailable 
 
  0     
  0 
19 (24.1) 
56 (70.9) 
  3 (  3.8) 
  1 (  1.3) 
Ethnicity 
   Hispanic 
   Non-Hispanic 
   unavailable 
 
  0 
78 (98.7) 
  1 (  1.3)     
 
 
The prevalence of CDI recurrence over the study period was 23.9% (n=208) 
among the 871 patients (95% CI = [21.2%, 26.8%]). The average age on index admission 
was 73.6 years (SD=10.7), where 77.8% (n=678) were ages 65 and older. Females 
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comprised over half of the sample (n=510, 58.6%). The majority of the sample was 
White (n=609, 69.9%), followed by Black/African American (n=234, 26.9%), and only 
0.9% (n=8) were Hispanic. The largest proportion of the patients were married (n=363, 
41.7%), followed by widowed (n=245, 28.1%), single (n=122, 14.0%) and divorced 
(n=120, 13.8%) with respect to marital status.  
 Almost two-thirds (n=576, 66.1%) resided in a private residence prior to initial 
admission, followed by skilled nursing facility (n=125, 14.4%). About one-third of the 
patients were discharged to either home/self-care (n=279, 32.0%) or a skilled nursing 
facility (n=261, 30.0%) after initial admission. CDI recurrence was more prevalent for 
those discharged to a skilled nursing facility (37.5% vs. 27.6% with no recurrence) and 
home health care (24.5% vs. 15.2% no recurrence) (p<0.001). The average length of stay 
for an index admission was 8.8 days (SD=8.6), with average length of stay at index 
admission for those with eventual recurrent CDI admission was 8.9 days (SD=8.3). The 
average number of days from first discharge to first recurrent admission was 71.2 days 
(SD=41.7). Here, 77.9% of patients with any recurrence over the study period had greater 
than or equal to 30 days between first discharge and first recurrent admission (n=159). 
Sample characteristics are detailed further in Table 8 overall and by recurrence status.  
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Table 8. Patient Characteristics of the Clostridium difficile (CDI) Sample  
Characteristic 
n (%) or M  SD 
Overall 
(N = 871) 
Recurrent CDI 
(n = 208; 23.9%) 
No recurrence 
(n = 663;76.1%) 
P-value 
Age at initial admission 
(years) 
   55 to < 65 
   ≥ 65 
73.6  10.7 
 
193 (22.2) 
678 (77.8) 
73.3  11.1 
 
  57 (27.4) 
151 (72.6) 
73.7  10.5 
 
136 (20.5) 
527 (79.5) 
0.640 
 
0.046 
Sex 
   Female 
   Male 
 
510 (58.6) 
361 (41.4) 
 
119 (57.2) 
  89 (42.8) 
 
391 (59.0) 
272 (41.0) 
0.712 
Race
1
 
   American Indian 
   Asian 
   Black/African American 
   White 
   Other 
   unavailable 
 
    6 (  0.7) 
    3 (  0.3) 
234 (26.9) 
609 (69.9) 
  16 (  1.8) 
    3 (  0.3) 
 
    1 (  0.5) 
    1 (  0.5) 
  60 (28.8) 
144 (69.2) 
    2 (  1.0) 
    0 
 
    5 (  0.8) 
    2 (  0.3) 
174 (26.2) 
465 (70.1) 
  14 (  2.1) 
    3 (  0.5) 
0.797 
Ethnicity 
   Hispanic 
   Non-Hispanic 
   unavailable 
 
    8 (  0.9) 
856 (98.3) 
    7 (  0.8) 
 
    0 
207 (99.5) 
    1 (  0.5) 
 
    8 (  1.2) 
649 (97.9) 
    6 (  0.9) 
0.317 
Marital status at 1
st
 admission 
   Divorced 
   Legally separated 
   Married 
   Single 
   Unknown 
   Widowed 
 
120 (13.8) 
  15 (  1.7) 
363 (41.7) 
122 (14.0) 
    6 (  0.7) 
245 (28.1) 
 
38 (18.3) 
  2 (  1.0) 
80 (38.5) 
33 (15.9) 
  1 (  0.5) 
54 (26.0) 
 
  82 (12.4) 
  13 (  2.0) 
283 (42.7) 
  89 (13.4) 
    5 (  0.8) 
191 (28.8) 
0.247 
Residence prior to admission 
   Assisted living 
   Group home 
   Nursing home 
   Other 
   Private residence 
   Skilled nursing facility 
   missing 
 
  28 (  3.2) 
    3 (  0.3) 
    5 (  0.6) 
  15 (  1.7) 
576 (66.1) 
125 (14.4) 
119 (13.7) 
 
   9 (  4.3) 
   1 (  0.5) 
    1 (  0.5) 
    3 (  1.4) 
129 (62.0) 
  27 (13.0)  
  38 (18.3) 
 
  19 (  2.9) 
    2 (  0.3) 
    4 (  0.6) 
  12 (  1.8) 
447 (67.4) 
  98 (14.8) 
 81 (12.2) 
0.791 
Living arrangements           
(all that apply) 
   Spouse/significant other 
   Alone 
   Children 
   Other 
 
 
287 (33.0) 
140 (16.1) 
147 (16.9) 
  98 (11.3) 
 
 
  63 (30.3) 
  32 (15.4) 
  31 (14.9) 
  27 (13.0) 
 
 
224 (33.8) 
108 (16.3) 
114 (17.2) 
  71 (10.7) 
n/a 
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Characteristic 
n (%) or M  SD 
Overall 
(N = 871) 
Recurrent CDI 
(n = 208; 23.9%) 
No recurrence 
(n = 663;76.1%) 
P-value 
   missing 244 (28.0)   65 (31.3) 179 (27.0) 
Discharge plan at 1
st
 admit 
   Home/Self Care 
   Short Term Hospital 
   Skilled Nursing Facility 
   Intermediate Care Facility 
   Home Health Care Svc 
   Left against/without/Elope 
   Expired 
   Federal Hospital 
   Hospice/Home 
   Hospice/Medical Facility 
   Rehab Facility 
   Long Term Care 
   Another Institution (n.d.) 
   Inpt rehab/Acute care hosp  
 
279 (32.0) 
  10 (  1.1) 
261 (30.0) 
    5 (  0.6) 
152 (17.5) 
    2 (  0.2) 
  79 (  9.1) 
    1 (  0.1) 
  19 (  2.2) 
  29 (  3.3) 
  14 (  1.6) 
  18 (  2.1) 
    1 (  0.1) 
    1 (  0.1) 
 
65 (31.3) 
  0 
78 (37.5) 
  1 (  0.5) 
51 (24.5) 
  1 (  0.5) 
  0 
  0 
  0 
  2 (  1.0) 
  3 (  1.4) 
  7 (  3.4) 
  0 
  0 
 
214 (32.3) 
  10 (  1.5) 
183 (27.6) 
    4 (  0.6) 
101 (15.2) 
    1 (  0.6) 
  79 (11.9) 
    1 (  0.6) 
  19 (  2.9) 
  27 (  4.1) 
  11 (  1.7) 
  11 (  1.7)  
    1 (  0.2) 
    1 (  0.2) 
<0.001 
Proton pump inhibitor (PPI) 
use prior to admission  
454 (52.1) 
 
114 (54.8) 340 (51.3) 0.419 
LOS in-hospital (days) 8.8  8.6 8.9  8.3 8.7  8.7 0.369 
No. CDI recurrences 
      0 
      1 
      2 
      3 
      4 
      5 
      6 
      7 
      8 
      9 
0.4  0.8 
663 (76.1) 
135 (15.5) 
  43 (  4.9) 
  21 (  2.4) 
    6 (  0.7) 
    1 (  0.1)  
    1 (  0.1) 
    0 
    0 
    1 (  0.1) 
1.6  1.0 
    0 
135 (64.9) 
  43 (20.7) 
  21 (10.1) 
    6 (  2.9) 
    1 (  0.5) 
    1 (  0.5) 
    0 
    0 
    1 (  0.5) 
- 
663 (100) 
    0 
    0 
    0 
    0 
    0 
    0 
    0 
    0 
    0 
n/a 
Days from 1
st
 discharge to 
1
st
recurrent admission 
      < 30 days 
      ≥ 30 days 
 
71.2  41.7 
  45 (  5.2) 
159 (18.3) 
 
71.2  41.7 
  45 (22.1) 
159 (77.9) 
 
 
- 
n/a 
*Note. n/a = Not available. Left against/without/elope = left against medical advice, left 
without being seen, elopement. Another Institution n.d. = not defined.  
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Research Question 1 
What sociodemographic variables are related to recurrent CDI admission? 
 In bivariate analyses, only age group at initial admission was statistically 
significantly related to recurrent CDI admission (p=0.046). Here, recurrent CDI was more 
prevalent (27.4% of those with recurrent CDI vs. 20.5% of no recurrence) in those 55 to 
64 years old (22% of the sample) relative to patients ages 65 and older (72.6% with 
recurrent CDI vs. 79.5% of no recurrence). Interestingly, age at initial admission 
continuously was not significantly different between recurrence groups (73.3 years ± 11.1 
vs. 73.7 ± 10.5, p=0.640). All other sociodemographic variables were not statistically 
significantly related to recurrent CDI admission (all p>0.100), and are subsequently 
detailed further next. 
Sex, race, ethnicity, and marital status were not significantly related to recurrent 
CDI admission (see Table 8).  Marital status was not statistically significantly related to 
recurrence, where some differences between recurrence groups were noted for those 
divorced (18.3% vs. 12.4% with no recurrence) and married (38.5% vs. 42.7% non-
recurrence) but were not significant (p = 0.247). Composition of the recurrence groups 
were not significantly difference between those having a private residence prior to 
admission (62.0% of recurrent CDI vs. 67.4% without any recurrence, p=0.791). Multiple 
combinations of living arrangements prior to admission were available in the medical 
record, and the most common documented living arrangements included with 
spouse/significant other (n=287, 33.0%), alone (n=140, 16.1%), and with children 
(n=147, 16.9%).  After multivariable logistic regression for recurrent CDI (see Table 16), 
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age continued to be an independent predictor for recurrent CDI when adjusting for other 
sociodemographics, frailty as measured by the FI-CDI, and PPI use prior to admission (p 
< 0.05 in all models). Specifically, the adjusted odds ratio for 55 to 64 years vs. ≥ 65 
varied from 2.123 (in Model 2) to 2.088 (in Model 3). In Model 3 with all 
sociodemographic, frailty using FI-CDI, and PPI use, the odds of any CDI recurrence 
increased by 108.8% for those in the 55 to 64 year age group relative to ≥ 65, adjusting 
for frailty and all other variables in this model (AOR = 2.088, 95% CI = [1.216, 3.583], p 
= 0.007)  
Research Question 2 
What sociodemographic variables are related to frailty during an initial 
admission for CDI?  
 For purposes of this study, frailty was measured by the FI-CDI, with a cut-off of 
0.25 and above indicating frailty.  Analyses were performed with the FI-CDI (n=450, 
51.7%). Sample characteristics of those with all variables for the FI-CDI are outlined in 
Table 9. The majority of this analysis sample was age 65 and older (n=334, 74.2%) and 
over half were female (n=256, 56.9%).  White (n=316, 70.2%) and Black/African-
American (n=118, 26.2%) races were predominant, and the Non-Hispanic population was 
largely represented (n=442, 98.2%).   
In bivariate analyses for frailty indices (see Table 10), continuous age on initial 
admission was weakly but significantly positively correlated with frailty as measured by 
the FI-CDI (rs =0.096, p = 0.043). When divided into clinically meaningful age groups, 
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patients of ages 55 to 64 had an average FI-CDI score of 0.34 (SD=0.11) relative to 0.38 
(SD=0.10) for patients 65 and older (p=0.003).  
Sex, ethnicity, and marital status were not significantly related to frailty during an 
initial admission for CDI as measured by the FI-CDI (see Table 10). The average female 
FI-CDI score was 0.37 (SD=0.11), similar to 0.37 (SD=0.09) for males. The average FI-
CDI score was 0.40 (SD=0.07) among the 8 Hispanic patients.  
Frailty scores were significantly higher for Black/African-American patients (0.40 
 0.10) relative to White patients (0.36  0.10) (overall p = 0.030, Holm adjusted 
pairwise comparison p = 0.029). Mean frailty scores for residence prior to admission 
were significantly different (p < 0.001); where skilled nursing facility (0.44  0.07) and 
assisted living (0.43  0.10) had the highest average FI-CDI scores. Those who expired at 
initial admission had an average FI-CDI score of 0.40 (SD=0.08).  
Additionally, PPI use prior to admission was significantly related to FI-CDI (0.39 
 0.10 vs. 0.35  0.10 non-use, p<0.001). Length of stay in hospital was weakly-to-
moderately positively significantly correlated with frailty for the FI-CDI (rs = 0.239, p 
<0.001). The number of CDI recurrences was not significantly correlated with frailty by 
the FI-CDI (rs= 0.056, p=0.236). The average frailty score for those without recurrence 
was 0.37 (SD=0.11) as measured by the FI-CDI. Average frailty scores for subsequent 
recurrences were similar (see Table 10). Days from first discharge to first admission 
showed low, non-significant correlation with frailty scores for the FI-CDI (rs=0.110, 
p=0.250).   
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Table 9. Demographic Characteristics of Patients with FI-CDI (n=450) 
 
Characteristic M  SD or n (%) 
Age at initial admission (years) 
   55 to < 65 
   ≥ 65 
72.3  10.6 
116 (25.8) 
334 (74.2) 
Sex 
   Female 
   Male 
 
256 (56.9) 
194 (43.1) 
Race 
   American Indian 
   Asian 
   Black/African American 
   White 
   Other 
   unavailable 
 
    5 (  1.1) 
    1 (<1.0) 
118 (26.2) 
316 (70.2) 
    9 (  2.0) 
    1 (<1.0) 
Ethnicity 
   Hispanic 
   Non-Hispanic 
   unavailable 
 
    4 (<1.0) 
442 (98.2) 
    4 (<1.0)     
 
 
Table 10. Bivariate Analysis of Patient Characteristics and Frailty Index Scores (n=450) 
 
Characteristic 
n (%) or M  SD 
FI-CDI 
(n=450; 51.7%) P-value 
Age at initial admission (years) 
   55 to < 65 
   ≥ 65 
rs = 0.096 
0.34 ± 0.11 
0.38 ± 0.10 
0.043 
0.003 
Sex 
   Female 
   Male 
 
0.37 ± 0.11 
0.37 ± 0.09 
0.941 
Race
1
 
   American Indian 
   Asian 
   Black/African American 
   White 
   Other 
 
0.36 ± 0.11 
n/a 
0.40 ± 0.10 
0.36 ± 0.10 
0.34 ± 0.16 
 
 
 
 
0.030 
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Characteristic 
n (%) or M  SD 
FI-CDI 
(n=450; 51.7%) P-value 
Marital status at 1
st
 admission 
   Divorced 
   Legally separated 
   Married 
   Single 
   Widowed 
 
0.38 ± 0.10 
0.47 ± 0.06 
0.36 ± 0.10 
0.37 ± 0.11 
0.38 ± 0.10 
0.072 
Residence prior to admission 
   Assisted living 
   Group home 
   Nursing home 
   Other 
   Private residence 
   Skilled nursing facility 
 
0.43 ± 0.10 
0.39 ± 0.13 
n/a 
0.39 ± 0.09 
0.35 ± 0.10 
0.44 ± 0.07 
 
<0.001 
Discharge plan at 1st admit 
   Home/Self Care 
   Transferred ST Hospital 
   Skilled Nursing Facility 
   Intermediate Care Facility 
   Home Health Care Svc 
   Left against/without/Elope 
   Expired 
   Federal Hospital 
   Hospice/Home 
   Hospice/Medical Facility 
   Rehab Facility 
   Long Term Care 
   Another Institution (n.d.) 
   Inpt rehab/Acute care hosp  
 
0.32  0.11 
n/a 
0.42  0.08 
n/a 
0.36  0.09 
n/a 
0.40  0.08 
n/a 
0.42  0.08 
0.42  0.08 
0.36  0.08 
0.40  0.06 
n/a 
n/a 
<0.001 
Proton pump inhibitor (PPI)  
use prior to admission (Yes) 
   No 
 
0.39  0.10 
0.35  0.10 
 
 
 
 
 
 
 
 
 
<0.001 
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Characteristic 
n (%) or M  SD 
FI-CDI 
(n=450; 51.7%) P-value 
LOS in-hospital (days) rs = 0.239 <0.001 
No. CDI recurrences 
   0 
   1 
   2 
   3 
   4 
   5 
   6 
   7 
   8 
   9 
rs = 0.056 
0.37  0.11 
0.38  0.10 
0.37  0.08 
0.39  0.08 
n/a 
n/a 
n/a 
n/a 
n/a 
n/a 
0.236 
Days from 1
st
 discharge to 1
st 
 recurrent 
admission 
   < 30 days 
   ≥ 30 days 
 
rs = 0.110 
0.37  0.10 
0.40  0.08 
 
0.250 
0.184 
   *Note. n/a = Not available. Left against/without/elope = left against medical advice, left 
without being seen, elopement. Another Institution n.d. = not defined.  
    
 
Research Question 3 
What is the prevalence of the frailty index variables among members of the 
sample?   
The frailty index (FI) was comprised of laboratory markers, chronic diseases, 
functional status and activity of daily living, and psychosocial components.  The 
laboratory markers comprising the FI for initial admission and discharge laboratory 
values are described in Table 11. Further description of the frailty index variables and 
comparisons between patients with and without recurrent CDI are outlined next. Overall 
sample characteristics were performed with non-missing data.  
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Laboratory Characteristics  
Hypoalbuminemia, defined for this study as albumin less than 3 g/dL, was present 
on 54.6% of the sample at time of initial admission (n=443), and 75.1% (n=609) had an 
albumin less than 3 g/dL at initial discharge. The average albumin on admission was 2.86 
g/dL (SD=0.68). Abnormal ALT was defined as less than 17 U/L or greater than 30 U/L, 
and over two-thirds (n=553, 70.2%) had abnormal ALT values as described at time of 
initial admission, and likewise at initial discharge (n=602, 74.6%). The average ALT on 
admission was 30.6 U/L (SD = 61.6). An elevated alkaline phosphatase, described as 
greater than 140 U/L on initial admission, was noted in 17.1% of the sample (n=138), 
with similar elevation noted in 14.3% of the sample at initial discharge (n=115). For 
those with at least one CDI recurrence, 15.4% (n=32) were elevated at initial admission 
and 11.1% (n=23) at initial discharge; there was no significant findings related to 
elevated alkaline phosphatase and recurrent CDI admission (all p>0.100). The average 
alkaline phosphatase on admission for the sample was 108.8 U/L (SD=78.5), and were 
similar for recurrent and non-recurrent CDI (see Table 11).  
A low hemoglobin was defined as less than 11.5 g/dL for males and less than 11.0 
g/dL females, respectively. The average hemoglobin (Hgb) for the sample on initial 
admission was 11.6 g/dL (SD =2.3), with an average Hgb 10.3 g/dL (SD=1.7) at 
discharge. There was no significant difference in the hemoglobin values for recurrent 
CDI versus non-recurrent CDI patients (p=0.316).  About one-fifth of the male sample 
(n=181, 20.8%) had a low hemoglobin on initial presentation, where as 22.6% of females 
had similar presentation on admission with low hemoglobin (n=196).  
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 An elevated creatinine, defined as greater than 1.2 mg/dL, was found in 52.1% 
(n=453) of the sample for initial admission. The average creatinine on admission was 2.1 
mg/dL (SD=2.3), where the recurrent and non-recurrent groups were similar on average. 
There were no significant differences between groups related to elevated creatinine (all 
p> 0.100). BUN was also measured, with elevated BUN defined as greater than 28 
mg/dL. The average BUN for the sample at initial admission was 33.5 mg/dL (SD=28.0), 
and were similar between the recurrent and non-recurrent groups. No significant finding 
was found related to elevated BUN and recurrent CDI at initial admission (p=0.846) or 
initial discharge (p = 0.143).  
 Leukocytosis defined as white blood cells greater than 9 K/uL or leukopenia, 
defined as white blood cells less than 3 K/uL, respectively, was noted in 64.1% (n=544) 
of the sample on initial admission. Specifically, leukocytosis was more prominent in the 
sample (n=518, 61.0%) on initial admission, and leukopenia was noted in 3.1% (n=26) on 
admission. The average WBC count was 12.8 K/uL on initial admission (SD=10.3) There 
was no statistically significant difference between recurrent and non-recurrent CDI 
patients for abnormal white blood cells (leukocytosis and leukopenia) at initial admission 
(p=0.757) or initial discharge (p=0.644).  
 Glucose levels averaged 144.9 mg/dL (SD=79.4) on initial presentation, with the 
majority of the sample (n=467, 53.9%) having greater than 120 mg/dL on initial 
admission. Over half of the sample was also found to have abnormal glucose levels (less 
than 70 mg/dL or greater than 120 mg/dL) on initial admission (n=496, 57.2%). No 
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significant differences were found with abnormal glucose levels at initial admission for 
recurrent and non-recurrent CDI patients (p=0.340).  
 Hyponatremia (sodium less than 135 mmol/L) and hypernatremia (sodium greater 
than 145 mmol/L) was noted in 35.4% of the sample on initial admission (n=308). 
Approximately one-third of the sample (n=277, 31.9%) were classified with 
hyponatremia on initial admission, and only a small proportion had hypernatremia (n=31, 
3.6%) on admission. Sodium levels were not statistically significant by recurrent CDI 
status (all p> 0.100).  
 The average platelet count for the sample on initial admission was 241.6 K/uL 
(SD=115.1). Thrombocytopenia, defined as a platelet count less than 150 K/uL, was 
present in 19.3% (n=165) on initial admission. Thrombocytosis, defined as platelets 
greater than 400 K/uL, was noted in only 8.8% (n=75) on admission. No significant 
differences were noted in platelet counts by recurrent CDI status (all p> 0.100). 
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Table 11. Laboratory Characteristics of the Clostridium difficile (CDI) Sample  
 
Characteristic 
n (%) or M  SD 
Overall 
(N = 871) 
Recurrent CDI 
(n = 208; 23.9%) 
No recurrence 
(n = 663; 76.1%) 
P-value 
1. Albumin (g/dL)  
     At 1
st
 admit (n=811; 93.1%) 
     At 1
st
 discharge  
       (n=811; 93.1%) 
     <3.0 at admit 
     <3.0 at discharge 
 
  2.86  0.68 
 
  2.53  0.64 
443 (54.6) 
609 (75.1) 
 
2.89  0.67 
 
2.52  0.59 
103 (49.5) 
142 (68.3) 
 
2.85  0.68 
 
2.53  0.65 
340 (51.3) 
467 (70.4) 
 
0.440 
 
0.766 
0.750 
0.643 
2. ALT (U/L)  
     At admit (n=788; 90.5%) 
    At discharge (n=807; 92.7%) 
    <17 at admit  
    >30 
    <17 or >30 
    <17 at discharge  
    >30 
    <17 or >30 
 
  30.6  61.6  
30.6  103.3 
405 (51.4) 
148 (18.8) 
553 (70.2) 
453 (56.1) 
149 (18.5) 
602 (74.6) 
  
 28.7  41.9 
 22.7  24.8 
103 (49.5) 
  39 (18.8) 
142 (68.3) 
116 (55.8) 
  33 (15.9) 
149 (71.6) 
 
31.1  66.5 
33.0  117.4 
302 (45.6) 
109 (16.4) 
411 (62.0) 
337 (50.8) 
116 (17.5) 
453 (68.3) 
 
0.815 
0.652 
0.247 
0.444 
0.044 
0.167 
0.706 
0.252 
 
3. Alkaline phosphatase (U/L) 
    At admit (n=806; 92.5%) 
    At discharge(n=806; 92.5%) 
    >140 at admit 
    >140 at discharge 
 
108.8  78.5 
108.3  100.9 
138 (17.1) 
115 (14.3) 
 
 111.4  87.5 
 109.3  120.8 
  32 (15.4) 
  23 (11.1) 
 
108.0  75.5 
108.0  94.0 
106 (16.0) 
  92 (13.9) 
 
0.947 
0.975 
0.965 
0.374 
4. Hemoglobin (g/dL)  
     At admit (n=870; 99.9%) 
     At discharge(n=870; 99.9%) 
     Male <11.5 at admit 
     Female <11.0  
     Male <11.5 at discharge 
     Female < 11.0 
 
11.6  2.3 
10.3  1.7 
181 (20.8) 
197 (22.6) 
265 (30.5) 
330 (37.9) 
 
11.5  2.3 
10.2  1.6 
  49 (23.6) 
  48 (23.1) 
  67 (32.2) 
  86 (41.3) 
 
11.7  2.3 
10.4  1.8 
132 (19.9) 
149 (22.5) 
198 (29.9) 
244 (36.8) 
 
0.316 
0.155 
0.301 
0.905 
0.579 
0.252 
5. Creatinine (mg/dL)  
    At admit (n=869; 99.8%) 
    At discharge (n=869; 99.8%) 
    >1.2 at admit 
    >1.2 at discharge 
 
2.1  2.3 
1.6  1.8 
453 (52.1) 
317 (36.5) 
 
2.1  2.2 
1.6  1.7 
106 (51.0) 
  72 (34.6) 
 
2.1  2.3 
1.6  1.8 
347 (52.3) 
245 (37.0) 
 
0.948 
0.711 
0.823 
0.618 
6. BUN (mg/dL)  
    At admit (n=867; 99.5%) 
    At discharge (n=869; 99.8%) 
    >28 at admit 
    >28 at discharge 
 
33.5  28.0 
23.9  23.6 
374 (43.1) 
216 (24.9) 
 
33.3  26.8 
21.4  17.4 
  91 (43.8) 
  43 (20.7) 
 
33.5  28.4 
24.7  25.2 
283 (42.7) 
173 (26.1) 
 
0.599 
0.701 
0.846 
0.143 
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Characteristic 
n (%) or M  SD 
Overall 
(N = 871) 
Recurrent CDI 
(n = 208; 23.9%) 
No recurrence 
(n = 663; 76.1%) 
P-value 
7. White blood cells (K/uL)  
    At admit (n=849; 97.5%) 
    At discharge (n=849; 97.5%) 
    <3 at admit 
    >9 
    <3 or >9 
    <3 at discharge 
    >9 
    <3 or >9 
 
12.8  10.3 
10.6  9.5 
  26 (  3.1) 
518 (61.0) 
544 (64.1) 
  22 (  2.6) 
402 (47.3) 
424 (49.9) 
 
12.3  6.9 
9.6  4.9 
    4 (  1.9) 
125 (60.1) 
129 (62.0) 
    3 (  1.4) 
  96 (46.2) 
  99 (47.6) 
 
13.0  11.2 
10.9  10.5 
  22 (  3.3) 
393 (59.3) 
415 (62.6) 
  19 (  2.9) 
306 (46.2) 
325 (49.0) 
 
0.945 
0.892 
0.408 
1.000 
0.757 
0.360 
0.927 
0.644 
8. Glucose (mg/dL)  
    At admit (n=867; 99.5%) 
    At discharge (n=869; 99.8%) 
    <70 at admit 
    >120 
    <70 or >120 
    <70 at discharge 
    >120  
    <70 or >120 
 
 144.9  79.4 
 127.5  53.6 
  29 (  3.3) 
467 (53.9) 
496 (57.2) 
  12 (  1.4) 
335 (38.6) 
347 (39.9) 
 
144.2  77.9 
130.2  53.9 
    3 (  1.4) 
109 (52.4) 
112 (53.8) 
    1 (  0.5) 
  78 (37.5) 
  79 (38.0) 
 
145.1  79.9 
126.7  53.5 
  26 (  3.9) 
358 (54.0) 
384 (57.9) 
  11 (  1.7) 
257 (38.8) 
268 (40.4) 
 
0.946 
0.666 
0.129 
0.750 
0.340 
0.312 
0.832 
0.608 
9. Sodium (mmol/L)  
    At admit (n=869; 99.8%) 
    At discharge (n=869; 99.8%) 
    <135 at admit 
    >145 
    <135 or >145 
    <135 at discharge 
    >145 
    <135 or >145 
 
136.5  5.8 
138.2  4.8 
277 (31.9) 
  31 (  3.6) 
308 (35.4) 
160 (18.4) 
  49 (  5.6) 
209 (24.1) 
 
136.4  4.7 
137.7  4.0 
  60 (28.8) 
    5 (  2.4) 
  65 (31.3) 
  42 (20.2) 
    7 (  3.4) 
  49 (23.6) 
 
136.5  6.1 
138.3  5.0 
217 (32.7) 
  26 (  3.9) 
243 (36.7) 
118 (17.8) 
  42 (  6.3) 
160 (24.1) 
 
0.757 
0.177 
0.349 
0.419 
0.190 
0.487 
0.150 
0.958 
10. Platelets (K/uL)  
     At admit (n=855; 98.2%) 
     At discharge(n=868; 99.7%) 
     <150 at admit 
     >400 
     <150 or >400  
     <150 at discharge      
     >400 
     <150 or >400 
 
 241.6  115.1 
 234.1  113.5 
165 (19.3) 
  75 (  8.8) 
240 (28.1) 
191 (22.0) 
  77 (  8.9) 
268 (30.9) 
 
240.8  121.7 
234.9  111.9 
  38 (18.3) 
  13 (  6.3) 
  51 (24.5) 
  40 (19.2) 
  17 (  8.2) 
  57 (27.4) 
 
241.8  113.1 
233.9  114.1 
127 (19.2) 
  62 (  9.4) 
189 (28.5) 
151 (22.8) 
  60 (  9.0) 
211 (31.8) 
 
0.703 
0.943 
0.860 
0.213 
0.303 
0.332 
0.809 
0.269 
 
*Note. All laboratory values correspond to the first available at admission and last 
available at discharge. Percentages overall are calculated with non-missing data. P-value 
is for comparing groups using t-test or Mann-Whitney U test for continuous variables and 
Chi-square or Fisher’s exact test for categorical variables.  
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Chronic Disease Characteristics  
 
Chronic diseases most common in this sample included hypertension (n=703, 
80.7%), arthritis (n=384, 44.1%), cancer (n=362, 41.6%), and diabetes (Type 1 and Type 
2) (n=356, 40.9%), as shown in Table 12. The chronic diseases found to be significantly 
more prevalent in recurrent CDI included hypertension (88.0% vs. 78.4%; p=0.003), 
heart failure (36.1% vs. 25.6%; p=0.005), and chronic kidney disease (34.1% vs 24.9%; 
p=0.011). Smoking status was assessed at time of admission, where 43.7% of the sample 
classified as former smoker (n=381), and 39.3% (n=342) classified as never smoker. 
More than half of the sample had ever smoked (n=515, 60.1%), with 63.9% of those with 
recurrent CDI (n=133) ever smoking relative to 57.8% without (n=383; p=0.169). The 
average BMI for the sample at initial admission was 27.0 kg/m
2 
(SD=7.5), with 26.9% of 
the sample (n=199) having BMI greater than 30 kg/m
2
 on initial admission. The recurrent 
and non-recurrent group had similar proportions of BMI greater than 30 kg/m
2
, with 
23.1% (n=48) of the recurrent group and 22.8% (n=151) of non-recurrent group 
(p=0.890).  
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Table 12. Chronic Diseases of the Clostridium difficile (CDI) Sample 
*Note. P-value is for comparing groups using t-test or Mann-Whitney U test for 
continuous variables and Chi-square or Fisher’s exact test for categorical variables. 
Overall percentages are calculated with non-missing data.  
 
 
  
Characteristic 
n (%) or M  SD 
Overall 
(N = 871) 
 Recurrent CDI 
(n = 208; 23.9%) 
No recurrence 
( n = 663; 76.1%) 
P-value 
11. Vitamin D deficiency   36 (  4.1)   10 (  4.8)   26 (  3.9) 0.719 
12. Arthritis 384 (44.1) 103 (49.5) 281 (42.4) 0.084 
13. Hypertension 703 (80.7) 183 (88.0) 520 (78.4) 0.003 
14. Stroke 223 (25.6)   63 (30.3) 160 (24.1) 0.092 
15. Cancer 362 (41.6)   95 (45.7) 267 (40.3) 0.194 
16. Diabetes (type 1 or 2) 356 (40.9)   95 (45.7) 261 (39.4) 0.125 
17. COPD 228 (26.2)   55 (26.4) 173 (26.1) 0.993 
18. Asthma 118 (13.5)   29 (13.9)   89 (13.4) 0.941 
19. BMI (kg/m
2
)  
     At admit (n=740; 85.0%) 
     At discharge (n=740; 85.0%) 
     <18 at admit 
     >30  
     <18 or >30 
     <18 at discharge 
     >30  
     <18 or >30   
 
27.0  7.5 
27.2  7.6 
  41 (  5.5) 
199 (26.9) 
240 (32.4) 
  43 (  5.8) 
200 (27.0) 
243 (32.8) 
 
26.9  7.2 
26.9  6.9 
  11 (  5.3)   
  48 (23.1) 
  59 (28.4) 
  10 (  4.8) 
  45 (21.6) 
  55 (26.4) 
 
27.1  7.6 
27.3  7.9 
  30 (  4.5) 
151 (22.8) 
181 (27.3) 
  33 (  5.0) 
155 (23.4) 
188 (28.4) 
 
0.782 
0.756 
0.745 
0.890 
0.702 
1.000 
0.766 
0.762 
20. Chronic Kidney Disease 236 (27.1)   71 (34.1) 165 (24.9) 0.011 
21. Depression 221 (25.4)   63 (30.3) 158 (23.8) 0.076 
22. Dementia   91 (10.4)   15 (  7.2)   76 (11.5) 0.105 
23. Heart Failure 245 (28.1)   75 (36.1) 170 (25.6) 0.005 
24. Smoking Status 
      Current daily smoker* 
      Current someday smoker* 
       Former smoker* 
       Never assessed 
       Never smoker 
       Passive smoke exposure* 
       Smoker status unknown 
       Ever smoking (n =857) 
 
110 (12.6) 
  16 (  1.8) 
381 (43.7) 
    6 (  0.7) 
342 (39.3) 
    2 (  0.2) 
  11 (  1.3) 
515 (60.1) 
 
  27 (13.0) 
    6 (  2.9) 
  97 (46.6) 
    0  
  74 (35.6) 
    0 
    3 (  1.4) 
132 (63.5) 
 
  83 (12.5) 
  10 (  1.5) 
284 (42.8) 
    6 (  0.9) 
268 (40.4) 
    2 (  0.3) 
    8 (  1.2) 
383 (57.8) 
0.598 
 
 
 
 
 
 
 
0.169 
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Functional Status and Activity of Daily Living Characteristics  
 Functional status and activity of daily living characteristics are given in Table 13. 
Over half of the sample was slightly limited with mobility (n=467, 57.4%) on initial 
admission, followed by very limited (n=239, 29.4%). The recurrent group had 60.1% 
(n=125) as slightly limited, compared to the non-recurrent group of 51.6% (n=342). 
About one-fifth of patients with recurrence (n=44, 21.2%) were very limited, compared 
to 29.4% very limited in the non-recurrent group (n=195). Performing Activities of daily 
living (ADLs) independently was noted in 51.1% (n=386) of the sample on initial 
admission, with no significant difference (p=0.836) in ADL performance for recurrent 
(n=89, 42.8%) and non-recurrent groups (n=297, 44.8%).  
 A score of 18 or less on the Braden scale is interpreted for individuals as at risk 
for pressure ulcers, and the average Braden scale score on initial admission for the 
sample was 16.3 (SD=3.1) in this study, with similar average scores for the recurrent 
(16.3  2.9) and non-recurrent groups (16.3  3.1). Over two-thirds of the sample (n=579, 
71.1%) had a Braden scale score  18 on admission. There were no significant 
differences in prevalence of admission Braden score  18 by recurrent CDI status 
(p=0.948).  Over one-quarter of the sample (n=236, 32.5%) had incontinence, and no 
significant difference in incontinence prevalence was noted for the recurrent group on 
admission (27.9% vs 26.8%, p=0.710).  
 Falls within the past six months were documented on 20.0% (n=131). No 
significant difference was noted in prevalence of falls within past six months for by 
recurrent CDI status (13.9% vs. 15.4% no recurrence, p=0.738). Fall risk at admission 
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was documented as low fall risk, moderate fall risk, and high fall risk. Over half of the 
sample (n=482, 59.1%) was classified as high fall risk. For those with recurrent CDI, the 
prevalence of high fall risk was 58.2% (n=121), similar when compared to non-recurrent 
group with 54.4% (n=361) (p = 0.306).  
 Polypharmacy, defined as seven medications or more on admission, was indicated 
for almost two-thirds of the sample on initial admission (n=569, 65.3%). The prevalence 
of polypharmacy was close to being significantly different by recurrence groups on 
admission (66.8% vs. 64.9%, p=0.060) and at discharge (66.8% vs. 64.6%, p=0.050).  
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Table 13. Functional Status and Activity of Daily Living of the Clostridium difficile 
(CDI) Sample 
Characteristic 
n (%) or M  SD 
Overall 
(N = 871) 
Recurrent CDI 
(n = 208; 23.9%) 
No recurrence 
 (n = 663; 76.1%) 
P-value 
25. Decreased Mobility,    
At admit (n=814; 93.5%) 
       Completely immobile* 
       Very limited* 
       Slightly limited* 
       No limitation 
    At discharge (n=814; 93.5%) 
       Completely immobile* 
       Very limited* 
       Slightly limited* 
       No limitation 
   
  
  27 (  3.3) 
239 (29.4) 
467 (57.4) 
  81 (10.0) 
 
  44 (  5.4) 
214 (26.3) 
469 (57.6) 
  87 (10.7)  
 
 
    7 (  3.4) 
  44 (21.2) 
125 (60.1) 
  15 (  7.2) 
 
    3 (  1.4) 
  46 (22.1) 
129 (62.0) 
  13 (  6.3) 
 
   
  20 (  3.0) 
195 (29.4) 
342 (51.6) 
  66 (10.0) 
 
  41 (  6.2) 
168 (25.3) 
340 (51.3) 
  74 (11.2) 
 
0.059 
 
 
 
 
0.002 
 
26. Independently performs  
      ADLs 
      At admission (n=756; 86.8%) 
             Yes 
              No 
     At discharge (n=756; 86.8%) 
              Yes 
              No 
 
 
 
386 (51.1) 
370 (48.9) 
 
384 (50.8) 
372 (49.2) 
 
  
   
89 (42.8) 
  82 (39.4) 
 
  88 (42.3) 
  83 (39.9) 
 
 
 
297 (44.8) 
288 (43.4) 
 
296 (44.6) 
289 (43.6) 
 
 
0.836 
 
 
0.911 
27. Braden scale (points) 
(n=814; 93.5%) 
    At discharge (n=814; 93.5%) 
     18 at admission       
 18 at discharge 
 
16.3  3.1 
16.6  3.5 
579 (71.1) 
492 (60.4) 
 
16.3  2.9 
16.9  2.8 
135 (64.9) 
127 (61.1) 
 
16.3  3.1 
16.5  3.7 
444 (67.0) 
365 (55.1) 
 
0.961 
0.904 
0.948 
0.061 
28. Incontinence (any yes)  
     At admit (n= 727; 83.5%) 
     At discharge (n= 727; 83.5%) 
 
236 (32.5) 
216 (29.7) 
 
  58 (27.9) 
  53 (25.5) 
 
178 (26.8) 
163 (24.6) 
 
0.710 
0.746 
29. Falls within past 6 mos.  
    At admission (n=656; 75.3%) 
    At discharge (n= 656; 75.3%)  
 
131 (20.0) 
148 (22.6) 
 
  29 (13.9) 
  36 (17.3) 
 
102 (15.4) 
112 (16.9) 
 
0.738 
0.907 
30. Fall Risk  
     At admission (n=816; 93.7%) 
        Low fall risk (0-5) 
        Moderate (6-13)* 
        High fall risk (>13)* 
    At discharge (n=816; 93.7%) 
        Low fall risk (0-5) 
        Moderate (6-13)* 
        High fall risk (>13)* 
 
 
163 (20.0) 
171 (21.0) 
482 (59.1) 
 
  87 (10.7) 
222 (27.2) 
507 (62.1) 
 
 
  38 (18.3) 
  33 (15.9) 
121 (58.2) 
 
  18 (  8.7) 
  46 (22.1) 
128 (61.5) 
 
 
125 (18.9) 
138 (20.8) 
361 (54.4) 
 
  69 (10.4) 
176 (26.5) 
379 (57.2) 
 
0.306 
 
 
 
0.334 
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*Note. P-value is for comparing groups using t-test or Mann-Whitney U test for 
continuous variables and Chi-square or Fisher’s exact test for categorical variables. 
Overall percentages are calculated with non-missing data.  
 
 
Psychosocial Characteristics 
 
 Support systems for the sample were predominantly children (n=452, 51.9%),  
spouse/significant other (n=340, 39.0%), other relatives (n=173, 19.9%), and 
friends/neighbors (n=128, 14.7%). Those with and without recurrence had similar 
findings for support system on initial admission. Physical abuse was denied by 99.3% of 
the sample on initial admission (n=739), with no statistically significant findings for 
physical abuse by recurrent CDI status (p=0.172). Physical abuse was confirmed by 0.3% 
(n=2) on admission.  Verbal abuse was also denied by 99.6% on initial admission 
(n=742), with no statistically significant findings for verbal abuse by recurrent CDI 
groups (p=0.534). Verbal abuse and sexual abuse were confirmed by 0.1% (n=1) on 
initial admission. Sexual abuse and self-neglect were denied by 99.9% (n=744) and 
99.3% (n=740), respectively, on initial admission. Self-neglect was confirmed by 0.1% 
(n=1) on admission. No statistical significant findings were noted for sexual abuse or 
self-neglect by recurrent CDI status (both p >0.100).  
 
  
Characteristic 
n (%) or M  SD 
Overall 
(N = 871) 
Recurrent CDI 
(n = 208; 23.9%) 
No recurrence 
 (n = 663; 76.1%) 
P-value 
31. Polypharmacy (≥7 meds) 
     At admit (n=748; 85.9%) 
     At discharge (n= 748; 85.9%) 
 
569 (76.1) 
567 (75.8) 
 
139 (66.8) 
139 (66.8) 
 
430 (64.9) 
428 (64.6) 
 
0.060 
0.050 
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Table 14. Psychosocial Characteristics of the CDI Sample  
Characteristic 
n (%) or M  SD 
Overall 
(N = 871) 
Recurrent CDI 
(n = 208; 23.9%) 
No recurrence 
(n = 663; 76.1%) 
P-value 
32. Support System  
     At initial admission  
     (all that apply) 
        Spouse/significant other 
        Children 
        Parent 
        Other relatives 
        Friends/neighbors 
        Church/faith community 
        Home care staff 
        Case manager/social worker 
        Other 
        none*  
     At discharge 
        Spouse/significant other 
        Children 
        Parent 
        Other relatives 
        Friends/neighbors 
        Church/faith community 
        Home care staff 
        Case manager/social worker 
        Other 
        none*  
 
 
 
340 (39.0) 
452 (51.9) 
  20 (  2.3) 
173 (19.9) 
128 (14.7) 
  53 (  6.1) 
  14 (  1.6) 
    1 (  0.1) 
  20 (  2.3) 
    7 (  0.8) 
 
305 (35.0) 
399 (45.8) 
  21 (  2.4) 
188 (21.6) 
130 (14.9) 
  51 (  5.9) 
    6 (  0.7) 
    1 (  0.1) 
  37 (  4.2) 
    8 (  0.9) 
 
 
 
  64 (30.8) 
103 (49.5) 
    8 (  3.8) 
  52 (25.0) 
  22 (10.6) 
  11 (  5.3) 
    2 (  1.0) 
    0 
  19 (  9.1) 
    1 (  0.5) 
 
  65 (31.3) 
105 (50.5) 
    8 (  3.8) 
  50 (24.0) 
  26 (12.5) 
  10 (  4.8) 
    2 (  1.0) 
    0 
  19 (  9.1) 
    2 (  1.0) 
 
 
 
276 (41.6) 
349 (52.6) 
  12 (  1.8) 
121 (18.3) 
106 (16.0) 
  42 (  6.3) 
  12 (  1.8) 
    1 (  0.2) 
    1 (  0.2) 
    6 (  0.9) 
 
240 (36.2) 
294 (44.3) 
  13 (  2.0) 
138 (20.8) 
104 (15.7) 
  41 (  6.2) 
    4 (  0.6) 
    1 (  0.2) 
  18 (  2.7) 
    6 (  0.9) 
 
n/a 
 
 
 
 
 
 
 
 
 
 
 
n/a 
 
 
33. Physical Abuse  
      At admit (n=744; 85.4%)   
         Denies 
         Denies and provider  
           concerned* 
         Yes in past* 
         Yes in present* 
      At discharge (n=744; 85.4%) 
         Denies 
         Denies and provider  
           concerned* 
         Yes in past* 
         Yes in present* 
 
 
739 (99.3) 
    3 (  0.4) 
 
    0 
    2 (  0.3) 
 
739 (99.3) 
    3 (  0.4) 
 
    0 
    2 (  0.3) 
 
 
165 (79.3) 
    2 (  1.0) 
 
    0 
    0 
 
165 (79.3) 
    2 (  1.0) 
 
    0 
    0 
 
 
574 (86.6) 
    1 (  0.2) 
 
    0 
    2 (  0.3) 
 
574 (86.6) 
    1 (  0.2) 
 
    0 
    2 (  0.3) 
 
 
 
 
0.172 
 
 
 
 
 
0.172 
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Characteristic 
n (%) or M  SD 
Overall 
(N = 871) 
Recurrent CDI 
(n = 208; 23.9%) 
No recurrence 
(n = 663; 76.1%) 
P-value 
34. Verbal Abuse 
      At admit (n=745; 85.5%) 
          Denies 
          Denies and provider  
            concerned* 
          Yes in past* 
          Yes in present* 
      At discharge (n=745; 85.5%) 
           Denies 
           Denies and provider  
             concerned* 
           Yes in past* 
           Yes in present* 
 
 
742 (99.6) 
    1 (  0.1) 
 
    1 (  0.1) 
    1 (  0.1) 
 
742 (99.6) 
    1 (  0.1) 
 
    1 (  0.1) 
    1 (  0.1) 
 
 
166 (79.8) 
    1 (  0.5) 
 
    0 
    0 
 
166 (79.8) 
    1 (  0.5) 
 
    0 
    0 
 
 
576 (86.9) 
    0 
 
    1 (  0.2) 
    1 (  0.2) 
 
576 (86.9) 
    0 
 
    1 (  0.2) 
    1 (  0.2) 
 
0.534 
 
 
 
 
 
0.534 
35. Sexual Abuse 
      At admit (n=745; 85.5%) 
           Denies 
           Denies and provider 
             concerned* 
           Yes in past* 
           Yes in present* 
      At discharge (n=745; 85.5%) 
           Denies 
           Denies and provider 
              concerned* 
           Yes in past* 
           Yes in present* 
 
 
744 (99.9) 
    0 
 
    1 (  0.1) 
    0 
 
744 (99.9) 
    0 
 
    1 (  0.1) 
    0 
 
 
167 (80.3) 
    0 
 
    0 
    0 
 
167 (80.3) 
    0 
 
    0 
    0 
 
 
577 (87.0) 
    0 
 
    1 (  0.2) 
    0 
 
577 (87.0) 
    0 
 
    1 (  0.2) 
    0 
 
1.000 
 
 
 
 
 
 
1.000 
 
 
 
 
36. Self-Neglect 
      At admit (n= 745; 85.5%) 
           Denies 
           Denies and provider  
             concerned* 
           Yes in past* 
           Yes in present* 
             (n= 745; 85.5%) 
            Denies 
            Denies and provider 
               concerned* 
           Yes in past* 
           Yes in present* 
 
 
740 (99.3) 
    4 (  0.5) 
 
    0 
    1 (  0.1) 
 
742 (99.6) 
    3 (  0.4) 
 
    0 
    0 
 
 
166 (79.8) 
    0 
 
    0 
    1 (  0.5) 
 
167 (80.3) 
    0 
 
    0 
    0 
 
 
574 (86.6) 
    4 (  0.6) 
 
    0 
    0 
 
575 (86.7) 
    3 (  0.5) 
 
    0 
    0 
 
0.159 
 
 
 
 
 
1.000 
 
 
 
 
*Note. P-value is for comparing groups using t-test or Mann-Whitney U test for 
continuous variables and Chi-square or Fisher’s exact test for categorical variables. 
Overall percentages are calculated with non-missing data.  
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Research Question 4 
What proportion of the sample has a frailty index score of 0.25 and above 
indicating frailty?  
 The FI-CDI was used to measure frailty in the sample. Due to missing data, the 
FI-CDI was available for calculation for 51.7% of the original sample (n=450) on 
admission and 53.7% of the original sample (n=468 at discharge).The FI-CDI revealed 
89.1% (n=401) classified as frail at admission with an index score of ≥0.25 and 88.5% 
(n=414) at discharge, with 10.9% (n=49) non-frail at admission and 11.5% (n=54) non-
frail at discharge. The FI-CDI average frailty scores were 0.37 (SD=0.10) on admission 
and 0.36 (SD=0.11) at discharge (see Table 15).  
 Figure 3 shows the distributions of FI-CDI by CDI recurrence status, with 
majority of those who recurred with an FI-CDI of 0.25 or greater (in overlapping purple). 
Boxplots of FI-CDI by CDI recurrence status are displayed in Figure 4. The median Fi-
CDI score is higher than for those with CDI recurrence versus without recurrence. A few 
index score outliers are noted for patients with both non-recurrence and CDI recurrence.  
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Figure 3. Histograms of FI-CDI Measure by No Recurrence (Red) and CDI Recurrence 
(Purple) 
 
 
 
 
Figure 4. Boxplots of FI-CDI Measure by CDI Recurrence Status 
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Research Question 5 
What is the relationship between the frailty index score during the initial 
admission for CDI and documented recurrence of CDI within a year?  
The FI-CDI scores for recurrent CDI group on admission and discharge were both 
0.38 (SD=0.09), compared to admit FI-CDI for patients without any recurrence (0.37  
0.11) and discharge (0.36  0.11) (p = 0.223). The FI-CDI was able to be applied to 
51.7% of the sample (n=450) at admission and 53.7% of the sample (n=53.7%) at 
discharge. For those with FI-CDI applied, 95.7% (n=111) of the recurrent CDI group had 
frailty scores ≥0.25 compared to 86.1% (n=303) of non-recurrent group at discharge, 
which was statistically significantly higher (p=0.008). While frailty was not found to be 
associated with CDI recurrence in these bivariate analyses at initial admission (p = .087), 
increased FI-CDI at initial admission was associated with increased odds of CDI 
recurrence after adjusting for sociodemographic factors. (AOR = 14.4, 95% CI = [1.120, 
198.0], p = 0.043 (see Table 16).  
 
Table 15. Bivariate Analysis of Frailty Index and Recurrent CDI Status  
 
Characteristic 
n (%) or M  SD 
Overall 
(N = 871) 
Recurrent CDI 
(n = 208; 23.9%) 
No recurrence 
(n = 663; 76.1%) P-value 
FI-CDI at admit  
(n=450; 51.7%) 
At discharge (n=468; 53.7%) 
 
≥ 0.25 (frailty) at admit 
< 0.25 
≥ 0.25 (frailty) at discharge 
< 0.25 
 
0.37  0.10 
0.36  0.11 
 
401 (89.1) 
  49 (10.9) 
414 (88.5) 
  54 (11.5) 
 
0.38  0.09 
0.38  0.09 
 
107 (93.9) 
    7 (  6.1) 
111 (95.7) 
    5 (  4.3) 
 
0.37  0.11 
0.36  0.11 
 
294 (87.5) 
   42 (12.5) 
 303 (86.1) 
  49 ( 13.9) 
 
0.223 
 
 
0.087 
 
0.008 
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Research Question 6 
What is the relationship between proton pump inhibitor (PPI) use prior to 
admission, frailty, and recurrent hospitalization for CDI?  
Bivariate analyses and logistic regression for recurrent CDI was performed to 
assess the relationship between PPI use prior to admission, frailty and recurrent 
hospitalization for CDI. From logistic regression findings, PPI use prior to admission was 
not found to be significantly associated with recurrent CDI, when adjusting for frailty and 
sociodemographics (AOR=1.183, 95% CI=[0.727, 1.934], p=0.500). 
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Table 16. Logistic Regression from Hierarchical Model Building for Recurrent CDI  
                (N =871) 
 
AOR 
(AOR 95% CI) 
Z value 
P-value 
Model 1. 
Sociodemographics 
(n = 625) 
Model 2. 
+FI-CDI 
(n = 383) 
Model 3.  
+PPI use 
(n = 383) 
Age 55 to < 65 vs. 
≥ 65 years 
1.596 
(1.014, 2.491) 
2.044 
0.041 
2.123 
(1.238, 3.637) 
2.745 
0.006 
2.088 
(1.216, 3.583) 
2.676 
0.007 
Female vs. Male 0.963 
(0.648, 1.437) 
-0.184 
0.854 
1.165 
(0.711, 1.924) 
0.603 
0.547 
1.140 
(0.692, 1.890) 
0.511 
0.609 
Non-White vs. 
White 
0.988 
(0.635, 1.516) 
-0.056 
0.955 
1.029 
(0.592, 1.762) 
0.105 
0.917 
1.050 
(0.602, 1.804) 
0.176 
0.860 
Not married vs. 
Married 
1.131 
(0.723, 1.770) 
0.540 
0.589 
0.993 
(0.558, 1.762) 
-0.023 
0.981 
1.006 
(0.564, 1.785) 
0.020 
0.984 
Private residence 
vs. Not private 
1.041 
(0.535, 2.162) 
0.112 
0.910 
1.052 
(0.470, 2.547) 
0.119 
0.905 
1.082 
(0.481, 2.629) 
0.184 
0.854 
Live Alone vs. 
Otherwise 
0.934 
(0.558, 1.544) 
-0.263 
0.793 
0.969 
(0.498, 1.858) 
-0.094 
0.925 
0.952 
(0.489, 1.829) 
-0.145 
0.884 
Discharged 
Home/Self-care vs. 
Otherwise 
0.734 
(0.483, 1.106) 
-1.465 
0.143 
1.010 
(0.594, 1.704) 
0.036 
0.971 
0.997 
(0.585, 1.684) 
-0.013 
0.990 
FI-CDI frailty 
index 
- 14.4 
(1.120, 198.0) 
2.028 
0.043 
11.9 
(0.873, 173.1) 
1.843 
0.065 
PPI use prior to 
admission 
- - 1.183 
(0.727, 1.934) 
0.675 
0.500 
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Summary 
 
 This chapter described the statistical analyses results for the exploration between 
frailty and recurrent CDI in the older adult. The sample was comprised of 871 patients 
ages 55 years and older who were hospitalized for CDI infection. The prevalence of 
recurrence for the study period was 23.9% (n=208), where patients in the sample had an 
average age of 73.6 years (SD=10.7) on admission and 9.1% expired during first 
hospitalization. Age remained significantly associated with recurrent admission in both 
bivariate analyses and logistic regression. Common co-morbidities included 
hypertension, arthritis, cancer, and diabetes for the sample. The FI-CDI measure of frailty 
applied to 450 patients on admission and 468 at discharge resulted in a prevalence of 
89.1% frail on admission and 88.5% of patients at discharge.  
FI-CDI scores were statistically significantly related to CDI recurrence after 
adjusting for sociodemographics. PPI use was found to not be associated in bivariate 
analysis or logistic modeling. 
 
 
 
115 
CHAPTER V 
DISCUSSION
 
 The purpose of this retrospective cohort study was to examine the relationship 
between frailty and recurrent CDI, specifically measuring frailty on an index admission 
with the researcher-derived FI-CDI. This chapter will discuss findings, limitations of 
study, implications for nursing, and recommendations for future research.  
Accumulation of Deficits Framework 
This study used the Accumulation of Deficits framework by Mitnitski, Mogilner, 
and Rockwood (2001), with operationalization of frailty performed through the 
researcher-derived frailty index, FI-CDI. This application of the FI-CDI is consistent with 
the clear guidelines by Searle and colleagues (2008), using variables associated with 
health, increasing with age, do not present early in the aging process, cover wide 
representation of organ systems, and used serially in the sample for measurement. 
For purposes of this study, CDI was an acquired infection from the environment, 
illustrated as an external stress that results in physiological changes for the individual. 
The frailty index variables were interdependent deficits that could accumulate in a 
person. Due to the number of deficits affecting potential recovery time of an individual, 
higher frailty scores were hypothesized to result in impairment and affect recovery time, 
potentially increasing the risk of recurrent CDI and hospital readmission. The FI-CDI, 
applied to 51.7% (n=450) of the original sample, revealed frailty prevalence of 89.1% 
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frail on admission. After adjusting for sociodemographics, frailty was statistically 
significantly related to CDI recurrence. This finding supported the framework, as the 
presence of the external stressor CDI on a frail individual was significantly associated 
with recurrence. This finding is consistent with impairment to fully recover in the 
presence of frailty, with subsequent recurrence and actual hospital admission. 
Furthermore, although older adults are at risk for recurrent CDI, chronological age does 
not completely explain this phenomenon (Collins et al., 2015).  
Sample 
 All CDI admission and readmission from December 31, 2012 to December 31, 
2016 were extracted from the participating hospital database by approved hospital 
personnel, and 871 patients qualified for the study with a total of 1,199 admissions. The 
sample size of this study was higher than three recently reported studies that examined 
the relationship between frailty and CDI. Milani et al. (2016) reported 84 subjects, while 
Venkat et al. (2016) reported 483 subjects. Behar and colleagues (2017) had a total 
sample size of 727 participants, but 410 were carriers without active CDI. The average 
age on initial admission for this study was 73.6 years (SD=10.7), similar to other studies 
(Milani et al., 2016; Van Esch et al., 2015; Venkat et al., 2016). Females comprised 
58.6% (n=510) of the overall sample, which is close to national trends of 64-65% female 
representation for CDI (Shrestha, Bime, & Taleban, 2018).  
 CDI recurrence over the study period was 23.9%, which is consistent with 
estimate recurrence rates of 10-40% after initial admission (Collins et al., 2015; Garey et 
al., 2008; Kelly & LaMont, 2008). The majority of the sample had recurrences greater 
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than or equal to 30 days between first discharge and subsequent recurrent admission. 
Although recurrent CDI usually happens within one to three weeks after antibiotic 
completion, recurrence can be months later (Cohen et al., 2010; Chopra & Krishna, 2014; 
McDonald et al., 2007), as found in this study.  
CDI recurrence was more prevalent for those discharged to a skilled nursing 
facility and home health care services. Collins et al. (2015) reported differing results that 
skilled nursing facility, hospice, and long-term care actually decreased the odds of CDI 
readmission. The average length of stay for an index admission was 8.8 days, with 
average length of stay at index admission for those with eventual recurrent CDI 
admission 8.9 days; this is slightly higher than a recent national estimate of 5.8 days for 
CDI admission (Shrestha, Bime, & Taleban, 2018).  
Interpretation of Findings 
Research Question 1 
 What sociodemographic variables are related to recurrent CDI admission?  
 Sociodemographic variables and recurrent CDI admission were examined for the 
initial 871 patients. Sex, race, ethnicity, and marital status were not associated with 
recurrent CDI admission. Interestingly, literature supports African-American race as an 
independent risk factor for recurrent CDI (Argamany et al., 2016; Freedberg et al., 2013), 
which was not found in this research study.  Age was the only sociodemographic variable 
related to recurrent CDI admission. Recurrent CDI was more prevalent in the ages 55 to 
64 years old compared to patients ages 65 and older. Age also remained an independent 
predictor for recurrent CDI after multivariable logistic regression for recurrent CDI 
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(Table 16). The odds of any CDI recurrence in the 55 to 64 year age group increased by 
108.8% compared to age 65 and older, after adjusting for sociodemographics, frailty, and 
PPI use. This finding is in contrast to literature which supports increased risk of 
recurrence with increasing age (Louie et al., 2013).  Collins et al. (2015) also did not find 
increasing age related to CDI readmission in a sample of persons ages 65 and older.  
Research Question 2 
What sociodemographic variables are related to frailty during an initial 
admission for CDI?  
 Continuous age on initial admission weakly correlated with frailty. Frailty 
prevalence is known to increase with age (Clegg et al., 2013). The frailty index of an 
individual increases an average of 10-fold between ages of 20 and 90 (Theou et al., 
2015). In prior research, frailty scores have shown to be higher in women versus men 
regardless of the variable combination (Mitnitski & Rockwood, 2015). Moreover, in this 
study, the average FI-CDI score for females was similar to males. Sex, ethnicity, and 
marital status were not significantly associated with frailty. However, frailty scores were 
significantly higher for African-American patients compared to Caucasian patients. This 
is consistent with literature that frailty prevalence is higher (65-85% more) among those 
African-American versus Caucasian (Bandeen-Roche et al., 2015). Statistically 
significant differences were noted with place of residence prior to admission, as patients 
living in skilled nursing facility and assisted living facilities had the highest average 
frailty scores, which is also consistent with increased frailty prevalence for institutional 
care (Bandeen-Roche et al., 2015).  
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The average FI-CDI score for those who expired on initial admission for CDI was 
0.40. A frailty score of 0.40 and above has shown sensitivity and specificity for adverse 
outcomes including inpatient mortality (Hubbard et al., 2017). The frailty index is 
associated with poor health outcomes, with a maximum possible frailty score around 0.7 
(Theou et al., 2015). The length of stay was weakly to moderately positively significantly 
correlated with frailty; yet the number of CDI recurrences showed no significant 
correlation with frailty. Frailty has been correlated with length of stay in the literature, 
similar to findings in this retrospective study (Drubbel et al., 2014; Evans et al., 2014; 
Singh et al., 2012).  Interestingly, no significant correlation was noted with frailty and 
days between admissions for CDI. Murphy and colleagues (2012) noted that the risk of 
readmission for CDI after all-cause hospitalization was highest within 12 weeks after 
discharge, with risk of readmission decreasing thereafter. Hospital presentation for 
reasons other than CDI was not included in this study.  
Research Question 3 
What is the prevalence of the frailty index variables among members of the 
population? 
The most prevalent co-morbidities in the sample included hypertension, arthritis, 
cancer, and diabetes; diabetes is known as a risk factor for frailty, and it also is an 
independent risk factor for treatment failure of CDI (Jung et al., 2010; Zaslavsky, et al. 
2016). Cancer and arthritis are both known for association with frailty and subsequent 
adverse effects (Cacciatore et al; 2014; Perez-Zepeda et al., 2016). In this study, 
hypertension, heart failure, and chronic kidney disease was found to be significantly more 
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prevalent in recurrent CDI. The burden of diseases and co-morbidities have been 
predictive of increased risk for CDI recurrence (Collins et al., 2015). Severe CDI has also 
been associated with heart failure (Rao et al., 2013). Although this study did not include 
severity of CDI, the significant prevalence of heart failure in those who recurred should 
prompt thorough investigation into other co-existing co-morbidities at time of admission. 
Thorough assessment of the patient with a known history of heart failure may serve to 
decrease risk of recurrence if co-existing health conditions are closely monitored while 
inpatient and in follow-up.  
As the average Body Mass Index (BMI) was 27.0 kg/m
2 
and 26.9% had a BMI 
greater than 30 kg/m
2
, nutritional needs remain a concern. The obese patient has also 
been found frail as well, with concerns for sarcopenic obesity in the setting of increased 
body fat and decreased skeletal muscle (Cooper et al., 2012).  Sarcopenic obesity is 
linked with impaired mobility in the older adult, contributing to frailty.  
Over half of the sample had a history of smoking at some point during the 
lifespan, and 12.6% of the sample endorsing daily smoking. As known in the literature, 
this lifestyle behavior contributes to frailty progression (Kojima et al., 2017; Ulley & 
Abdelhafiz, 2017). Although prevalence of current daily smokers, former smokers, and 
ever smoking in lifetime was similar for recurrent and non-recurrent group, this lifestyle 
habit contributes to the potential for frailty over time.  
Laboratory abnormalities most present in the sample included hypoalbuminemia, 
abnormal ALT, low hemoglobin, elevated creatinine, elevated BUN, leukocytosis, 
elevated glucose level, and hyponatremia. Leukocytosis and hypoalbuminemia are 
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biomarkers that are not only contributors to the development of frailty but strongly 
associated with mortality in the hospitalized older adult (Fontana et al., 2013). Low or 
low normal hemoglobin has been shown to be an independent risk factor for frailty 
(Chaves et al., 2005). Sodium imbalances may be a culprit for hospitalization, falls, and 
mental status changes, contributing to frailty (Morley, 2015). Elevated creatinine is 
considered a risk factor for 30-day mortality in the older adult with CDI, and individuals 
with chronic kidney disease were more likely to have CDI recurrence.  
 Although over half of the population had slightly limited mobility, over half of the 
sample was high fall risk, increasing risk for future falls. In addition, 20.0% of the sample 
had fallen within the past six months at time of admission; with frailty as a predictor of 
future fall risk, the notable prevalence of fall risk in the sample is concerning (Li et al., 
2014; Liu et al, 2016; Sanchez-Garcia et al., 2017). Over two-thirds had a Braden score  
18, which is a reflection of multiple domains that contribute to the frailty trajectory (Ogg, 
2016). The combination of increased fall risk, mobility impairment, and nutritional issues 
are factors that contribute to frailty and decline.  Recognition of these deficits are 
imperative in the hospital setting.  
Support systems were documented as present in the majority of the sample, 
including children, spouse/significant other, other relatives, and friends/neighbors, and 
less than one percent reported physical and verbal abuse in present. Self-neglect was 
reported in less than one percent in present. The psychosocial domain should be 
recognized, as the lack of psychosocial support is a known contributor to frailty 
(Hoogendijk et al., 2014a). Those with solitary living arrangements have been associated 
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with frailty (Ng et al., 2014), while those with increased social support have been 
associated with decreased frailty Woo et al., 2005). Physical abuse, verbal abuse, sexual 
abuse, and self-neglect were largely denied by the sample but recognition of elder abuse 
is paramount in providing care. Risk factors for elder abuse including frailty, physical 
decline, and difficulty with ADLs, should be assessed during acute hospitalizations of 
this vulnerable population, as literature has approximated 6% of older community-
dwelling adults as victims of abuse (Cooper et al., 2008).  Self-neglect, also leading to 
greater likelihood of frailty, has been shown to be an independent risk factor for early 
demise (Papaioannaou et al., 2012). Frailty may precipitate worsening self-neglect; 
therefore, careful assessment of the older adult is necessary for intervention as 
appropriate.  
Research Question 4  
What proportion of the sample has a frailty index score of 0.25 and above 
indicating frailty?  
The FI-CDI was used to measure frailty of those in the sample with all FI-CDI 
variables available (n=450), with 89.1% frail on admission. Prior research utilizing 
various frailty indices have estimated a wide range of frailty prevalence, depending on 
outcome and population studied. When using a frailty index for acutely hospitalized older 
adults, prevalence of frailty ranged from 27% to 87.1% (Chong et al., 2017; Dent et al., 
2014; Eeles et al., 2012; Joseph et al., 2015; Krishan et al., 2014; Patel et al., 2014). The 
majority of the analysis sample with FI-CDI applied was frail, which was consistent with 
the upper limits of frailty prevalence already reported in the literature for hospitalized 
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older adults. However, reported frailty prevalence in the specific population of those with 
acute hospitalization for CDI is sparse. Known existing studies using a frailty index with 
CDI patients have been in the outpatient setting or utilizing a modified frailty index in the 
post-surgical setting for complicated CDI; these did not report frailty prevalence of the 
sample in findings (Van Esch et al., 2015; Venkat et al., 2016).  
Research Question 5  
What is the relationship between the frailty index score during the initial 
admission for CDI and documented recurrence of CDI within a year?  
 The majority of those who had recurrent CDI admission were classified as frail on 
initial admission, without a significant difference in average continuous FI-CDI scores 
for recurrent and non-recurrent group. However, there was a significant difference in 
frailty prevalence for the recurrent CDI group at discharge compared to the non-recurrent 
group at discharge. Additionally, although initial admission frailty was not associated 
with CDI recurrence in bivariate analyses, an increased continuous frailty score was 
associated with increased odds of CDI recurrence after adjusting for sociodemographic 
variables, which contributes to the knowledge gap of the relationship between frailty and 
recurrent CDI. This research study provides new knowledge, as prior studies examining 
CDI and frailty have not examined recurrent CDI and frailty (Behar et al., 2017; Milani et 
al., 2016; Van Esch et al., 2015; Venkat et al., 2016). Behar et al. (2017) reported 
asymptomatic carriage of Clostridium difficile had a higher likelihood of prior CDI and 
were more frail than non-carriers, but frailty was described by assessing malnutrition and 
activities of daily living. Milani et al. (2016) measured frailty in older adults (65 and 
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older) with the Clinical Frailty Scale, noting similar frailty scores in those with CDI and 
those without CDI. Van Esch et al. (2015) used a frailty index that showed no difference 
in frailty index scores between CDI group and non-CDI group. Finally, Venkat et al. 
(2016) reported increased modified frailty index scores predicting morbidity and 
mortality of those who had undergone colectomy for CDI due to complicated/severe 
features. These studies did not examine recurrent CDI and frailty, which this study has 
done and contributed to a knowledge gap in the literature.  
Research Question 6 
What is the relationship between proton pump inhibitor (PPI) use prior to 
admission, frailty, and recurrent hospitalization for CDI?  
PPI use prior to admission was found to be significantly associated with frailty on 
admission in bivariate analysis; however, PPI use prior to admission was not significantly 
associated with recurrent CDI, adjusting for frailty and sociodemographics. PPI use has 
been associated with increased risk for CDI incidence and recurrence (Linsky et al., 
2010; McDonald et al., 2015; Roughead, Chan, Choi 2016; Trifan et al., 2017), but 
literature is mixed regarding findings. As PPI use was not significantly associated with 
recurrent CDI in this study, further research is needed to assess relationship and possible 
confounding variables.  
Limitations of the Study 
There are several limitations of this study due to the retrospective design of this 
cohort study and use of electronic health record. Laboratory values were assessed with 
the first available value and last value at discharge; however, timing of laboratory 
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analysis could vary across the sample with time obtained and resulted. The majority of 
laboratory values for the FI-CDI are obtained when providing care for acute presentation 
to the hospital, including complete blood count, comprehensive metabolic panel or basic 
metabolic panel. When using EHR data, specific patient characteristics may not always 
be accurately and completely documented by clinical staff and providers. Patients who 
expired during the initial admission were excluded from further analyses regarding 
recurrence. Information about antibiotic exposure prior to presentation for initial and 
recurrent admission was not obtained, as this was not available for this study. During 
hospitalization, the severity of CDI was not able to be determined, nor was the level of 
care such as intensive care, general admission, and treatment regimen. Discharge 
disposition was captured for the sample, but this does not describe events after discharge 
such as compliance with outpatient treatment, appropriate sanitization of the living 
environment, presentations to other hospital system, support system at home, and even 
death. Additionally, it is unknown if discharge locations for individuals were the same as 
pre-admission, as the prevalence of recurrent CDI was greater in those discharged to 
skilled nursing facility or home health care after initial admission. Hospital-acquired or 
community-acquired CDI was unable to be determined from this study, which could 
affect recurrence and morbidity. Although care was taken to define an initial admission, 
the researcher does not know if it was truly their first lifetime admission for CDI; 
however, the study period allowed review of admissions to determine presentation. If an 
individual had been admitted several years before the data that was used for this study, 
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the CDI presentation was likely from a different strain and would not be defined as a 
recurrence due to significant span of time between admissions.  
Implications for Nursing 
Nursing staff and advanced practice nurses have the opportunity to recognize the 
presence of frailty on admission for an acutely hospitalized patient with CDI. 
Hospitalized frail older adults are at risk for prolonged recovery during and after 
hospitalization, increased length of stays, need for higher acuity of care, and have an 
increased mortality rate compared to non-frail individuals (Hatheway et al., 2017; 
Muscedere et al., 2017; Vermeiren et al., 2016). The deficits that comprised the FI-CDI 
noted multiple clinical domains and laboratory values that were abnormal, capturing a 
snapshot of function for organ systems, which could be intervened upon to promote 
health and recovery and mitigate frailty (Howlett & Rockwood, 2013). Specifically, a 
large portion of the sample displayed hypoalbuminemia, raising concern for malnutrition 
and need to address nutrition during hospitalization and post-discharge. 
Hypoalbuminemia is associated with the development of frailty and mortality, thus 
attention to this is warranted (Fontana et al., 2013). Addition of nutritional 
supplementation and palatable flavors could be used to improve calorie intake and 
stimulate appetite (Lucas & Kennedy-Malone, 2014). BUN and creatinine were elevated 
in approximately half the sample, which is likely multifactorial in the setting of acute 
diarrheal illness, and this improved through hospitalization. However, close attention to 
laboratory markers during admission are vital to care of the whole patients, as 
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hypoalbuminemia and elevated creatinine are risk factors for 30-day mortality in the 
older adult with CDI (Bloomfield et al., 2012; Leibovici-Weissman et al., 2017).  
Approximately two-thirds of the sample had a Braden scale less than 18, raising 
concern for pressure ulcer risk (Braden & Bergstrom, 1994), and bedside nursing has the 
opportunity to intervene directly with mobility measures, frequent turning, serial 
assessment and detailed documentation. Intervention to reduce pressure ulcer risk will in 
turn address an aspect that is one of many contributors to frailty.  
Frailty recognition is vital to provide care and intervention as appropriate. Use of 
the FI-CDI includes multiple potential deficits that are associated with the frailty 
trajectory, consistent with the Accumulation of Deficits approach. Instead of focusing 
only on individual domains such as fall risk and Braden scale scores, incorporating 
multiple domains provides a larger range of intervention opportunity to potentially 
change the frailty pathway. Identifying an FI-CDI score of 0.25 and greater provides a 
classification for frailty. In addition, using a continuous score provides more precise 
measurements of frailty and prediction of adverse outcomes. Scores of 0.4 and above 
raise concern for ADL dependence and a significantly higher risk of mortality (Hubbard 
et al., 2017). Each increase of 0.1 has been shown to be associated with increased 
incidence of adverse outcomes (Hubbard et al., 2017). Identifying FI-CDI scores on 
admission will guide interventions and care throughout the hospitalization and post-
discharge.  
Interestingly, initial frailty prevalence on admission was not associated with 
recurrent CDI, but discharge frailty prevalence was significant for recurrent CDI. This 
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finding raises the need for identification of frailty throughout hospitalization instead of 
only on admission. Utilization of EHR may calculate a frailty score quickly, as this data 
is readily available on admission. The FI-CDI may be efficiently calculated with existing 
EHR data, triggering interventions from a multidisciplinary standpoint. For instance, 
variables in the FI-CDI that are abnormal could trigger nutrition consults, physical 
therapy, psychological support, pharmacy support, and internists support through 
awareness of chronic diseases present that may be overlooked due to focusing on acute 
illness.  
Proper sanitization of living arrangements must be reviewed with individuals 
returning home, as spores are known to survive up to months on surfaces, even in harsh 
environments (Keller & Surawicz, 2014). Patient education is paramount in preventing 
the spread of CDI. Education should begin during hospitalization, as proper hand 
washing and sanitization while inpatient may help decrease health-care acquired 
infections. Transport from hospital to other facilities via hospital-approved transport or 
emergency medical services should exercise contact precautions to decrease risk of CDI 
transmission of a known or suspected infected individual.  
During inpatient admission, patients should be placed in a private room with 
dedicated bathroom and equipment; however, in nursing homes or other facilities, private 
rooms may not be available. If private rooms are not available for those infected or 
known colonized status, patients should be grouped together with same infecting 
organism (McDonald et al., 2018). Contact precautions should be followed, and 
discontinuation of precautions may be considered if resolution of diarrhea is documented 
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for at least 48 hours (McDonald et al., 2018). Cleaning of rooms and any reusable 
equipment must be performed with a United States Environmental Protection Agency 
appropriate sporicidal bleach disinfectant (McDonald et al., 2018). Disinfecting with “no-
touch” methods such as ultraviolet radiation or hydrogen peroxide vapor has been 
employed by facilities but limited data exists and further research is needed.  Daily 
inpatient disinfecting of surfaces is recommended, coupled with appropriate contact 
precautions, washing of hands with soap and water, and dedicated equipment (McDonald 
et al., 2018). As an outpatient, all surfaces should be cleaned with bleach, hand washing 
with soap and water, and dedicated bathroom if possible.  
Since 2013, hospitals that participate in the Centers for Medicare and Medicaid 
Services (CMS) Hospital Inpatient Quality Reporting Program have reported CDI 
infection data to the National Healthcare Safety Network, with the goal of movement 
towards prevention of CDI (Centers for Disease Control and Prevention, 2015b). The 
U.S. Department of Health and Human services also have target reductions of 30% for 
facility onset of CDI and CDI hospitalizations by 2020 (Centers for Disease Control and 
Prevention, 2015b). Therefore, as increased frailty scores on admission is associated with 
increased odds of CDI recurrence, findings suggest that assessment and targeted 
intervention for the frail older adult may decrease the possibility of readmission for CDI 
recurrence. Ensuring nutritional and hydration needs are met and early mobilization of 
hospitalized individuals is recommended as necessary interventions to decrease geriatric 
syndromes that contribute to frailty (Hatheway et al., 2017; Hubbard et al., 2017).  
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Recommendations for Future Research 
This study confirms the need for future research regarding recurrent CDI, age, and 
frailty. The present study noted a significant finding of younger age (55 to 64) related to 
recurrent CDI relative to patients 65 and older. When age was measured continuously, no 
significant difference between recurrence and non-recurrence groups were noted. Yet, 
age (55-64) remained an independent predictor for recurrent CDI when adjusting for 
other sociodemographics, frailty, and PPI prior to admission. Future studies could explore 
other variables such as severity of course, acuity level, hospital-acquired or community-
acquired infection, and discharge follow-up to assess compliance with treatment regimen.  
Frailty prevalence in hospitalized older adults with CDI needs further research, as 
existing literature is sparse. Applying the FI-CDI on admission and discharge is 
necessary to capture this patient population and determine overall frailty prevalence.  
Further replication of the FI-CDI could be used in prospective studies to determine risk of 
adverse outcomes beyond CDI recurrence and readmission. In this study, the FI-CDI was 
an assessment of frailty status, whereby future research could employ the FI-CDI as a 
tool to predict adverse outcomes to include readmission for other reasons, 
institutionalization, and emergency room presentation, as the deficit accumulation 
approach has been shown to significantly predict mortality and hospitalization 
(Vermeiren et al., 2016). A meta-analysis by Vermeiren et al. (2016), reviewed 31 
articles for frailty measurements and prediction of adverse outcomes. The deficit 
accumulation approach was used in seven of these articles, with findings of significantly 
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predicting mortality and hospitalization (Vermeiren et al., 2016). Therefore, using the FI-
CDI for purposes beyond prediction of CDI recurrence needs further exploration.  
 Future research is also needed to explore PPI use and CDI risk and recurrence, as 
this remains controversial in the literature (Freedberg et al., 2013; Linksy et al., 2010; 
McDonald et al., 2015; Roughead et al., 2016; Trifan et al., 2017). Although PPI use 
prior to admission was significantly associated with frailty in bivariate analyses, PPI use  
was not significantly associated with recurrent CDI. Prospective studies capturing other 
possible cofounders such as antibiotic exposure prior to admission, choice of antibiotic 
during admission, post-discharge events, length of therapy on PPI, choice of PPI, and 
continuation of PPI after discharge should be undertaken. 
Finally, healthcare costs both inpatient and outpatient are a concern, as the United 
States burden of CDI is approximately 500,000 cases annually (Lessa et al., 2015). 
Inpatient costs for CDI are over 4.8 billion, and costs for care in long-term care facilities 
still deserves further research (Dubberke & Olsen, 2012). Yu and colleagues (2016) 
performed a retrospective cohort study exploring costs for care of adults age 65 and older 
with Medicare of Medicaid residing in nursing homes with CDI. The authors estimated 
$15,000 expended per case and ultimately 800 million in healthcare costs for those in 
nursing homes with CDI (Yu, Baser, & Wang, 2016). Further research utilizing the FI-
CDI to predict adverse outcomes should be undertaken, with exploration of resulting 
healthcare cost implications resulting from FI-CDI application during acute 
hospitalization.   
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Summary 
This retrospective cohort study has explored the relationship between CDI and 
frailty by using a researcher-derived FI-CDI, with frailty scores significantly related to 
CDI recurrence after adjusting for sociodemographics. The age group 55 to less than 65 
remained significantly associated with recurrent admission, compared to 65 and older 
members of the sample. PPI use was not associated with recurrent CDI prior to 
admission, but PPI use was significantly related to frailty with bivariate analysis. PPI use 
prior to admission was not significantly associated with recurrent CDI, when adjusted for 
frailty and sociodemographics. This study has helped narrow the knowledge gap 
regarding frailty and recurrent CDI. The use of the EHR offers the opportunity to 
aggregate existing clinical data to estimate risk and vulnerability that requires further 
assessment and targeted intervention beyond usual care. The older adult hospitalized with 
CDI should be assessed for frailty, as findings from this study confirm a relationship 
between frailty and recurrent CDI. Further research is needed to advance understanding 
of CDI and frailty to build the science base for implementing best practices for person-
centered care.  
 
133 
REFERENCES
 
Abellan van Kan, G., Rolland, Y., Bergman, H., Morley, J.E., Kritchevsky, S.B., & 
Vellas, B. (2008). The I.A.N.A. task Force on frailty assessment of older people 
in clinical practice. The Journal of Nutrition, Health, and Aging. 12 (1), 29-37. 
doi: 10.1007/BF02982161 
Adams, J.S. & Hewison, M. (2010). Update in vitamin D. Journal of Clinical 
Endocrinology and Metabolism, 95 (2), 471-478. doi: 10.1210/jc.2009-1773 
Adams, P., Ghanem, T., Stachler, R., Hall, F., Velanovich, V., & Rubinfeld, I. (2013). 
Frailty as a predictor of morbidity and mortality in inpatient head and neck 
surgery. JAMA Otolaryngoly Head and Neck Surgery, 139 (8), 783-789. doi: 
10.1001/jamaoto.2013.3969 
Afilalo, J. (2011). Frailty in patients with cardiovascular disease: Why, when, and how to 
measure. Current Cardiovascular Risk Reports, 5(5) 467-472. doi: 
10.1007/s12170-011-0186-0 
Alasmari, F., Seiler, S.M., Hink, T., Burnham, C.A., & Dubberke, E.R. (2014). 
Prevalence and risk factors for asymptomatic Clostridium difficile carriage. Clinic 
Infectious Diseases, 59 (2), 216-222. Doi: 10.1093/cid/ciu258 
 
 
 
134 
Almeida, O.P., Hankey, G.J., Yeap, B.B., Golledge, J., Norman, P.E., & Flicker, L 
(2015). Depression, frailty, and all-cause mortality: A cohort study of men older 
than 75 years. Journal of the American Medical Directors Association, 16 (4), 
296-230. doi: 10.1016/j.jamda.2014.10.023 
Andela, R.M., Dijkstra, A., Slaets, J.P., & Sanderman, R. (2010). Prevalence of frailty on 
Clinical wards: Description and implications. International Journal of Nursing 
Practice, 16 (1), 14-22. doi: 10.1111/j.1440-172X.2009.01807.x 
Ansryan, L.Z., Aronow, H.U., Borenstein, J.E., Mena, V., Haus, F., & Palmer, K. (2018). 
Systems addressing frail elder care: A description of a successful model. The 
Journal of Nursing Administration, 48 (1), 11-17. doi: 
10.1097/NNA.0000000000000564 
Argamany, J.R., Delgado, A., & Reveles, K.R. (2016). Clostridium difficile infection 
health disparities by race among hospitalized adults in the United States, 2001 to 
2010. BMC Infectious Diseases, 16 (1), 454, doi: 10. 1186/s12879-016-1788-4 
Armstrong, J.J., Mitnitski, A., Launer, L.J., White, L.R., Rockwood, K. (2015). Frailty in 
the Honolulu-Asia aging study: Deficit accumulation in a male cohort followed to 
90% mortality. The Journals of Gerontology. Series A. Biological Sciences and 
Medical Sciences, 70 (1), 125-131. doi: 10.1093/gerona/glu089. 
Armstrong, J.J., Stolee, P., Hirdes, J.P., & Poss, J.W. (2010). Examining three frailty 
conceptualizations in their ability to predict negative outcomes for home-care 
clients. Age and Ageing, 39 (6), 755-758.  doi: 10.1093/ageing/afq121 
 
135 
Bandeen-Roche, K., Seplaki, C.L., Huang, J., Buta, B., Kalyani, R.R., Varadhan, R., 
…Kasper, J.D. (2015). Frailty in older adults: A nationally representative profile 
in the United States. The Gerontological Society of America, 70 (11), 427-1434. 
Doi: 10.1093/gerona/glv133 
Bandeen-Roche, K., Xue, Q.L., Ferrucci, L., Walston, J., Guralnik, J.M, Chaves, P., … 
Fried, L.P.  (2006). Phenotype of frailty: Characterization in the women’s health 
and aging studies. The Journals of Gerontology: Series A, Biological Sciences 
and Medical Sciences, 61 (3), 262-266. doi: 10.1093/gerona/61.3.262 
Beers, M.H. & Berkow, R. (Eds). (2000). The Merck Manual of Geriatrics (Vol. 3). 
Whitehouse Station, NJ: Merck Research Laboratories.  
Behar, L., Chadwick, D., Dunne, A., Jones, C.I., Proctor, C., Rajkumar, C., … Llewelyn, 
M.J. (2017). Toxigenic Clostridium difficile colonization among hospitalized 
adults: Risk factors and impact on survival. Journal of Infection, 75 (1), 20-25. 
doi: 10.1016/j.jinf.2017.04.006 
Berardelli, M., DeRango, F., Morelli, M., Corsonello, A., Mazzei, B., Mari, V., … 
Passsarino, G. (2013). Urinary incontinence in the elderly and in the oldest old: 
Correlation with frailty and mortality. Rejuvenation Research, 16 (3), 206-211. 
doi:10.1089/rej.2013.1417 
Bergstrom, N., & Braden, B.J. (2002). Predictive validity of the Braden scale among 
black and white subjects. Nursing Research, 51 (6), 398-403.  
 
 
136 
Bertolotti, M., Lonardo, A., Mussi, C., Baldelli, E., Pellegrini, E., Ballestri, S., … Loria, 
P. (2014). Nonalcoholic fatty liver disease and aging: Epidemiology to 
management. World Journal of Gastroenterology: WJG, 20(39), 14185–14204. 
doi: 10.3748/wjg.v20.i39.14185 
Biedermann, L. & Rogler, G. (2015). The intestinal microbiota: its role in health and 
disease. European Journal of Pediatrics, 174 (2), 151-167. doi : 10.1007/s00431-
014-2476-2 
Binks, F.A. (1968). Approach to disability and breakdown. British Medical Journal, 1, 
269-274. 
Bishop, N.A., Lu, T., Yankner, B.A. (2010). Neural mechanisms of ageing and cognitive 
decline. Nature, 464 (7288), 529-535. doi:10.1038/nature08983 
Blodgett, J. M., Theou, O., Howlett, S. E., & Rockwood, K. (2017). A frailty index from 
common clinical and laboratory tests predicts increased risk of death across the 
life course. Geroscience, 39 (4), 447-455. Doi: 10.1007/s11357-017-9993-7 
Bloomfield, M.G., Sherwin, J.C., & Gkrania-Klotasas, E. (2012). Risk factors for 
mortality in Clostridium difficile infection in the general hospital population: A 
systematic review. Journal of Hospital Infection, 82 (1), 1-12. doi: 
10.1016/j.jhin.2012.05.008 
Boyle, P., Buchman, A., Wilson, R., Leurgans, S., & Bennett, D. (2010). Physical frailty 
is associated with incident mild cognitive impairment in community-based older 
persons. Journal of The American Geriatrics Society, 58(2), 248-255. 
doi:10.1111/j.1532-5415.2009.02671.x 
 
137 
Braden, B. J. & Bergstrom, N. (1994). Predictive validity of the Braden scale for pressure 
sore risk in a nursing home population. Research in Nursing & Health, 17 (6), 
459–470. doi:10.1002/nur.4770170609 
Bridgden, M., & Heathcote, J.C. (2000). Problems in interpreting laboratory tests. 
Postgraduate Medicine, 107 (7), 145-158.  
British Geriatrics Society (2014). Fit for Frailty Part 1. Retrieved from 
http://www.bgs.org.uk/campaigns/fff/fff_full.pdf 
Bruminhent, J., Wang, Z.X., Hu, C., Wagner, J., Sunday, R., Bobik, B., … Flomenberg, 
P.  (2014). Clostridium difficile colonization and disease in patients undergoing 
hematopoietic stem cell transplantation. Biology of Blood and Marrow 
Transplantation 20 (9), 1329-1334. doi: 10.1016/j.bmt.2014.04.026 
Cacciatore, F., Della-Morte, D., Basile, C., Mazella, F., Mastrobuoni, C., Salsano, E., 
…Abete, P. (2014). Long-term mortality in frail elderly subjects with 
osteoarthritis. Rheumatology, 53 (2), 293-299. doi: 10.1093/rheumatology/ket348 
Cacciatore, F., Testa, G., Galizia, G., Della-Morte, D., Mazzella, F., Langellotto, A., 
…Abete, P. (2013). Clinical frailty and long-term mortality in elderly subjects 
with diabetes. Acta Diabetologica, 50 (2), 251-260. doi: 10.1007/s00592-012-
0413-2 
Cappola, A.R., Xue, Q.L., & Fried, L.P. (2009). Multiple hormonal deficiencies in 
anabolic hormones are found in frail older women: The women’s health and aging 
studies. Journals of Gerontology. Series A, Biological Sciences and Medical 
Sciences, 64 (2), 243-248.doi: 10.1093/gerona/gln026 
 
138 
Centers for Disease Control and Prevention. (2015a, February 25). Healthcare Associated 
Infections. Retrieved from 
http://www.cdc.gov/HAI/organisms/cdiff/Cdiff_infect.html. 
Centers for Disease Control and Prevention (2015b). Tracking Clostridium difficile 
infection. Retrieved from https://www.cdc.gov/hai/organisms/cdiff/tracking-
cdiff.html 
Cesari, M., Calvani, R., & Marzetti, E. (2017). Frailty in older persons. Clinics in 
Geriatric Medicine, 33, 293-303. doi: 10.1016/j.cger.2017.02.002 
Chakra, C.N.A., Pepin, J., Sirard, S., & Valiquette, L. (2014). Risk factors for recurrence, 
complications, and mortality in Clostridium difficile infection: A systematic 
review. PloS ONE, 9 (6), e98400, doi: 10.1371/journalpone.0098400 
Chaves, P., Semba, R., Leng, S., Woodman, R., Ferrucci, L., Guralnik, J., & Fried, L. 
(2005). Impact of anemia and cardiovascular disease on frailty status of 
community-dwelling older women: The women's health and aging studies I and 
II. Journals of Gerontology Series A: Biological Sciences & Medical Sciences, 60 
(6), 729-735. doi: 10.1093/gerona/60.6.729 
Chintanaboina, J., Navabi, S., Suchniak-Mussari, K., Stern, B., Bedi, S., Lehman, E.B., & 
Tinsley, A. (2017). Predictors of 30-day mortality in hospitalized patients with 
Clostridium difficile infection. Southern Medical Journal, 110 (8), 546-549. doi: 
10.14423/SMJ.0000000000000687 
 
 
139 
Chong, E., Ho, E., Baldevarona-Llego, J., Chan, M,, Wu, L., Tay, L., … Lim, W.S. 
(2017). Frailty in hospitalized older adults: Comparing different frailty measures 
in predicting short and long-term patient outcomes. Journal of the American 
Medical Directors Association, 18 (7), 638e7-638e11. doi: 
10.1016/j.jamda.2017.04.011 
Chopra, T. & Krishna, A. (2014). Managing Clostridium difficile infection on the verge 
of the postantibiotic era. Annals of Long Term Care, 22 (7-8), 29-31. 
Cigolle, C.T., Ofstedal, M.B., Tian, Z., & Blaum, C.S. (2009). Comparing models of 
frailty: The health and retirement study. Journal of the American Geriatrics 
Society, 57 (5), 830-839. doi: 10.1111/j.1532-5415.2009.02225.x. 
Claesson, M.J., Cusack, S., O'Sullivan, O., Greene-Diniz, R., de Weerd, H., Flannery, E, 
…O'Toole, P.W. (2011). Composition, variability, and temporal stability of the 
intestinal microbiota of the elderly. Proceedings of the National Academy of 
Sciences of the United States of America, 108 (Supp 1), 4586-4591. doi: 
10.1073/pnas.1000097107 Clark, T. & Wiselka, M. (2008). Clostridium difficile 
infection. Clinical Medicine, 8 (5), 544-547. doi:10.7861/clinmedicine.8-5-544 
Clegg, A., Bates, C., Young, J., Ryan, R., Nichols, L., Teale, E.A., … Marshall, T. (2016) 
Development and validation of an electronic frailty index using routine primary 
care electronic health record. Age and Ageing, 45 (3), 353-360. doi: 
10.1093/ageing/afw039  
Clegg, A., Young, J., Illiffe, S., Rikkert, M.O., & Rockwood, K. (2013). Frailty in elderly 
people. Lancet, 381 (9868), 752-762, doi:10.1016/S0140-6736(12)62167-9.  
 
140 
Cohen, M. (2008). Research assessment of elder neglect and its risk factors in a hospital 
setting. Internal Medicine Journal, 38 (9), 704-707. doi: 10.1111/j.1445-
5994.2008.01630.x 
Cohen, S., Gerding, D., Johnson, S., Kelly, C., Loo, V., McDonald, L., . . . Wilcox, M. 
(2010). Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 
2010 Update by the Society for Healthcare Epidemiology of America (SHEA) 
and the Infectious Diseases Society of America (IDSA). Infection Control and 
Hospital Epidemiology, 31(5), 431-455. doi: 10.1086/651706 
Collins, C.E., Ayturk, M.D., Anderson, F.A., Santry, H.P. (2015). Predictors and 
outcomes of readmission for Clostridium difficile in a national sample of 
Medicare beneficiaries. The Journal of Gastrointestinal Surgery, 19 (1), 88-99, 
doi: 10.1007/s11605-014-2638-6. 
Cooper, C., Dere, W., Evans, W., Kanis, J. A., Rizzoli, R., Sayer, A. A.…Reginster J. Y. 
(2012). Frailty and sarcopenia: Definitions and outcome parameters. Osteoporosis 
International, 23 (7), 1839–1848. doi:10.1007/s00198-012-1913 –1 
Cooper, C., Selwood, A., Livingston, G. (2008). The prevalence of elder abuse and 
neglect: A systematic review. Age and Ageing, 37 (2), 151-160. 
doi:10.1093/ageing/afm194 
 
 
 
 
141 
Cornely, O.A., Crook, D.W., Esposito, R., Poirier, A., Somero, M.S., Weiss, K., … 
Gorbach, S. (2012). Fidaxomicin versus vancomycin for infection with 
Clostridium difficile in Europe, Canada, and the USA: A double-blind, non-
inferiority, randomized controlled trial. The Lancet Infectious Diseases, 12 (4), 
281-289. doi: 10.1016/S1473-3099(11)70374-7 
Cozar-Llisto, A., Ramos-Martinez, A.R., Cobo, J. (2016). Clostridium difficile infection 
in special high-risk populations. Infectious Diseases and Therapy, 5 (3), 253-269. 
doi: 10.1007/s40121-016-0124-z 
Crawford, T., Huesgen, E., & Danziger, L. (2012). Fidaxomicin: A novel macrocyclic 
antibiotic for the treatment of Clostridium difficile infection. American Journal of 
Health System Pharmacy, (11), 933-943. doi: 10.2146/ajhp110371 
Crobach, M.J.T., Planche, T., Eckert, C., Barbut, F., Terveer, E.M., Dekkers, O.M., 
Wilcox, M.H., & Kuijper, E.J. (2016). European society of clinical microbiology 
and infectious diseases: Update of the diagnostic guidance document for 
Clostridium difficile infection. Clinical Microbiology and Infection, 22, S63-S81, 
doi: 10.1016/j.cmi.2016.03.010 
D’Agostino, R.B., Collins, S.H., Pencina, K.M., Kean, Y., and Gorbach, S. (2014). Risk 
estimation for recurrent Clostridium difficile infection based on clinical factors. 
Clinical Infectious Diseases, 58 (10), 1386-1393, doi: 10.1093/cid/ciu107. 
Dent, E., Chapman, I., Howell, S., Piantadosi, C., Visvanathan, R. (2013). Frailty and 
functional decline indices predict poor outcomes in hospitalized older people. Age 
and Ageing, 43 (4), 477-484. doi: 10.1093/ageing/aft181 
 
142 
Dent, E., Kowal, P., & Hoogendkijk, E. (2016). Frailty measurement in research and 
clinical Practice: A review. European Journal of Internal Medicine, 31, 3-10. doi: 
10.1016/j.ejim.2016.03.00 
Dominiquez-Rodriquez, A., Abreu-Gonzales, P., Jimenez-Sosa, A., Gonzalez, J., 
Cabellero-Estevez, N., Martin-Casanas, F.V.,… Aranda, J.M. (2015). The impact 
of frailty in older patients with non-ischaemic cardiomyopathy after implantation 
of cardiac resynchronization therapy defibrillator. Europace, 17 (4), 598-602. 
doi:10.1093/europace/euu333  
De Alba, I. & Amin, A. (2014). Pneumonia readmissions: risk factors and implications. 
The Ochsner Journal, 14 (4), 649-654.  
Drubbel, I., Numans, M. E., Kranenburg, G., Bleijenberg, N., de Wit, N. J., & 
Schuurmans, M. J. (2014). Screening for frailty in primary care: A systematic 
review of the psychometric properties of the frailty index in community-dwelling 
older people. BMC Geriatrics, 14 (1), 27. doi:10.1186/1471-2318-14-27 
Dubberke, E. R. & Olsen, M.A. (2012). Burden of Clostridium difficile on the healthcare 
system. Clinical Infectious Diseases, 55 (Supp 2), S88-S92. doi: 
10.1093/cid/cis335 
Edwards, N., & Baird, C. (2005). Interpreting laboratory values in older adults. Medsurg 
Nursing, 14(4), 220-229.  
Eeles, E.M., White, S.V., O’Mahony, S.M., Bayer, A.J., & Hubbard, R.E. (2012). The 
impact of frailty and delirium on mortality in older inpatients. Age and Ageing. 41 
(3), 412-416. doi: 10.1093/ageing/afs021 
 
143 
Ekerstad, N., Swahn, E., Janzon, M., Alfredsson, J., Lofmark, R., Lindenberger, M. 
(2011). Frailty is independently associated with short-term outcomes for elderly 
patients with Non-ST-segment elevation myocardial infarction. Circulation, 124 
(22), 2397-2404. doi: 10.1161/CIRCULATIONAHA.111.025452 
Engel, G.L. (1981(. Clinical application of the biopsychosocial model. American Journal 
of Psychiatric, 137, 535-544.  
Evans, S.J., Sayers, M., Mitnitski, A., Rockwood, K. (2014). The risk of adverse 
outcomes in hospitalized older patients in relation to a frailty index based on a 
comprehensive geriatric assessment. Age and Ageing, 43 (1), 127-132. doi: 
10.1093/ageing/aft156. 
Farhat, J.S., Velanovich, V., Falvo, A.J., Mathilda, H., Swartz, A., Patton, J.H., & 
Rubinfeld, H.S. (2012). Are the frail destined to fail? Frailty index as predictor of 
surgical morbidity and mortality in the elderly. The Journal of Trauma and Acute 
Care Surgery, 72 (6), 1526-1530. doi: 10.1097/TA.0b013e3182542fab.  
Faul, F., Erdfelder, E., Lang, A.-G. & Buchner, A. (2007). G*Power 3: A flexible 
statistical power analysis program for the social, behavioral, and biomedical 
sciences. Behavior Research Methods, 39, 175-191. doi: 10.3758/BF03193146  
Federal Interagency Forum on Aging Related Statistics (2017, September 14). Population 
Aging In the United States: A Global Perspective. Retrieved from  
 https://agingstats.gov/images/olderamericans_agingpopulation.pdf 
FernÃ¡ndez-Garrido, J., Ruiz-Ros, V., Buigues, C., Navarro-Martinez, R., & Cauli, O. 
(2014).  
 
144 
Clinical features of prefrail older individuals and emerging peripheral biomarkers: A 
systematic review. Archives of Gerontology & Geriatrics, 59 (1), 7-17. 
doi:10.1016/j.archger.2014.02.008 
Ferrucci, L., Cavazzini, C., Corsi, A., Bartali, B., Russo, C.R., Lauretani, F.,…Guralnik, 
J.M. (2002). Biomarkers of frailty in older persons. Journal of Endocrinological 
Investigation, 25 (Supp 10), 10-15. 
Fontana, L., Addante, F., Copettie, M., Paroni, G., Fontana, A., Sancarlo, D., … Pilotto, 
A. (2013). Identification of a metabolic signature for multidimensional 
impairment and mortality risk in hospitalized older patients. Aging Cell, 12, (3), 
459-466. doi: 10.1111/acel.12068 
Freedberg, D.E., Salmasian, H., Friedman, C., & Abrams, J.A. (2013). Proton pump 
inhibitors and risk for recurrent Clostridium difficile infection among inpatients. 
The American Journal of Gastroenterology, 108 (11), 194-1801, doi: 
10.1038/ajg.2013.333 
Freedberg, D.E., Salmasian, H., Cohen, B., Abrams, J.A., & Larson, E.L. (2016). Receipt 
of antibiotics in hospitalized patients and risk for Clostridium difficile infection in 
subsequent patients who occupy the same bed. JAMA Internal Medicine, 176 
(12),1801-1808, doi:10.1001/jamainternmed.2016.6193 
Fried, L.P. Ferrucci, L., Darer, J., Williamson, J.D., & Anderson, G. (2004). Untangling 
the concepts of disability, frailty, and comorbidity: Implications for improved 
targeting and care. The Journals of Gerontology: Series A 59 (3), M255-M263. 
Doi: 10.1093/gerona/59.3.M255 
 
145 
Fried, L.P., Tangen, C.M., Walston, J., Newman, A.B., Hirsch, C., Gottdiener, J., 
Seeman, T., … McBurnie, M.A. (2001). Frailty in older adults: Evidence for a 
phenotype. Journal of Gerontology, 56 (3), 146-156. doi: 
10.1093/gerona/56.3.M146 
Frith, J., Day, C. P., Henderson, E., Burt, A. D., & Newton, J. L. (2009). Non-alcoholic 
fatty liver disease in older people. Gerontology, 55(6), 607-613, 
doi:10.1159/0000235677 
Galizia, G., Cacciatore, F., Testa, G., Della-Morte, D., Mazella, F., Langelloto, A., 
…Abete, P. (2011). Role of clinical frailty on long-term mortality of elderly 
subjects with and without chronic pulmonary disease. Aging Clinical and 
Experimental Research, 23 (2), 118-125. Doi: 10.1007/BF03351076 
Garey, K.W., Sethi, S., Yadav, Y., DuPont, H.L. (2008). Meta-analysis to assess risk 
factors for recurrent Clostridium difficile infection. Journal of Hospital Infection, 
70 (4), 298-304. doi: 10.1016/j.hin.2008.08.012 
Gavrilov, L.A. & Gavrilova, N.S. (2001). The Reliability Theory of Aging and 
Longevity. Journal of Theoretical Biology, 213, 527-545. doi: 
10.1006/jtbi.2001.2430 
George, E.M., Burke, W.M., Hou, J.Y., Tergas, A., Chen, L., Neugut, A., … Wright, J.D. 
(2015). Measurement and validation of frailty as a predictor of outcomes in 
women undergoing major gynecological surgery. BJOG, 123 (3), 455-461. Doi: 
10.1111/1471-0528.13598 
 
146 
Gobbens, R.J., van Assen, M.A., Luijkx, K.G., Wijnen-Sponselee, M.T., & Schols, J.M. 
(2010) The Tilburg frailty indicator: Psychometric properties. Journal of the 
American Directors Association, 11 (5), 344-355. doi: 
10.1016/j.jamda.2009.11.003 
Hall, A.J., Curns, A.T., McDonald, L.C., Parashar, U.D., Lopman, B.A. (2012). The roles 
of Clostridium difficile and norovirus among gastroenteritis-associated deaths in 
the United States, 1999-2007. Clinical Infectious Diseases, 55 (2) 216-223.doi: 
10.1093/cid/cis386 
Harries, T. H., Thornton, H., Crichton, S., Schofield, P., Gilkes, A., & White, P. T. 
(2017).  
Hospital readmissions for COPD: a retrospective longitudinal study. NPJ Primary Care 
Respiratory Medicine, 27 (31), 1-6. doi: 10.1038/s41533-017-0028-8 
Hatheway, O.L., Mitnitski, A., & Rockwood, K. (2017). Frailty affects the initial 
treatment response and time to recovery of mobility in acutely ill older adults 
admitted to the hospital. Age and Ageing, 46 (6), 920-925. doi: 
10.1093/ageing/afw257.  
Hensgens, M.P., Goorhuis, A., Dekkers, O.M., & Kuijper, E.J. (2012). Time interval of  
increased risk for Clostridium difficile infection after exposure to antibiotics. 
Journal of Antimicrobial Chemotherapy, 67 (3), 742-748. doi:10.1093/jac/dkr508 
Hessen, M.T. (2010). In the clinic. Clostridium difficile infection. Annals of Internal 
Medicine, 153 (7), ITC41-ITC415. doi:10.7326/0003-4819-153-7-201010050-
01004 
 
147 
Hodari, A., Hammoud, Z.T., Borgi, J.F., Tsiouris, A., & Rubinfeld, I.S. (2013). 
Assessment of morbidity and mortality after esophagectomy using a modified 
frailty index. The Society of Thoracic Surgeons, 96 (4), 1240-1245. doi: 
10.1016/j.athoracsur.2013.05.051 
Hoogendijk, E. O., van Hout, H. J., van der Horst, H. E., Frijters, D. M., Dent, E., 
Deeg,D. H., & Huisman, M. (2014a). Do psychosocial resources modify the 
effects of frailty on functional decline and mortality? Journal of Psychosomatic 
Research, 77 (6), 547-551. doi:10.1016/j.jpsychores.2014.09.017 
Hoogendijk, E. O., van Hout, H. J., Heymans, M. W., van der Horst, H. E., Frijters, D.M., 
Broese van Groenou, M. I., & ... Huisman, M. (2014b). Explaining the association 
between educational level and frailty in older adults: Results from a 13-year 
longitudinal study in the Netherlands. Annals of Epidemiology, 24 (7), 538-
544.e2. doi:10.1016/j.annepidem.2014.05.002 
Howlett, S. E., & Rockwood, K. (2013). New horizons in frailty: Ageing and the deficit-
scaling problem. Age & Ageing, 42, (4), 416-423. doi: 10.1093/ageing/aft059 
Howlett, S. E., Rockwood, M. R., Mitnitski, A., Rockwood, K., & Rockwood, M. H. 
(2014). Standard laboratory tests to identify older adults at increased risk of death. 
BMC Medicine, 12 (1), 171. doi:10.1186/s12916-014-0171-9 
Hubbard, R.E., Peel, N.M., Samanta, M., Gray, L.C., Mitnitski, A., & Rockwood, K. 
(2017) Frailty status at admission to hospital predicts multiple adverse outcomes. 
Age and Ageing, 46 (5), 801-806. doi: 10.1093/ageing/afx081 
 
148 
Inouye, S.K. (1998). Delirium in hospitalized older patients: Recognition and risk factors. 
Journal of Geriatric Psychiatry and Neurology, 11, 118-125. 
Jackson, M., Jeffery, I.B., Beaumont, M., Bell, J.T., Clark, A.G., Ley, R.E., O’Toole, 
P.W., Spector, T.D., & Steves, C.J. (2016). Signatures of early frailty in the gut 
microbiota. Genome Medicine, 8 (8), doi: 10.1186/s13073-016-0262-7. 
Jha, S.R., Hannu, M.K., Chang, S., Montgomery, E., Harkess, M., Wilhelm, K., 
…MacDonald, P.S. (2016). The prevalence and prognostic significance of frailty 
in patients with advanced heart failure referred for heart transplantation. 
Transplantation,100 (2), 429-436. doi: 10.1097/TP.0000000000000991 
Johannesen, M. & LoGiudice, D. (2013) Elder abuse: A systematic review of risk factors 
in community-dwelling elders, Age and Ageing, 42 (3), 292-298. doi: 
10.1093/ageing/afs195 
Johnson, B.C., Ma, S.S., Goldenberg, J.Z., Thorlund, K., Vandvik, P.O., Loeb, M., 
Guyatt, G.H. (2012). Probiotics for the prevention of Clostridium difficile-
associated diarrhea: A systematic review and meta-analysis. Annals of Internal 
Medicine, 157 (12), 878-888. doi:10.7326/0003-4819-157-12-201212180-00563 
Johnson, M.S., Bailey, T.L., Schmid, K.K., Lydiatt, W.M., & Johanning, J.M. (2014). A 
frailty index identifies patients at high risk of mortality after tracheostomy. 
Otolaryngology-Head and Neck Surgery, 150 (4), 568-573. Doi: 
10.1177/0194599813519749. 
  
 
149 
Joseph, B., Pandit, V., Khalil, M., Kulvatunyou, N., Zangbar, B., Friese, R., …Rhee, P. 
(2015). Managing older adults with ground-level falls admitted to a trauma 
service: The effect of frailty. Journal of the American Geriatrics Society, 63 (4), 
745-749.  doi: 10.1111/jgs.13338 
Joseph, B., Pandit, V., Zangbar, B., Kulvatunyou, N., Hashmi, A., Green, D.J., … Rhee, 
P. (2014). Superiority of frailty over age in predicting outcomes among geriatric 
Trauma patients: A prospective analysis. JAMA Surgery, 149 (8), 766-772. doi: 
10.1001/jamasurg.2014.296 
Jung, K.S., Park, J.J., Chon, Y.E., Jung, E.S., Lee, H.J., Jang, H.W., … Cheon, J.H. 
(2010). Risk factors for treatment failure and recurrence after metronidazole 
treatment for Clostridium difficile-associated diarrhea. Gut and Liver, 4 (3), 332-
337.doi:10.5009/gnl.2010.4.3.332 
Kanapuru, B. & Ershler, W.B. (2009). Inflammation, coagulation, and the pathway to 
frailty. American Journal of Medicine, 122 (7), 605-613. 
doi:10.1016/j.amjmed.2009.01.030. 
Karam, J., Tsiouris, A., Shepard, A., Velanovich, V., & Rubinfeld, I. (2013). Simplified 
frailty index to predict adverse outcomes and mortality in vascular surgery 
patients. Annals of Vascular Surgery, 27 (7), 904-908. Doi: 
10.1016/j.avsg.2012.09.015 
Kee, V.R. (2012). Clostridium difficile infection in older adults: A review and update on 
its management. The American Journal of Geriatric Pharmacotherapy, 10 (1), 
14-23. doi: 10.1016/j.amjopharm.2011.12.004 
 
150 
Kelaiditi, E., Cesari, M., Caneveilli, M., van Kan, G.A., Ousset, P.J., Gillette-Guyonnet, 
S., … IANA/IAGG. (2013). Cognitive frailty: rational and definition from an 
(IANA/IAGG) International consensus group. The Journal of Nutrition, Health, 
and Aging, 17 (9), 726-734. doi: 10.1007/s12603-013-0367-2.  
Keller, J.M. & Surawicz, C.M. (2014). Clostridium difficile infection in the elderly. 
Clinical Geriatric Medicine, 30:  79-93. doi: 10.1016/j.cger.2013.10.008 
Keller, D.S., Bankwitz, B., Nobel, T., & Delaney, C.P. (2014). Using frailty to predict 
who will fail early discharge after laparoscopic colorectal surgery with an 
established recovery pathway. Diseases of the Colon and Rectum, 57 (3), 337-
342. Doi: 10.1097/01.dcr.0000442661.76345.f5 
Kelly, C.P. (2012). Can we identify patients at high risk of recurrent Clostridium difficile 
infection? Clinical Microbiology and Infection, 18 (Supp 6), 21-27. doi: 
10.1111/1469-0691.12046 
Kelly, C.P., & LaMont, T. (2008). Clostridium difficile-more difficult than ever. The New 
England Journal of Medicine, 359 (80), 1932-1940. doi: 
10.1056/NEJMra0707500 
Kelso, T. (1990). Laboratory values in the older adult. Emergency Medicine Clinics of 
North America, 8 (2), 241-254.  
Kim, H., Higgins, P.A., Canaday, D.H., Burant, C.J., & Hornick, T. R. (2014). Frailty 
assessment in the geriatric outpatient clinic. Geriatrics and Gerontology 
International, 14 (1), 78-83. doi: 10.1111/ggi.12057 
 
151 
Kim, J.W., Lee, K.L., Jeong, J.B., Kim, B.G., Shin, S., Kim, J.S., …Song, I.S. (2012). 
Proton pump inhibitors as a risk factor for recurrence of Clostridium-difficile-
associated diarrhea. World Journal of Gastroenterology, 16 (28), 3573-3577, doi: 
10.3748/wjg.v16.i28.3573 
King, K.E., Fillenbaum, G.G., & Cohen, H.J. (2017). A cumulative deficit laboratory 
test-based frailty index: Personal and neighborhood associations. Journal of the 
American Geriatrics Society, 65 (9), 1981-1987. doi: 10.1111/jgs.14983 
Kojima, G., Illife, S., Jivraj, S., Liljas, A., & Walters, K. (2017). Does current smoking 
predict future frailty? The English longitudinal study of ageing. Age and Ageing, 
17, 1-6. doi: 10.1093/ageing/afx136. 
Krishnan, M., Beck, S., Havelock, W., Eeles, E., Hubbard, R.E., & Johansen, A. (2014). 
Predicting outcome after hip fracture: Using a frailty index to integrate 
comprehensive geriatric assessment results. Age and Ageing, 43 (1), 122-126. doi: 
10.1093/ageing/aft084 
Kulminski, A., Ukraintseva, S.V., Akushevich, I., Arbeev, K.G., Land, K., Yashin, A. 
(2007). Accelerated accumulation of health deficits as a characteristic of aging. 
Experimental Gerontology, 42 (10), 963-970.  
Kulminski, A.M., Ukraintseva, .SV., Kulminskaya, I.V., Arbeev, K.G., Land, K., & 
Yashin, A.I.(2008).  Cumulative deficits better characterize susceptibility to death 
in elderly people than phenotypic frailty: Lessons from the cardiovascular health 
study. Journal of the American Geriatrics Society, 56 (5), 898-903, doi: 
10.1111/j.1532-5415.2008.01656.x 
 
152 
Kyne, L., Merry, C., O’Connell, B., Kelly, A., Keane, C., O’Neill, D. (1999). Factors 
associated with prolonged symptoms and severe disease due to Clostridium 
difficile. Age and Ageing, 28 (2), 107-113. doi: 10.1093/ageing/28.2.107 
Lai, J.C., Feng, S., Terrault, N.A., Lizaola, B., Hayssen, H., Covinsky, K. (2014). Frailty 
predicts waitlist mortality in liver transplant candidates. American Journal of 
Transplantation, 14 (8), 1870-1879. doi: 10.1111/ajt.12762 
Lang, P.O., Michel, J.P., & Zekry, D. (2009). Frailty syndrome: A transitional state in a 
dynamic process. Gerontology, 55 (5), 539-549. doi: 10.1159/000211949 
Lee, J.L., Burnett, J., & Dyer, C.B. (2016). Frailty in self-neglecting older adults: a 
secondary Analysis. Journal of Elder Abuse and Neglect, 28 (3), 152-162. doi: 
10.1080/08946566.2016.1185986 
Lee, D. R., Kawas, C. H., Corrada, M. M., Kawas, C. H., Gibbs, L., & Corrada, M. M. 
(2016). Prevalence of Frailty and Factors Associated with Frailty in Individuals 
Aged 90 and Older: The 90+ Study. Journal of the American Geriatrics Society, 
64 (11), 2257-2262. doi: 10.1111/jgs.14317 
Leibovici-Weissman, Y., Atamna, A., Schlesinger, A., Eliakim-Raz, N., Bishara, J. and 
Yahav, D. (2017) Risk factors for short- and long-term mortality in very old 
patients with Clostridium difficile infection: A retrospective study. Geriatrics and 
Gerontology International, 17 (10), 1378–1383. doi:10.1111/ggi.12866 
 
  
 
153 
Lekan, D.A., Wallace, D.C., McCoy, T.P., Hu, J., Silva, S.G., & Whitson, H.E. (2017). 
Frailty assessment in hospitalized older adults using the electronic health record. 
Biological Research for Nursing, 19 (2), 213-228. doi: 
10.1177/1099800416679370 
Lessa, F.C., Mu, Y., Bamber, W.M., Beldavs, Z.G., Dumyati, G.K., Dunn, J.R. … 
McDonald, C. (2015). Burden of Clostridium difficile infection in the United 
States. New England Journal of Medicine. 372, 825-834. doi: 
10.1056/NEJmoa1408913 
Li, G., Ioannidis, G., Pickard, L., Kennedy, C., Papaioannou, A., Thabane, L., & Adachi, 
D. (2014). Frailty index of deficit accumulation and falls: Data from the Global 
Longitudinal Study of Osteoporosis in Women (GLOW) Hamilton Cohort. BMC 
Musculoskeletal Disorders, 15, doi: 10.1186/1471-2474-15-185 
Linsky, A., Gupta, K., Lawler, E.V., Fonda, J.R., Hermos, J.A. (2010). Proton pump 
inhibitors and risk for recurrent Clostridium difficile infection. Archives of 
Internal Medicine, 170 (9), 772-778. doi: 10.1001/archinternmed.2010.73 
Lipsitz, L.A. (2002). Dynamics of stability: The physiologic basis of functional health      
and frailty. The Journals of Gerontology, 57 (3), B115-125.  
Liu, Z., Que, S., Xu, J., & Peng, T. (2014). Alanine aminotransferase-old biomarker and 
new concept: A review. International Journal of Medical Sciences, 11 (9), 925-
935. doi:10.7150/ijms.8951 
 
 
154 
Liu, Z., Wang, Q., Zhi, T., Zhu, Y., Wang, Y, Wang, …Jiang, X. (2016). Frailty index 
and its relation to falls and overnight hospitalizations in elderly Chinese people: A 
population based study. The Journal of Nutrition, Health, and Aging. 20 (5), 561-
568. doi: 10.1007/s12603-015-0625-6  
Louie, T.J., Cannon, K., Byrne, B., Emery, J., Ward, L., Eyben, M., & Krulicki, W. 
(2012). Fidaxomicin preserves the intestinal microbiome during and after 
treatment of Clostridium difficile infection (CDI) and reduces both toxin re-
expression and recurrence of CDI. Clinical Infectious Diseases, 55 (S2), S132-
142. doi: 10.1093/cid/cis338 
Louie, T.J., Miller, M.A., Crook, D.W., Lentnek, A., Bernard, L., High, K.P., …Gorbach, 
S.L. (2013).  Effect of age on treatment outcomes in clostridium difficile 
infection. Journal of the American Geriatrics Society, 61 (2), 222-230. doi: 
10.1111/jgs.12090 
Lucas, R. W., & Kennedy-Malone, L. (January 01, 2014). Frailty in the older adult: will 
you recognize the signs? The Nurse Practitioner, 39, 3, 28-34.  
 doi: 10.1097/01.NPR.0000443228.72357.96 
Lucicesare, A., Hubbard, R.E., Fallah, N., Forti, P., Searle, S.D., Mitnitski, A., … 
Rockwood, K. (2010). Comparison of two frailty measures in the Conselice Study 
of Brain Ageing. Journal of Nutrition, Health, and Aging, 14 (4), 278-281.doi: 
10.1007/s12603-010-0061-6 
  
 
155 
Makizako, H., Shimada, H., Doi, T., Yoshida, D., Anan, Y., Tsutsumimoto, K., … 
Suzuki, T. (2015). Physical frailty predicts incident depressive symptoms in 
elderly people: Prospective findings from the study of health promotion for the 
elderly. Journal of the American Medical Directors Association, 16 (3), 194. doi: 
10.1016/j.jamda.2014.08.017 
Manini, T., & Clark, B. (2012). Dynapenia and aging: An update. Journals of 
Gerontology Series A: Biological Sciences & Medical Sciences, 67 (1), 28-40 doi: 
10.1093/gerona/glr010 
Mariat, D., Firmesse, O., Levenez, F., Guimaraes, V.D., Sokol, H., Dore, J., …Furet, J.P. 
(2009). The Firmicutes/Bacteroidetes ratio of the human microbiota changes with 
age. BMC Microbiology, 9 (9), 123.  doi:10.1186/1471-2180-9-123 
Maxwell, C. & Wang, J. (2017). Understanding frailty: A nurse’s guide. The Nursing 
Clinics of North America, 52 (3), 349-361. Doi: 10.1016/j.cnur.2017.04.003 
McAdams-DeMarco, M.A., Law, A., Salter, M.L., Boyarsky, B., Gimenez, L., Jaar, B.G., 
…Segev, D.L. (2013). Frailty as a novel predictor of mortality and hospitalization 
in individuals of all ages undergoing hemodialysis. Journal of the American 
Geriatrics Society, 61 (6), 896-901. doi: 10.1111/jgs.12266 
McDonald, L.C., Coignard, B., Dubberke, E., Song, X., Horan, T., & Kutty, P.K. (2007). 
Recommendations for surveillance of Clostridium difficile-associated disease. 
Infection Control and Hospital Epidemiology, 28, 140-145. doi: 10.1086/511798 
  
 
156 
McDonald, L.C., Gerding, D.N., Johnson, S., Bakken, J.S., Carroll, K.C., Coffin, S.E., 
…Wilcox, MH. (Published online February 15, 2018). Clinical Practice 
Guidelines for Clostridium difficile infection in adult and children: 2017 Update 
by the Infectious Diseases Society of America (IDSA) and Society for  
  Healthcare Epidemiology of America (SHEA). Clinical Infectious Diseases, doi: 
10.1093/cid/cix1085 
McDonald, E.G., Milligan, J., Frenette, C., & Lee, T.C. (2015). Continuous proton pump 
inhibitor therapy and the associated risk of recurrent Clostridium difficile 
infection. JAMA Internal Medicine, 175 (5), 784-791. doi: 
1001/jamainternmed.2015.42 
McMillan, G.J. & Hubbard, R.E. (2012). Frailty in older inpatients: What physicians 
need to know. QJM, 105 (11), 1059-1065. Doi: 10.1093/qjmed/hcs125 
Michikawa, T. (2016). Prevalence, adverse health, and risk factors in association with 
sensory impairments: Data from a prospective cohort study of older 
Japanese. Environmental Health and Preventive Medicine, 21, 6, 403-
409.doi.org/10.1016/j.archger.2010.06.003 
Milani, C., Ticinesi, A., Gerritsen, J., Nouvenne, A., Lugli, G. A., Mancabelli, L., 
Turroni, F., ... Ventura, M. (2016). Gut microbiota composition and Clostridium 
difficile infection in hospitalized elderly individuals: A metagenomic study. 
Scientific Reports, 6. 25945   doi: 10.1038/srep25945 
  
 
157 
Miller, D.B., & O’Callaghan, J.P. Aging, stress and the hippocampus. Ageing 
ResearchReviews, 4 (2), 123-140. doi: 10.1016/j.arr.2005.03.002 
Miller, A.J., Theou, O., McMillan, M., Howlett, S.E., Tennankore, K.K., & Rockwood, 
K. (2017). Dysnatremia in relation to frailty and age in community-dwelling 
adults in the National Health and Nutrition Examination Survey. The Journals of 
Gerontology: Series A, 72 (3), 376-381. doi: 10.1093/gerona.glw114  
Mitnitski, A., Collerton, J., Martin-Ruiz, C., Jagger, C., von Zglinicki, T., Rockwood, K., 
& Kirkwood, T. L. (2015). Age-related frailty and its association with biological 
markers of ageing. BMC Medicine, 13 (1), 161. doi:10.1186/s12916-015-0400-x 
Mitnitski, A.B., Mogilner, A.J., Rockwood, K. (2001). Accumulation of deficits as a 
proxy measure of aging. Scientific World Journal, 1, 323-336. 
doi:10.1100/tsw.2001.58 
Mitnitski, A., & Rockwood, K. (2015). Aging as a process of deficit accumulation: Its 
utility and origin. Interdisciplinary Topics in Gerontology, 40, 85-98. doi: 
10.1159/000364933 
Mitnitski, A., Song, X., and Rockwood, K. (2013). Assessing biological aging: The 
origin of deficit accumulation. Biogerontology, 14 (6), 709-717. doi: 
10.1007/s10522-013-9446-3 
Mooney, C.J., Elliot, A.J., Douthit, K.Z., Marquis, A., & Seplaki, C.L. (2016). Perceived 
control mediates effects of socioeconomic status and chronic stress on physical 
frailty: Findings from the health and retirement study. Journals of Gerontology: 
Psychological Science, 00 (00) 1-10, doi: 10.1093/geronb/gbw096 
 
158 
Morley, J. E. (2015). Dehydration, Hypernatremia, and Hyponatremia. Clinics In 
Geriatric Medicine, 31 (3), 389-399. doi:10.1016/j.cger.2015.04.007 
Morley, J. E., Vellas, B., van Kan, G. A., Anker, S. D., Bauer, J. M., Bernabei, R., … 
Walston, J. (2013). Frailty consensus: A call to action. Journal of the American 
Medical Directors Association, 14(6), 392–397. doi: 10.1016/j.jamda.2013.03.022 
Morrison, R.H., Hall, N.S., Said, M., Rice, T., Groff, H., Brodine, S.,…Lederman, E. 
(2011). Risk factors associated with complications and mortality in patients with 
Clostridium difficile infection. Clinical Infectious Diseases, 53 (12), 1173-1178. 
doi: 10.1093/cid/cir668 
Moudgal, V. & Sobel, J.D. (2012). Clostridium difficile colitis: A review. Hospital 
Practice, 40 (1), 139-148. doi: 10.3810/hp.2012.02.954 
Mulki, R., Baumann, A.J., Alnabelsi, T., Sandhu, N., Alhamshari, Y., Wheeler, D.S., 
Perloft, S., & Katz, P.O. (2016). Body mass index greater than 35 is associated 
with severe Clostridium difficile infection. Alimentary Pharmacology and 
Therapeutics, 10.1111/apt.13832 
Murphy, C.R., Avery, T.R., Dubberke, E.R., & Huang, S.S. (2012). Frequent hospital 
readmissions for Clostridium difficile infection and the impact on estimates of 
hospital-associated C. difficile burden. Infection Control and Hospital 
Epidemiology, 33 (1), 20-28. doi: 10.1086/663209 
  
 
159 
Muscedere, J. , Waters, B., Varambally, A., Bagshaw, S.M., Boyd, G. , Maslove, D., 
…Rockwood, K. (2017). The impact of frailty on intensive care unit outcomes: A 
systematic review and meta-analysis. Intensive Care Medicine, 43 (8), 1105-1122. 
doi: 10.1007/s00134-017-4867-0 
Musgrave, C.R., Bookstaver, P.B., Sutton, S.S., and Miller, A.D. (2011). Use of 
alternative or adjuvant pharmacologic treatment strategies in the prevention and 
treatment of Clostridium difficile infection. International Journal of Infectious 
Diseases, 15 (7), 438-448, doi: 10.1016/j.ijid.2011.03.017 
National Institute on Aging, National Institutes of Health, and World Health 
Organization. (2011, October). Global Health and Aging. Retrieved from 
https://www.nia.nih.gov/sites/default/files/2017-06/global_health_aging.pdf 
Ng, T. P., Feng, L., Nyunt, M. Z., Larbi, A., & Yap, K. B. (2014). Frailty in older 
persons: Multisystem risk factors and the frailty risk index (FRI). Journal of the 
American Medical Directors Association, 15(9), 635-642. 
doi:10.1016/j.jamda.2014.03.008 
Nguyen, T.N., Cumming, R.G., Hilmer, S.N. (2016). The impact of frailty on mortality, 
length of stay and re-hospitalization in older patients with atrial fibrillation. 
Heart, Lung, and Circulation, 25 (16), 551-557. doi: 10.1016/j.hlc.2015.12.002 
  
 
160 
Obeid, N.M, Azuh, O., Reddy, S., Webb, S., Reickert, C., Velanovich, V., Horst, H.M., 
& Rubinfeld, I. (2012). Predictors of critical care-related complications in 
colectomy patients using the national surgical quality improvement program: 
Exploring frailty and aggressive laparoscopic approaches. The Journal of Trauma 
and Acute Care Surgery, 72 (4), 878-883. Doi: 1097/TA.0b013e31824d0f70.  
O’ Connor, C.M. (2017). High heart failure readmission rates: is it the health system’s 
fault? JACC: Heart Failure, 5 (5), doi: 10.1016/j.jchf.2017.03.011 
Ogg, M. J. (2016). Clinical issues--august 2016. Association of Operating Room 
Nurses.AORN Journal, 104 (2), 165-173. doi:10.1016/j.aorn.2016.06.010173. 
Osborne, J. W. (2015). Best Practices in Logistic Regression. Los Angeles: SAGE 
Papaioannou, E., Raiha, I., & Kivela, S. (2012). Self-neglect of the elderly. An overview. 
European Journal of General Practice, 18 (3), 187-190. doi: 
10.3109/13814788.2012.688019 
Partridge, J.S.L., Harari, D., & Dhesi, J.K. (2012). Frailty in the older surgical patient: A 
review. Age and Ageing, 41 (2), 142-147. doi: 10.1093/ageing/afr182 
Patel, K.V., Brennan, K.L., Brennan, M.L., Jupiter, D.C., Shar, A., & Davis, M.L. (2014). 
Association of a modified frailty index with mortality after femoral neck fracture 
in patients aged 60 years and older. Clinical Orthopedics and Related Research, 
472, 1010-107. oi: 10.1007/s11999-013-3334-7.  
Piedmont Triad Regional Council (2012). About the Region. Retrieved from 
 http://www.ptrc.org/index.aspx?page=3 
 
161 
Pérez-Zepeda, M. U., Cárdenas-Cárdenas, E., Cesari, M., Navarrete-Reyes, A. P., & 
Gutiérrez-Robledo, L. M. (2016). Cancer and frailty in older adults: A nested 
case-control study of the Mexican health and aging study. Journal of Cancer 
Survivorship: Research and Practice, 10 (4), 736–742. Doi: 10.1007/s11764-016-
0519-6 
Pol, R. A., van Leeuwen, B. L., Visser, L., Izaks, G. J., van den Dungen, J. J., Tielliu, I. 
F., & Zeebregts, C. J. (2011). Standardised frailty indicator as predictor for 
postoperative delirium after vascular surgery: A prospective cohort study. 
European Journal of Vascular and Endovascular Surgery, 42(6), 824–830. 
 doi: 10.1016/j.ejvs.2011.07.006 
Postma, N., Kiers, D., & Pickkers, P. (2015). The challenge of Clostridium difficile 
infection: Overview of clinical manifestations, diagnostic tools, and therapeutic 
options. International Journal of Antimicrobial Agents, 46, (S47-S50). doi: 
10.1016/j.ijantimicag.2015.11.001 
Purser, J.L., Kuchibhatla, M.N., Fillenbaum, G.G., Harding, T., Peterson, E.D., & 
Alexander, K.P. (2006). Identifying frailty in hospitalized older adults with 
significant coronary artery disease. Journal of the American Geriatrics Society, 54 
(11), 1674-1681.doi: 10.1111/j.1532-5415.2006.00914.x 
Rao, K., Micic, D., Chenoweth, E., Deng, L., Galecki, A., Ring, C., Young, V.B., 
Aronoff, D.M., & Malani, P.N. (2013). Decreased functional status as a risk factor 
for severe Clostridium difficile infection among hospitalized older adults. Journal 
of American Geriatric Society, 61 (10), 1738-1742. doi: 10.1111/jgs.12442 
 
162 
R Core Team (2017). R: A language and environment for statistical computing. R 
Foundation for Statistical Computing, Vienna, Austria. URL: http://www.R-
project.org/. 
Reiner, A.P., Aragaki, A.K., Gray, S.L., Wactawski-Wende, J., Cauley, J.A., Cochrane, 
B.B.,... LaCroix, A.Z., (2009). Inflammation and thrombosis markers and incident 
frailty in postmenopausal women. American Journal of Medicine, 122 (10), 947-
954. 10.1016/j.amjmed.2009.04.016 
Ridda, I., Lindley, R., & MacInytre, R.C. (2008). The challenges of clinical trials in the 
exclusion zone: The case of the frail elderly. Australasian Journal on Ageing, 27 
(2), 61-66. doi: 10.1111/j.1741-6612.2008.00288.x 
Ritt, M., Bollheimer, L.C., Sieber, C.C., & Gabmann, K.G. (2016). Prediction of one-
year mortality by five different frailty instruments: A comparative study in 
hospitalized geriatric patients. Archives of Gerontology and Geriatrics, 66, 66-72. 
doi: 10.1016/j.archger.2016.05.004 
Rockwood, K. (2005). What would make a definition of frailty successful? Age and 
Ageing. 14, 432–434. doi: 10.1093/ageing/afi146 
Rockwood K, Andrew M, Mitnitski A. (2007). A comparison of two approaches to 
measuring frailty in elderly people. The Journals of Gerontology, 62 (7), 738–
743. doi: 10.1093/gerona/62.7.738 
Rockwood, K. & Mitnitski, A. (2011). Frailty defined by deficit accumulation and 
geriatric medicine defined by frailty. Clinics in Geriatric Medicine, 27 (1), 17-26. 
doi:10.1016/j.cger.2010.08.008 
 
163 
Rockwood, K., & Mitnitski, A. (2007). Frailty in relation to the accumulation of deficits. 
The Journals of Gerontology, 62 (7), 722-727.  
Rockwood, K., Mitnitski, A., Song, X., Steen, B., & Skoog, I. (2006). Long-term risks of 
death and institutionalization of elderly people in relation to deficit accumulation 
at age 70. Journal of American Geriatrics Society, 54, 975-979.  
Rockwood, K., Song, X., MacKnight, C., Bergman, H., Hogan, D.B., McDowell, I., & 
Mitnitski, A. (2005).  A global clinical measure of fitness and frailty in elderly 
people. Canadian Medical Association Journal, 173 (5), 489-495.doi: 
10.1503/cmaj.050051 
Rolfson, D. B., Majumdar, S. R., Tsuyuki, R. T., Tahir, A., & Rockwood, K. (2006). 
Validity and reliability of the Edmonton Frail Scale. Age and Ageing, 35, (5),    
526-9. 
Rolland, Y., & Morley, J. (2016). Frailty and polypharmacy. Journal of Nutrition, Health 
& Aging, 20(6), 645-646. doi:10.1007/s12603-015-0510-3. 
Roughead, E.E., Chan, E.W., Choi, N.K., Griffiths, J., Jin, X.M., Lee, J., …Pratt, N.L. 
(2016). Proton pump inhibitors and risk of Clostridium difficile infection: A 
multi-country study using sequence symmetry analysis. Expert Opinion on Drug 
Safety, 15 (12), 1589-1595. doi: 10.1080/14740388.2016.1238071 
Ruiz, M., Reske, T., Cefalu, C., & Estrada, J. (2013). Management of elderly and frail 
elderly patients: The importance of comprehensive geriatrics assessment and the 
need for guidelines. American Journal of Medical Sciences, 346 (1), 66-69.doi: 
10.1097/MAJ.0b013e31826d59aa 
 
164 
Rybka, K., Orzechowska, B., Siemieniec, I., Leszek, J., Zacynska, E., Pajak, J., & Blach-
Olszewska, Z. (2003). Age-related anti-viral non-specific immunity of human 
Leukocytes. Medical Sciences Monitor, 9 (12), BR413-417.  
Sanchez-Garcia, S., Garcia-Pena, C., Salva, A., Sanchez-Arenas, R., Granados-Garcia,V., 
Cuadros-Moreno, J., … Cardenas-Bahena, A. (2017). Frailty in community-
dwelling older adults: Association with adverse outcomes. Clinical Interventions 
in Aging, 26 (12), 1003-1011. doi: 10.2147/CIA.S139860.  
Shrestha, M.P., Bime, C., Taleban, S. (2018). Decreasing Clostridium difficile-associated 
fatality rates among hospitalized patients in the United States: 2004-2014. The 
American Journal of Medicine, 131 (1), 90-96. doi: 
10.1016/j.amjmed.2017.07.022 
Sahin, E., Depinho, R.A. (2010). Linking functional decline of telomeres, mitochondria 
and stem cells during ageing. Nature, 464 (7288), 520-528. 
doi:10.1038/nature08982 
Sams, A. W. & Kennedy-Malone, L. (2017). Recognition and management of 
Clostridium difficile in older adults. The Nurse Practitioner, 42 (5), 50-55. doi: 
10.1097/01/NPR.0000512254.47992.8e.  
Schuurmans, H., Steverink, N., Lindenberg, S., Frieswijk, N., & Slaets, J.P. (2004). Old 
or frail: What tells us more? The Journals of Gerontology: Series A Biological 
Sciences and Medical Sciences, 59 (9), M962-M965.  
 
 
165 
Schmid, D., Kuo, H.W., Simons, E., Kanitz, E.E., Wenisch, J., Allerberger, F., & 
Wenisch, C. (2014). All-cause mortality in hospitalized patients with infectious 
diarrhea: Clostridium difficile versus other enteric pathogens in Austria from 2008 
to 2010. Journal of Infection and Public Health, 7, 133-144. Doi: 
10.1016/j.jiph.2013.07.010 
Searle, S.D., Mitnitski, A., Gahbauer, E.A., Gill, T.M., & Rockwood, K. (2008). A 
standard procedure for creating a frailty index. BMC Geriatrics, 8 (24), doi: 
10.1186/1471-2318-8-24 
Shapiro, J.S., McCoy, R.G., Takahashi, P.Y., Thorsteinsdottir, B., Peterson, S.M., 
Naessens, J.M.,… Borkenhagen, L.S. (2017). Medication use leading to hospital 
readmission in frail elders. The Journal for Nurse Practitioners, 13 (10), 708-715. 
doi:10.1016/j.nurpra.2017.08.015 
Shilpak, M.G., Stehman-Breen, C., Fried, L.F., Song, X., Siscovick, D., Fried, L.P., 
…Newman, A.B. (2004). The presence of frailty in elderly persons with chronic 
renal insufficiency. American Journal of Kidney Disease, 43(5), 861-867. Doi: 
10.1053/j.ajkd.2003.12.049 
Simor, A.E. (2010). Diagnosis, management, and prevention of Clostridium difficile 
infection in long-term care facilities: A review. Journal of the American 
Geriatrics Society, 58 (8), 1556-1564. doi: 10.1111/j.1532-5415/2010/02958.x 
 
 
 
166 
Sinclair, A., Morley, J.E., Rodriguez-Manas, L., Paolisso, G., Bayer, T., Zeyfang, A., 
Lorig, K. (2012). Diabetes mellitus in older people: position statement on behalf 
of the international association of gerontology and geriatrics (IAGG), the 
European Diabetes Working Party for Older People (EDWPOP), and the 
International Task Force of Experts in Diabetes. Journal of American Medical 
Directors Association, 13 (6) 497-502. doi: 10.1016/j.jamda.2012.04.012 
Singer, J.P., Diamond, J.M., Gries, C.J., McDonnough, J., Blanc, P.D., Shah, R., … 
Lederer, D.J. (2015). Frailty phenotypes, disability, and outcomes in adult 
candidates for lung transplantation. American Journal of Respiratory and Critical 
Care Medicine, 192 (11) 1325-1334. doi: 10.1164/rccm.201506-1150OC 
Singh, I., Gallacher, J., Davis, K., Johansen, A., Eeles, E., & Hubbard, R.E. (2012). 
Predictors of adverse outcomes on an acute geriatric rehabilitation ward. Age and 
Ageing, 41 (2), 242 246. doi: 10.1093/ageing/afr179. 
Song, X., Mitnitski, A., & Rockwood, K. (2010). Prevalence and 10-year outcomes of 
frailty in older adults in relation to deficit accumulation. Journal of The American 
Geriatrics Society, 58 (4), 681-687. doi:10.1111/j.1532-5415.2010.02764.x 
Surawicz, C.M., Brandt, L.J., Binion, D.G., Ananthakrishnan, A.N., Curry, S.R., 
Gilligan, P.H., McFarland, L.V., … Zuckerbraun, B.S. (2013). Guidelines for 
diagnosis, treatment, and prevention of Clostridium difficile infections. The 
American Journal of Gastroenterology.108:  478-498. doi:10.1038/ajg.2013.4 
 
167 
Tedesco, F.J., Barton, R.W., Alpers, D.H. (1974). Clindamycin-associated colitis: A 
prospective study. Annals of Internal Medicine, 81(4):429-433. doi:10.7326/0003-
4819-81-4-429 
Theou, O., Brothers, T. D., Rockwood, M. R., Haardt, D., Mitnitski, A., & Rockwood, K. 
(2013). Exploring the relationship between national economic indicators and 
relative fitness and frailty in middle-aged and older Europeans. Age and Ageing, 
42 (5), 614-619. doi: 10.1093/ageing/aft010 
Theou, O., Walston, J., & Rockwood, K. (2015). Operationalizing frailty using the frailty 
phenotype and deficit accumulation approaches. Interdisciplinary Topics in 
Gerontology and Geriatrics, 41, 66-73. doi: 10.1159/000381164.  
Theou, O. & Rockwood, K. (2015). Comparison and clinical applications of the frailty 
phenotype and frailty index approaches. In O. Theou & K. Rockwood (Eds.). 
Frailty in Aging. Biological, Clinical, and Social Implications (74-84). Germany: 
Karger.  
Ticinesi, A., Nouvenne, A., Folesani, G., Prati, B., Morelli, I., Guida, L., Turroni, F., 
Ventura, M., Lauretani, F., Maggio, M., Meschi, T. (2015). Multimorbidity in 
elderly hospitalized patients and risk of Clostridium difficile infection: A 
retrospective study with the Cumulative Illness Rating Scale (CIRS). BMJ Open, 
5 (10), 1-6. doi:10.1136/bmjopen-2015-009316 
 
 
 
168 
Tleyjeh, I.M., Bin Abdulhak, A.A., Riaz, M., Garbati, M.A., Al-Tanir, M., Alasmari F.A 
Baddour, L. (2013). The association between histamine 2 receptor antagonist use 
and Clostridium difficile infection: A systematic review and meta-analysis. PLoS 
ONE, 8(3), e56498. doi: 10.1371/journal.pone.0056498 
Tongeren, S.P., Slaets, J.P., Harmsen, H.J., Welling, G. W. (2005). Fecal microbiota 
composition and frailty. Applied and Environmental Microbiology, 71 (10), 6438-
6442. Doi: 10.1128/AEM.71.10.6438-6442.2005 
Trifan, A., Stanciu, C., Girleanu, I., Stoica, O.C., Singeap, A.M., Maxim, R., 
…Boiculese, L.(2017). Proton pump inhibitors therapy and risk of Clostridium 
difficile infection: Systematic review and meta-analysis. World Journal of 
Gastroenterology, 23  (35), 6500-6515. doi: 10.3748/wjg.v23.i35.6500 
Tschudin-Sutter, S., Carroll, K. C., Tamma, P. D., Sudekum, M. L., Frei, R., Widmer, 
A.F., Ellis, B. C., ... Perl, T. M. (2015). Impact of toxigenic Clostridium difficile 
colonization on the risk of subsequent C. difficile infection in intensive care unit 
patients. Infection Control & Hospital Epidemiology, 36 (11), 1324-1333.doi: 
10.1017/ice.2015.177 
Ulley, J., & Abdelhafiz, A. H. (2017). Frailty predicts adverse outcomes in older people 
with diabetes. The Practitioner, 261 (1800), 17-20.  
Van Esch. G., Van Broeck, J., Delmée, M., & Catry, B. (2015). Surveillance of 
Clostridium difficile infections in a long-term care psychogeriatric facility: 
Outbreak analysis and policy improvement. Archives of Public Health, 73 (1), 18. 
doi: 10.1186/s13690-015-0067-y 
 
169 
Van Iersel, M.B. & Rickkert, M. G. (2006). Frailty criteria give heterogeneous results 
when applied in clinical practice. Journal of the American Geriatrics Society, 54 
(4), 728-239. doi: 10.1111/j.1532-5415.2006.00668_14.x 
Venkat, R., Telemi, E., Oleksandr, O., & Nfonsam, V. (2016, February). Frailty predicts 
postoperative morbidity/mortality after colectomy for C. difficile colitis. Paper 
Presented at the meeting of Academic Surgical Congress, Jacksonville, Florida. 
Abstract retrieved from http://www.asc-abstracts.org/abs2016/68-13-frailty-
predicts-postoperative-morbiditymortality-after-colectomy-for-c-difficile-colitis/ 
Vermeiren, S., Vella-Azzopardi, R., Beckwee, D., Habbig, A., Scafoglieri, A., Jansen, B., 
& Bautmans, I. (2016). Frailty and the prediction of negative health outcomes: A 
meta-analysis. Journal of the American Medical Directors Association, 1 (17), 
1163.e1-1163.e17. doi: 10.1016/j.jamda/2016.09.010 
Vidán, M. T., Blaya‐Novakova, V., Sánchez, E., Ortiz, J., Serra‐Rexach, J. A., & Bueno, 
H. (2016). Prevalence and prognostic impact of frailty and its components in non‐
dependent elderly patients with heart failure. European Journal of Heart Failure, 
18, 869-875.doi:10.1002/ejhf.518 
Vittinghoff, E., & McCulloch, C. E. (2007). Relaxing the rule of ten events per variable 
in logistic and cox regression. American Journal of Epidemiology, 165 (6), 710–
718. doi: 10.1093/aje/kwk052  
Walston, J.D. & Bandeen-Roche, K. (2015). Frailty: A tale of two concepts. BMC 
Medicine, 13, 185. doi: 10.1186/s12916-015-0420-6 
 
170 
Walston, J., Buta, B., & Xue, Q. (2018). Frailty screening and interventions: 
Considerations for clinical practice. Clinics in Geriatric Medicine, 34 (1), 25-38. 
doi: 10.1016/j.cger.2017.09.004 
Walston, J., Xue, Q., Semba, R.D., Ferrucci, L., Cappola, A.R., Ricks, M., … Fried, L.P. 
(2006). Serum antioxidants, inflammation, and total mortality in older women. 
American Journal of Epidemiology, 163 (1), 18-26, doi: 10.1093/aje/kwj007  
Warnier, R.M.J., Van Rossum, E., Van Velthuijsen, E., Mulder, W.J., Schols, J.M.G.A., 
Kempen, G.I.J.M. (2016). Validity, reliability and feasibility of tools to identify 
frail older patients in inpatient hospital care: A systematic review. The Journal of 
Nutrition, Health, and Aging,20 (2), 219-230.  doi: 10.1007/s12603-015-0567-z 
Waters, D.L., Vawter, R., Qualls, C.. Chode, S., Armamento-Villareal, R., & Villareal, 
D.T. (2013). Long-term maintenance of weight loss after lifestyle intervention in 
frail, obese older adults. Journal of Nutrition, Health and Aging, 17(1), 3-7. doi: 
10.1007/s12603-012-0421-5 
Wenisch, J.M., Schmid, D., Tucek, T., Kuo, H.W., Allerberger, F., Michl, V.,…& 
Wenisch, C. (2012). A prospective cohort study on hospital mortality due to 
Clostridium difficile infection. Infection, 40 (5):479-84. doi: 10.1007/s15010-012-
0258-1. 
Woo, J., Goggins, W., Sham, A., & Ho, S.C,. (2005). Social determinants of frailty 
Gerontology, 51, 402-408. doi: 10.1159/000088705 
 
171 
Wou, F., Gladman, J.R.F., Bradshaw, L., Franklin, M., Edmans, J., & Conroy, S.P. 
(2013). The predictive properties of frailty-rating scales in the acute medical unit. 
Age and Ageing, 42, 776-781. Doi: 10.1093/ageing/aft055.  
Yashin, A. I., Arbeev, K. G., Kulminski, A., Akushevich, I., Akushevich, L., & 
Ukraintseva, S. V. (2007). Cumulative index of elderly disorders and its dynamic 
contribution to mortality and longevity. Rejuvenation Research, 10, 1, 75-86. doi: 
10.1089/rej.2006.0500 
Yoon, S.S. & Brandt, L.J. (2010). Treatment of refractory/recurrent C. difficile associated 
disease by donated stool transplanted via colonoscopy: A case series of 12 
patients. Journal of Clinical Gastroenterology, 44 (8), 562-566. doi: 
10.1097/MCG.0b013e3181dac035 
Youngster, I., Mahabamunuge, J., Systrom, H.K., Sauk, J., Khalili, H., Levin, 
J.,…Hohmann,.L. (2016). Oral, frozen fecal microbiota transplant capsules for 
recurrent Clostridium difficile infection. BMC Medicine, 14 (1), 134-137. doi: 
10.1186/s12916-016-0680-9 
Yang, S., Rider, B.B., Baehr, A., Ducoffe, A.R., & Hu, D.J. (2016). Racial and ethnic 
disparities in health care-associated Clostridium difficile infections in the United 
States: State of the science. American Journal of Infection Control, 44, 91-96. doi: 
10.1016/j.ajic.2015.08.007 
Yu, H., Baser, O., & Wang, L. (2016). Burden of Clostridium difficile-associated disease 
among patients residing in nursing homes: A population-based cohort study. BMC 
Geriatrics, 16 (193). doi: 10.1186/s12877-016-0367-2.  
 
172 
Zaslavsky, O., Thompson, H., & Demiris, G. (2012). The role of emerging information 
technologies in frailty assessment. Research in Gerontological Nursing, 5 (3), 
216-228. doi: 10.3928/19404921-20120410-02 
Zaslavsky, O., Walker, R. L., Crane, P. K., Gray, S. L., & Larson, E. B. (2016). Glucose 
levels and risk of frailty. Journals of Gerontology Series A: Biological Sciences & 
Medical Sciences, 71 (9), 1223-1229. doi:10.1093/gerona/glw024 
Ziakas, P.D., Zacharioudakis, I.M., Zervou, F.N., Grigoras, C., Pliakos, E.E., & 
Mylonakis, E. (2015). Asymptomatic carriers of toxigenic C.difficile in long-term 
care facilities: A meta-analysis of prevalence and risk factors. PloS One, 10 (2), 
e0117195. doi: 10.1371/journal.pone.0117195 
Zilberberg, M.D., Shorr, A.F., Wang, L., Baser, O., & Yu, H. (2016). Development and 
validation of a risk score for Clostridium difficile infection in Medicare 
beneficiaries: A population-based cohort study. Journal of the American 
Geriatrics Society, 64 (8), 1690-1695. Doi: 10.111/jgs.14236  
 
 
